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The Business of Health in Africa
Partnering with the Private Sector to Improve People’s Lives 
This report describes opportunities for  
engaging and supporting a well managed  
and effectively regulated private sector  
to improve the region’s health.  We hope  
that governments, donors, investors,  
nongovernmental organizations, and health  
care providers will find this research a useful  
addition to traditional public sector approaches. 
Message from the  
Executive Vice President and CEO
S
ub-Saharan Africa has about 11 percent of the world’s people, but it carries 24 
percent of the global disease burden in human and financial costs. Almost half 
the world’s deaths of children under five take place in Africa. 
This challenge is significant but not insurmountable. There is a tremendous oppor-
tunity to leverage the private sector in ways that improve access and increase the 
financing and quality of health care goods and services throughout Africa. 
In a region where public resources are limited, the private sector is already a sig-
nificant player. Around 60 percent of health care financing in Africa comes from pri-
vate sources, and about 50 percent of total health expenditure goes to private provid-
ers. Just as important, the vast majority of the region’s poor people, both urban and 
rural, rely on private health care. A poor woman with a sick child is as likely to go to 
a private hospital or clinic as to a public facility. 
This report describes opportunities for developing, engaging, and supporting a well 
managed and effectively regulated private sector to improve the region’s health. We 
hope that governments, donors, investors, nongovernmental organizations, and health 
care providers will find this research a useful addition to traditional public sector ap-
proaches. We look forward to exploring partnerships with African companies, banks, 
and investors, as well as policy experts and other stakeholders in health care. Despite 
the scope of Africa’s health challenge, I am optimistic about what can be achieved in 
the next few years.
I want to thank the partners and colleagues who made this report possible. Their 
diverse contributions are a powerful example of the value of collaboration. 
Lars H. Thunell
Executive Vice President and CEO
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There are many who deserve 
recognition for the help they provided 
us in developing this report. 
Lastly, we extend our gratitude to 
the individuals who shared their 
thoughts with our team on the 
many issues we examined to 
develop a picture of this 
most complex of issues. 
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Sub-Saharan Africa accounts for  
11 percent of the world’s population,  
yet bears 24 percent of the global disease  
burden and commands less than  
one percent of global health expenditure.
It also faces a severe shortage of trained  
medical personnel, with just three percent  
of the world’s health workers deployed  
in Sub-Saharan Africa.
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Executive Summary
Health care in most of Sub-Saharan Africa re-mains the worst in the world. Despite de-cades of foreign assistance, few countries in 
the region are able to spend even the $34–$40 per 
person per year that the World Health Organiza-
tion (WHO) considers the minimum necessary to 
provide a population with basic health care.1 In 
spite of the billions of dollars of international aid 
dispensed, an astonishing 50 percent of Sub-Saha-
ran Africa’s total health expenditure is financed 
by out-of-pocket payments from its largely im-
poverished population. In addition, the region 
lacks the infrastructure, facilities, and trained 
personnel necessary to provide and deliver even 
minimal levels of health services and goods. 
This study, conducted by IFC with assistance 
from McKinsey & Company, estimates that over 
the next decade, $25–$30 billion in new invest-
ment will be needed in health care assets, includ-
ing hospitals, clinics, and distribution warehouses, 
to meet the growing health care demands of Sub-
Saharan Africa.
This IFC report highlights the critical role the 
private sector can play in meeting the need 
for more and higher-quality health care in Sub- 
Saharan Africa. It also identifies policy changes 
that governments and international donors can 
make to enable the private sector to take on an 
ever more meaningful role in closing Africa’s 
health care gap.
It is important to acknowledge at the outset 
that many in the public health community oppose 
in principle a role for the private sector in health 
care. Indeed, there are legitimate concerns about 
the role of private providers. The private sector in 
Sub-Saharan Africa is diverse and fragmented, and 
as a result, quality can be inconsistent. Moreover, 
the lack of regulatory and accreditation frame-
works combined with a largely uninformed patient 
population can sometimes allow an unscrupulous 
minority to prevail over responsible providers—to 
the detriment of the reputation of all.
The truth is, however, that for-profit compa-
nies, non-profit organizations, and social enterpris-
es, along with insurers, providers, and manufactur-
ers, already play an important role in providing 
health care to the region. They account for as 
much as 50 percent of health care provision, and 
their role is growing. 
The	Widening	Gap
Sub-Saharan Africa accounts for 11 percent of the 
world’s population, yet bears 24 percent of the 
global disease burden and commands less than one 
percent of global health expenditure.2 Increased 
attention from outside donors has resulted in some 
remarkable initiatives, funneling billions of dollars 
to help combat HIV/AIDS, tuberculosis (TB), and 
malaria the worst health scourges of the region. 
But most of the area lacks the infrastructure and 
facilities necessary to provide and deliver minimal 
levels of health services and products. It also faces 
a severe shortage of trained medical personnel, 
with just three percent of the world’s health work-
ers deployed in Sub-Saharan Africa.3 
Furthermore, Sub-Saharan Africa’s improving 
economic performance means that the demand 
among all sectors of society for health care is 
poised to increase still further. This study esti-
mates that the market for health care will more 
than double by 2016, going up to $35 billion.
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The	Potential	for	Complementary	
Solutions
Although the importance of the private sector 
varies by country, it is surprisingly large and con-
stitutes an important, diverse component of the 
region’s health care systems. Of total health ex-
penditure of $16.7 billion in 2005,4 roughly 60 
percent5—predominantly out-of-pocket payments 
by individuals—was financed by private parties, 
and about 50 percent6 was captured by private 
providers.7 
The formal element of the private sector con-
sists of non-public entities that include for-profit 
commercial companies, non-profit organizations, 
and social enterprises. Individual public sector 
health workers also provide private sector services, 
both formally and informally, and an informal 
health sector of healers, midwives, and individual 
medicine sellers also provides care. 
The private sector is often perceived as serving 
only the rich, but often the opposite is the case. In 
fact, private sector providers, including for-profit 
and social enterprises, fill an important medical 
need for poor and rural populations underserved 
by the public sector.
In addition, the private sector frequently pro-
vides services or products that might not other-
wise be available, such as advanced medical equip-
ment and procedures. In many cases the private 
sector can also provide higher-quality services. To-
gether, these benefits are likely to lead to improved 
health outcomes across the region.
What	Can	Be	Done	to	Further	Leerage	
the	Priate	Sector	to	Improe	Access		
to	Health	Care?
From interviews with all segments of Sub-Saharan 
Africa’s health care community, five main impera-
tives emerged that together create an agenda that 
can mobilize the responsible development of pri-
vate sector health care in the region. 
Develop and enforce quality standards. Initial 
efforts at enhanced regulation could have large 
and immediate benefits. Financial and technical 
support is needed to strengthen the ability of 
public and private regulatory bodies to develop 
and enforce transparent and effective quality 
standards.
Foster risk pooling programs. Risk pooling ar-
rangements—such as government-funded nation-
al payment schemes,8 commercial insurance, or 
community non-profit mutuelles—have enor-
mous potential to improve the financing of health 
care in the region, thereby encouraging the devel-
opment of higher-quality, more organized private 
sector providers.
Mobilize public and donor money to the private 
sector. Donors can help build health care capacity 
by earmarking some aid to fund private sector 
entities directly while also assisting local govern-
ments to expand their procurement capabilities 
and manage contracts with the private sector. Em-
ployers can foster the development of the local 
private health care sector by outsourcing provi-
sion of health care for their employees.
Modify local policies and regulations to foster 
the role of the private sector. Opportunities exist 
to reform the regulations that inadvertantly im-
pede the development of the private health sec-
tor. The primary areas of focus should be stream-
lining bureaucratic processes that limit market 
entry, liberalizing human resource regulations 
that perversely reduce the number of active 
health care workers, and reducing tariffs and oth-
er import barriers that impede access to or raise 
the cost of health supplies. 
Improve access to capital. Entrepreneurs and 
business enterprises in Sub-Saharan Africa have 
trouble securing financing from established insti-
tutions. Three initiatives could tackle this issue: (i) 
educating local banks about the true risk profile of 
the health care sector; (ii) using international 
financial backing to encourage local financial insti-
tutions to lend to health care enterprises, includ-
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ing small and medium-sized enterprises (SMEs); 
and (iii) developing equity-focused financing ve-
hicles for health care enterprises.
The	Case	for	Inesting	in	Health	Care
The weak investment climate in Sub-Saharan Af-
rica has long posed a daunting challenge to entre-
preneurs and their potential backers alike, but 
signs of positive change abound. Political stability 
has improved, reflecting a steep decline in the in-
cidence armed conflict. Economic growth in most 
of the continent has been strong for the past half 
decade, and inflation is down. Reform is also be-
ginning to take hold. In 2007, according to the 
World Bank’s Doing Business report, Africa ranked 
third in the world (behind the Eastern Europe-
Central Asia group and the OECD countries) in 
the pace of economic reform. 
Investment opportunities in health care  
are growing apace
The expected improvement in Africa’s macro-
economic climate over the next decade will ex-
pand the health care gap, as higher incomes will 
create new demand. The biggest individual in-
vestment opportunities will be in building and 
improving the sector’s physical assets. Around 
550,000–650,000 additional hospital beds will 
need to be added to the existing base. An addi-
tional 90,000 physicians, about 500,000 nurses, 
and 300,000 community health workers will be 
required over and above the numbers that will 
graduate from existing medical colleges and 
training institutions. Demand for better distribu-
tion and retail systems and for pharmaceutical 
and medical supply production facilities will also 
be strong. An estimated $25–$30 billion in new 
investments will be needed to meet demand be-
tween now and 2016—of which $11–$20 billion 
is likely to come from the private sector. 
A broad range of investment opportunities ex-
ist across all components of the health care indus-
try in the region (as described in detail in the an-
nexes to this report). These opportunities can 
deliver compelling financial returns and have an 
enormous potential development impact. 
Health care provision accounts for roughly half 
the investment opportunity, with the remainder 
split across distribution and retail, pharmaceutical 
and medical product manufacturing, insurance, 
and medical education. These investments will 
fund capacity expansion, new businesses, and ren-
ovation of existing assets. About half of these in-
vestments are expected to be made by for-profit 
entities, the remaining portion of private sector 
investment being equally spread between social 
enterprises and nongovernmental organizations 
(NGOs).
The vast majority of the investment opportuni-
ties in the near term will be in the SME sector. 
Only a quarter of the opportunities are expected 
to have a project size larger than $3 million. This 
report also highlights the availability of invest-
ment opportunities in social enterprises that, 
while delivering lower financial returns, can have 
a tremendous role in the positive development of 
Sub-Saharan Africa. 
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Different types of investors will all find  
significant opportunities
The vast range of financial and developmental op-
portunities that the health industry presents in 
Sub-Saharan Africa will require significant involve-
ment by all segments of the investor community. 
Financially driven private investors will find sus-
tained industry growth combined with opportu-
nities for consolidation. 
Angel investors can engage with innovative social 
enterprises to deliver great returns while address-
ing some of the most pressing health care chal-
lenges facing the region.
Double-bottom line investors, such as develop-
ment finance institutions and foundations, can 
collaborate to provide “patient capital” to achieve 
financial returns over the longer term while deliv-
ering significant developmental impact. 
Donors can play a key role by financing those en-
terprises that are not financially viable, but have 
the promise to play a crucial role in the develop-
ment of high-quality private sector health care. 
In conclusion, the private sector, including both 
for-profit and social enterprises, already plays and 
will continue to play a pivotal role in improving 
the health of the people of Sub-Saharan Africa. 
Donors, governments, and the investment com-
munity each face a unique and important set of 
opportunities in developing a responsible, sustain-
able, and vibrant private health care sector in the 
region. 
Ultimately, however, the vigor of the private 
health sector in Sub-Saharan Africa will rely on 
the commitment, creativity, and integrity of the 
people of Africa.
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Project Scope and Approach 
IFC commissioned this report to bring focus to the role of the private sector in the financing and provision of health care in Sub-Saharan Af-
rica and to develop an agenda for its improve-
ment. 
For the sake of clarity, it is worth explicitly not-
ing that this paper is not an advocate for the priva-
tization of the financing and provision of health-
related goods and services in Sub-Saharan Africa. 
Rather, it seeks to highlight the important role 
that the private sector—an often neglected com-
ponent of Africa’s health care systems—already 
plays and to outline ways in which that sector 
could be better engaged and harnessed, thereby 
improving its sustainability and the health out-
comes it delivers.
Project	Scope
For the purposes of this study, “health care” is 
defined to include:
• Primary health care; 
• Secondary and tertiary health care;
• Public health, including vaccination, sanitation, 
and family planning;
• Health programs, including HIV/AIDS, TB, 
and malaria;
• Health care financing;
• Pharmaceutical production;
• Medical equipment and supplies production;
• Distribution and retailing of pharmaceuticals 
and equipment; and
• Medical and health professional training.
The term “private sector” is defined to include: 
• For-profit organizations;
• Social enterprises sometimes referred to else-
where as “not-for-profits”;
• Non-profits including NGOs and faith-based 
organizations; and
• Privately motivated individuals and groups of 
individuals.
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•  Angola
•  Benin
•  Botswana
• Burkina Faso
• Burundi
• Cameroon
• Cape Verde
• Central African Republic
• Chad
• Comoros
• Congo
• Côte d’Ivoire
• Democratic Republic of Congo
• Djibouti
• Equatorial Guinea
Broadly, the geographic scope of the study is Sub-Saharan Africa. More specifically, 
the project covers the following 45 countries: 
• Eritrea
• Ethiopia
• Gabon
• Gambia
• Ghana
• Guinea
• Guinea-Bissau
• Kenya
• Lesotho
• Liberia
• Madagascar
• Malawi
• Mali
• Mauritania
• Mauritius
• Mozambique
• Namibia
• Niger
• Nigeria
• Rwanda
• São Tomé & Príncipe
• Senegal
• Sierra Leone
• Sudan
• Swaziland
• Tanzania
• Togo
• Uganda
• Zambia
• Zimbabwe
For most of the study’s analysis, South Africa 
was excluded due to the relatively high standing 
of its health sector and the maturity of its financial 
markets. However, South Africa was considered 
when evaluating investment opportunities in 
manufacturing. Further, interviews were conduct-
ed with investors and operators based in South 
Africa to gather their perspectives on opportuni-
ties for investment in other parts of the region. 
Project	approach
The study sought to develop an understanding of 
the private health sector landscape in Sub-Saha-
ran Africa through literature review and extensive 
consultations with a range of key stakeholders. A 
team of consultants from McKinsey & Company 
conducted almost 400 interviews with stakehold-
ers from private health enterprises, government 
officials and policymakers, development organiza-
tions, and financing institutions, in addition to 
health care experts and operators outside the re-
gion. A full list of interviewees is included in the 
acknowledgements section at the conclusion of 
this report. 
Given the broad geographic scope of the proj-
ect, in-person visits and more detailed analysis were 
limited to nine countries: the Democratic Republic 
of Congo, Ghana, Kenya, Mozambique, Nigeria, 
Rwanda, Senegal, Tanzania, Uganda, and South 
Africa (for the exploration of pharmaceutical and 
medical equipment manufacturing only). 
These countries were chosen because they re-
flected the diverse environments found across 
Sub-Saharan Africa. Key criteria for country selec-
tion included socio-demographic factors such as 
population size, per-capita gross domestic product 
(GDP), and language, as well as health indicators 
including life expectancy, health spending, and 
private sector contribution to health provision. 
Additional considerations included investment 
climate metrics such as foreign direct investment 
and ease of doing business (as judged by the World 
Bank’s Doing Business report).
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In Senegal Institut Santé Service trains  
nurses, laboratory technicians and assistant  
doctors…; Vidagas, a commercial  
heating fuel supplier, distributes vaccines  
free to rural clinics in Mozambique…;  
a TB patient receives treatment administered  
and paid for by Hygeia, a Nigerian HMO…;  
and in Tanzania a mother and child sleep  
under a long-lasting insecticide treated bed  
net manufactured locally by A-Z Textile Mills.
Introduction
That Sub-Saharan Africa confronts a health crisis of overwhelming proportions is widely understood. The spread of HIV/AIDS, the 
insidious scourge of malaria, and the persistence 
of debilitating parasitic diseases are all well docu-
mented. Increasingly, so-called lifestyle ailments—
cancer, diabetes, and heart disease—are also af-
flicting Africans.9 Compounding the continent’s 
health crisis is the poor state of its health systems, 
which are ill-equipped to cope with these chal-
lenges. As a result, these ailments sap the energy, 
creativity and productivity of the region’s 670 
million10 inhabitants. Every year, malaria alone 
costs an estimated $12 billion in lost wages across 
Sub-Saharan Africa11 and, as an example, life ex-
pectancy in Swaziland is just 30 years, compared 
to 81 in Switzerland.12
For years, many of the world’s best minds and a 
great deal of money have been applied to trying to 
heal this global travesty. And, so far, despite positive 
steps forward, Sub-Saharan Africa is not on track to 
meet its Millennium Development Goals as they 
relate to health. The hard but inescapable truth is 
that foreign assistance can only go so far in improv-
ing the overall health of Africa’s populations. 
It is easy to see why. The vast majority of health 
care financing comes from the pockets of Africans 
(either through taxes or out-of-pocket payments). 
The vast majority of health-related goods and ser-
vices are also provided by African enterprises. In 
essence, Africa’s health care systems are run by Af-
ricans and for Africans. Given these factors, as well 
as the tremendous strain on public finances in 
most African nations, many of these systems are 
dominated by the private sector. Indeed, health 
care in Sub-Saharan Africa is primarily associated 
with private initiatives. Almost two-thirds of total 
health expenditure, and at least half of health care 
provision in the region are accounted for by the 
private sector.13 In many countries these numbers 
are higher, and would be higher still if more ac-
curate assessments of the informal sector were 
available.
This report demonstrates that the private sector 
is currently playing, and will continue to play, a vi-
tal role in the financing and provision of health care 
in Sub-Saharan Africa, and that engaging the entre-
preneurial talents of the private sector is essential 
in improving access to health care in the region. 
The report recognizes that harnessing the talents of 
the private sector will require new approaches to 
collaboration between public and private players, 
new approaches from donors and other stakehold-
ers, and strategies that are tailored to local realities. 
The	Continuing	Health	Care	Gap
Sub-Saharan Africa has far more than its share of 
the world’s health problems. The region accounts 
for 11 percent of the world’s population and 24 
percent of the global disease burden, yet com-
mands less than one percent of global health ex-
penditure.14 These disparities have been a stimu-
lus for the launch of several important global 
financial support initiatives. In 2002 the Global 
Fund to fight AIDS, TB, and Malaria was created 
to harness the world’s resources against three dis-
eases that plague Sub-Saharan Africa. Commit-
ments to Africa account for almost half of the 
fund’s $7 billion budget for its first five years. The 
overall level of aid to the region has also increased. 
Over the last decade bilateral and multilateral do-
nors combined have provided about $8 billion15 in 
aid to Sub-Saharan Africa. And during the 2005 
G8 summit in Gleneagles, members committed 
to double foreign aid by 2010, with an additional 
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$25 billion for Africa.16 Overall, approximately 
ten percent of Africa’s health care expenditure is 
financed directly by donor aid.17 
However, in spite of the influx of outside fi-
nancial assistance, most countries in the region 
still spend far less on health care than the recom-
mended WHO standard of $34–$40 per capita 
needed to provide essential health services.18 
Sub-Saharan Africa depends on out-of-pocket 
payments by its largely impoverished population 
to finance around half of its total health expendi-
ture.19 Further, the region generally lacks the 
infrastructure and facilities to provide and deliv-
er minimal levels of health goods and services. 
Even with an anticipated growth in public spend-
ing and external aid, Sub-Saharan Africa will not 
be able to fund basic health care for years to 
come.
The region’s health care gap is not only a ques-
tion of inadequate financial resources, but also a 
question of a severe shortage of trained medical 
personnel. Sub-Saharan Africa is home to just 
three percent of the world’s health workers yet it 
supplies health professionals to the developed 
world.20 In 2002 up to 30 percent of nurses from 
Senegal and Ghana21 were working outside Sub-
Saharan Africa. 
The	Need	for	Complementary	Solutions
The sheer size of the health care challenge facing 
Sub-Saharan Africa has forced a reassessment of 
traditional approaches to addressing its needs. 
Governments, multilateral agencies, and develop-
ment finance institutions throughout the region 
have begun to accept that engaging and develop-
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ing the private sector should be an important part 
of any overall strategy to improve health care.
This not particularly radical. Other countries 
have already embraced the private sector as a 
means of improving health care provision. In Bo-
livia,22 for example, the government has success-
fully utilized a non-profit primary care clinic net-
work (ProSalud) to deliver public health goals. 
ProSalud, founded in 1985, serves over 500,000 
patients in and around urban areas. New facilities 
are established in consultation with the govern-
ment. In 1994 ProSalud was able to expand 
significantly with the passage of the “Popular Par-
ticipation Law,” which eased restrictions on non-
governmental organizations receiving public sec-
tor contracts to deliver health services. In India, 
the private health sector has developed in a more 
haphazard and under-regulated environment and 
in response to an often inadequate public sector. 
The private sector now provides more than 80 
percent of outpatient services and 60 percent of 
inpatient services in that country.23 Even in China, 
the Vice-Minister of Finance has said that China 
will encourage investment from all sectors of soci-
ety, including the private sector, in order to ac-
complish the goals laid out in the Five Year Health 
Plan. That plan24 seeks to provide access to a basic 
medical network for the entire population by 
2010.
Sub-Saharan Africa already has a private sector 
that plays a major role in delivering positive health 
outcomes. Contrary to conventional wisdom, it 
does not serve only the urban upper- and middle-
classes, but also can be found in remote rural re-
gions and in the poorest sections of many cities. 
Though its importance varies from country to 
country, in many areas it is an indispensable part 
of the health care system, complementing and, in 
some cases, directly supporting the public sector. 
Market solutions alone, however, are no pana-
cea for Sub-Saharan Africa’s health challenges. 
The private sector is diverse and fragmented, and 
therefore, quality can be variable and oversight 
difficult. In the short term, rapid growth in the 
private sector may also exacerbate the shortage 
of qualified medical personnel working in the 
public sector by drawing them toward higher-
paying, for-profit activities. Ultimately, however, 
higher paying jobs will help stem the more in-
sidious “brain drain” where medical professionals 
leave their countries. Still, an appropriately man-
aged and regulated private sector can increase 
quality standards and efficiencies and take some 
of the financial burden off the public sector. 
Harnessing market forces to address the re-
gion’s health challenges will require increased 
engagement and stewardship from the public 
sector and other stakeholders. Investments in the 
private health sector can lead to long-term, sus-
tainable increases in funding and health infra-
structure. However, new thinking is required re-
garding how best to leverage the capacity and 
resources of the private sector through invest-
ment, partnerships, and public sector oversight. 
This report seeks to begin the process of de-
veloping those new approaches and has two pri-
mary objectives:
• To highlight the importance of the private 
health sector in Sub-Saharan Africa, suggesting 
ways in which key policy makers, donors, and 
other stakeholders can engage and develop it as 
a complement to over-stretched public sector 
health care systems; and
• To identify opportunities for investors to par-
ticipate in the expected growth in health care 
spending in Sub-Saharan Africa over the next 
decade.
While not seeking to detract from the role of 
national governments in delivering health care, 
this report aims to demonstrate that the health 
of the region’s inhabitants would be improved 
through a more formalized, integrated, regulat-
ed, and better capitalized private sector. 
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…the private health sector in Sub-Saharan Africa  
is surprisingly large and constitutes an important, 
diverse component of the region’s health care  
systems. Of total health expenditure of  
$16.7 billion in 2005, around 60 percent  
(predominantly out-of-pocket payments by  
individuals), was financed by private parties.  
Private providers captured about half  
of that total expenditure. 
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The vibrancy and positive contribution of the private sector to health care in Sub-Saharan Africa is very encouraging. Examples of pri-
vate sector participation—complementing and 
supplementing the public sector and improving 
quality, accessibility, and efficiency in health 
care—can be found throughout the region.
Reactions to the private sector among donors, 
ministries of health, and other public policy offi-
cials vary. Some know little about the sector, and 
some are ideologically opposed to its participation 
in health care, believing that the financing and 
provision of health care should be strictly within 
the public sector’s domain. Many others recognize 
its potential, but are suspicious of the profit mo-
tive and have legitimate concerns about consis-
tency of quality and the difficulty of regulating a 
diverse group of entities. 
The private sector already plays a major role in 
the financing and delivery of health care through-
out Sub-Saharan Africa. It is also clear that all fu-
ture scenarios for health care in the region will 
include a major role for the private sector. Signifi-
cant increases in demand for health care services 
are expected in many countries and, if the right 
environment is created, the private sector, work-
ing within a plural system, can significantly help 
to improve the scope, scale, quality, and efficiency 
of access to those services. 
This section of the report examines the role 
that the private sector plays in health care in the 
region today as well as its potential for growth.
The	Priate	Sector	Already	Plays		
an	Important	Role	in	Health	Care		
in	Sub-Saharan	Africa
Its size varies by country but the private health sec-
tor in Sub-Saharan Africa is surprisingly large and 
constitutes an important, diverse component of 
the region’s health care systems. It covers all of the 
elements along the health value chain, including 
provision, financing, manufacturing, distribution, 
and retail. Of total health expenditure of $16.7 bil-
lion in 2005,25 around 60 percent26 (predominant-
ly out-of-pocket payments by individuals), was fi-
nanced by private parties. Private providers 
captured about half of that total expenditure.27 
The share of the health care market held by the 
private sector varies widely across countries and 
regions based on a variety of political, historical, 
and economic factors. In some countries, includ-
ing Uganda and Ghana, private sector usage is 
over 60 percent, while in others, such as Namibia, 
it is less than ten percent. Figure 1.1 summarizes 
the self-reported usage of private sector health 
care for children across countries of the region. 
The formal element of the private sector con-
sists of a wide variety of non-public entities, in-
cluding commercial for-profit companies, non-
profits, and not-for-profit, or “social enterprises.” 
These three groups differ from one another along 
three criteria: their primary financial goal, their 
financing and capital sources, and their fees. These 
differences are summarized in Figure 1.2. 
In addition, there is an extensive informal 
health sector that includes traditional healers, 
midwives, and individual medicine sellers. While 
not the focus of this report, the informal sector is 
an important, if not well-documented, source of 
care, especially among rural and poor populations. 
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Zambia’s estimated 40,000 traditional healers, for 
example, garner approximately 60 percent of to-
tal household health spending,28 equivalent to 
roughly 13 percent of total spending on health 
care from all sources in that country. In a study of 
health care practice patterns among rural popula-
tions in Nigeria, 12 percent of initial visits to a 
provider were to traditional healers.29 Throughout 
this report, estimates for private sector participa-
tion in health care are based on national health 
accounts and include at least some portion—
which is likely to be an under-estimate—of this 
informal sector.
Finally, public health workers operating in the 
private sector are an important component of 
both the formal and informal segments. For ex-
ample, in Mozambique the vast majority of the 
850 public sector doctors also engage in part-time 
activities in private facilities.30 
Overall, for expenditures captured by private 
entities region-wide, for-profit providers garner 
about 65 percent, social enterprises 15 percent, 
non-profits ten percent, and traditional healers 
ten percent (Figure 1.3).31 
There	are	Concerns	with	the	Role	of	the	
Priate	Sector
When completing this research, many in the pub-
lic health community took the opportunity to 
make clear their opposition in principle to the in-
volvement of the private sector—particularly for-
profit entities—in health care. 
Even those not opposed in principle often crit-
icized the adverse societal impact the private sec-
tor can have on health care. They pointed to ex-
amples of poor quality, inefficiency, and a range of 
unethical business practices. 
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In Sub-Saharan Africa, the private sector is di-
verse and fragmented and, as a result, quality can 
be inconsistent and sometimes poor—even when 
intentions are good. These conditions, coupled 
with the lack of accreditation and a largely unin-
formed (and in some cases illiterate) population, 
have created an environment in which an unscru-
pulous minority can sometimes prevail over re-
sponsible providers.
While many private sector providers are hon-
est and well-intentioned, there are too many ex-
amples in which the pursuit of excessive profits 
leads to unethical business practices such as under- 
or over-servicing, collusion, false billing, price 
gouging, and unlicensed practice.32 The transgres-
sions of the less scrupulous minority reinforce gov-
ernments’ already deeply seated suspicions of the 
private sector in the provision of health care. And, 
just like their public sector counterparts, even re-
sponsible private health care providers sometimes 
fail to deliver an appropriate level of care.33, 34 
The region is also plagued by substandard drugs 
(often resulting from small, sub-scale manufactur-
ers without the skills, processes, and technologies 
required to produce to a higher standard) and 
counterfeit drugs (often linked to organized 
crime). Drugs with inadequate levels of active in-
gredient are all too common, and some have none 
at all. For example, in a study of 27 drugs on the 
WHO essential drug list from pharmacies in La-
gos and Abuja, 48 percent of samples did not 
comply with pharmacopeia standards for active 
ingredient content. For some drugs (metronida-
    Figure 1.2
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zole and pyrazinamide) no sample was found that 
met the standard.35 In another instance, a WHO 
survey of the quality of anti-malarials in seven 
Sub-Saharan African nations found that the ma-
jority of drugs in private facilities (pharmacies, 
drug shops, and street vendors) failed quality test-
ing. Specifically, 47 percent of chloroquine tablets 
failed content testing and 71 percent of sulpha-
doxine/pyrimethamine tablets failed dissolution 
testing.36 
In Sub-Saharan Africa, all people, including 
middle- and upper-income populations, suffer 
from the often poor quality of local medical pro-
viders and products. As is often the case world-
wide, however, the sins of the private sector fall 
disproportionately on the poor. Lower-income 
and/or rural populations, lacking the education, 
funds, or alternative options that would facilitate 
access to higher-quality providers, are most pro-
foundly affected by the failings of private health 
care in Sub-Saharan Africa. 
The poor and rural populations rely more heav-
ily on informal private sector providers, especially 
unregulated drug peddlers, while upper- and mid-
dle-class city dwellers benefit more often from 
higher-quality providers and facilities. In a survey 
of 1,594 people in four rural areas in southeast Ni-
geria, for example, 58 percent of those in the low-
est income quartile, in comparison to 42 percent 
of those in the highest, patronized either tradition-
al healers or medicine dealers.37, 38 And in a study 
of treatment provided by rural shopkeepers in Ke-
nya,39 only 3.7 percent of children received an ad-
equate dose of chloroquine for fever.
The private sector can also create headaches 
for governments. Aggravating an already worri-
some external “brain drain,” the diversion of 
trained health care personnel to local for-profit 
and non-profit private sector jobs is a major chal-
lenge for health officials struggling to staff public 
facilities.40 
Effectiely	Harnessing	the	Priate	
Sector	Can	Hae	Positie	Impact	on	
Health
While legitimate concerns about private sector 
participation in health care exist, the sheer size 
of the region’s health challenge has driven a 
growing realization—including among govern-
ments throughout the region—that engaging and 
developing the private sector should be an im-
portant part of the strategy to improve health 
care. By serving broad segments of the popula-
tion, increasing access, expanding the range of 
services and products available, and improving 
the quality of services, the private sector can 
have a positive impact on health and the quality 
of life in Sub-Saharan Africa.
The Private Sector Serves the Poor
Studies consistently show that the private sector 
cares for people from a wide distribution of in-
comes, including poor and rural populations. In 
Ethiopia, Kenya, Nigeria, and Uganda, more than 
40 percent of people in the lowest economic quin-
tile receive health care from private, for-profit pro-
viders (Figure 1.4). In addition, the portion of health 
care provided by informal health workers and tradi-
tional healers is significant. The private sector also 
has a broad geographic reach among rural popula-
tions. Based on self-reported usage, over 50 percent 
of the rural populations of Nigeria  and Uganda and 
use for-profit private providers (Figure 1.5). 
When the services of faith-based organizations 
and other non-profits are included, the coverage of 
poor and rural populations increases further. The 
Christian Health Association of Nigeria for exam-
ple, represents church medical institutions across 
the country, which serve about 40 percent of the 
population, targeting urban slums and poor rural 
areas. It works with state and local governments to 
provide low-cost medical goods and services. 
Surprisingly, in many Sub-Saharan African 
countries it is the wealthy, not the poor, who dis-
proportionately benefit from public health spend-
ing. For example, in Mauritania, 72 percent of hos-
pital subsidies benefit the richest 40 percent of the 
population. Figure 1.6 shows that in Ghana, one-
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third of public health spending benefits the richest 
quintile, while just 12 percent of public health 
spending goes to the poorest quintile. The num-
bers are similar for Tanzania.
A similar pattern holds true for government 
subsidies of rural and urban care. In 2002, al-
though more than three out of four Rwandans 
lived in rural areas, more than 80 percent of pub-
lic health care spending was directed to facilities 
in urban areas. 
The disproportionate benefit that higher-in-
come, urban populations have received from 
public spending can be explained in part by the 
high cost of operating specialized hospitals and 
teaching institutions, which are commonly lo-
cated in urban areas where higher-income popu-
lations are concentrated. The political activity of 
wealthier, urban populations has also helped to 
ensure that they are the beneficiaries of public 
health spending. 
Given the concentration of public health ser-
vices in urban areas, private sector providers (in-
cluding for-profit and social enterprises) are filling 
an important medical need using strategies that 
successfully target underserved, rural patient pop-
ulations. 
The Private Sector Can Increase the Scope and 
Scale of Service Offerings for Private and 
Public Patients
The private sector often provides services or prod-
ucts that might not otherwise be available. In Mo-
zambique, for example, the Ministry of Health 
recently purchased its first MRI machine. Previ-
ously, the only available machines were in private 
facilities. Even today, heart surgery is only avail-
able in Mozambique at the Instituto Do Coração, 
a non-profit cardiology and cardiac surgery facili-
ty. Again in Mozambique, Village Reach, a non-
profit organization with a mission of improving 
the coverage and quality of health systems in sus-
tainable ways, provides “last mile” distribution for 
vaccines to public rural clinics where public distri-
bution infrastructure does not exist. In Senegal, 
the only widely available health insurance prod-
uct besides the employer-based Institut de Pré-
voyance Maladie (IPM) is provided through com-
munity financing mechanisms characterized by 
voluntary membership and community involve-
ment in design and management of the scheme.
Even for services in which the public sector plays 
the dominant role, the private sector can ameliorate 
resource limitations that frequently constrain ca-
pacity. In Ghana, public nursing schools have the 
resources to accept only 40 to 50 percent of quali-
fied applicants in spite of a serious shortage of nurs-
es. Private initiatives are expected to help fill that 
gap. Although fees, at about $2,500 per year, will be 
close to 50 percent higher than at government insti-
tutions, private programs are projected to be well 
subscribed. Graduates can expect to find jobs im-
mediately that pay about $4,000 annually—enough 
to make the higher fees affordable. In Tanzania, Bu-
gando Medical School, an entirely private medical 
college operated by the Catholic Church, trains 30 
doctors a year. Bugando, Hubert Kairuki Memorial 
University (a for-profit institution), and one other 
private medical school account for over half41 of 
newly qualified doctors in Tanzania. 
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Opportunities also exist for the public sector to 
increase its capacity by contracting out either a 
discrete function or a set of services to competent 
private sector players. A frequently cited example 
of this approach is the contracting of nutrition ser-
vices in Senegal and Madagascar in the 1990s. The 
programs, which were run by NGOs, provided 
monthly growth monitoring, weekly nutrition ed-
ucation, food supplements for malnourished chil-
dren, and referrals to health services. They reached 
more than 450,000 women and children in each 
country, and in less than 18 months severe malnu-
trition among six- to 11-month-old children in 
Senegal dropped from six percent to zero. The re-
sults in Madagascar were also impressive, with the 
proportion of malnourished children dropping 
from 30 to ten percent.42 
The Private Sector Can Have a Positive Impact 
on the Quality of Care
Although many of the concerns that public sector 
officials express about the private sector are legiti-
mate, publicly provided care also often falls far short 
of acceptable standards.43 Even though it has a very 
high degree of variability overall, the private sector 
has a number of benefits: it often provides care of 
comparable quality to the public sector, it is fre-
quently preferred by patients, and in some notable 
cases, it is setting the benchmark for higher quality.
Patients choose private providers rather than 
their public counterparts for a variety of reasons. 
In private settings, caregivers are thought to have 
greater autonomy and flexibility, allowing them to 
respond more fully to patients’ needs and de-
mands. This perceived benefit can take many 
forms, including greater accessibility, flexible pay-
ment plans, continuity of care, metrics of per-
ceived quality (such as cleanliness, convenience, 
wait times, and friendliness) and availability of 
physician providers and pharmaceuticals.44, 45, 46, 47 
In many large cities, the private sector fre-
quently operates specialized facilities that pre-
dominantly serve the middle- and upper-classes. 
Their need to attract and retain a demanding and 
educated clientele means they must offer a higher 
level of services. In Lagos, Lagoon is one such pri-
vate tertiary hospital, with modern equipment 
that serves upper-middle-class patients who might 
otherwise travel abroad for care. Such entities can 
serve as a national benchmark for public and pri-
vate sector providers, raising expectations and 
benefiting the broader population. 
Beyond these high-end centers, private facili-
ties that serve the lower- and middle-classes can 
outperform the public sector on measures valued 
by patients, in part explaining their widespread 
use. One such example is R-Jolad Hospital, which 
opened in Lagos, Nigeria, in 1982 as a self-sustain-
able, physician-owned, full-service facility with a 
mission to “serve the masses.” 
Respondents from 18 Sub-Saharan African 
countries were significantly more satisfied with the 
skills, equipment, and drug supplies of private in- 
patient hospitals (Figure 1.7). And in a survey of 
rural farmers in Tanzania, more than two-thirds of 
respondents preferred private providers and drug 
dispensaries, citing convenience, courteous staff, and 
quality of care, among other benefits (Figure 1.8). 
Many of these patient-perceived benefits do 
not necessarily translate into higher standards of 
care or better health outcomes, but the private 
sector has the potential to achieve both through 
increased access to care and increased availability 
of pharmaceuticals and medical supplies. In 
R-Jolad	Hospital
Every day on a busy street in Lagos, over 200 men, women, and 
children walk through the doors of R-Jolad Hospital. From its be-
ginnings as a small, private clinic in 1982, R-Jolad has gradually 
expanded into a full-service 150-bed hospital. Dr. Oladipo found-
ed R-Jolad with the mission of serving the masses and has insti-
tuted a tiered fee structure that charges patients what they are 
able to pay, sometimes as low as $1 for a visit. This is important, 
as half the patients of R-Jolad earn less than $2 per day. However, 
according to patients, affordability is only part of the reason they 
choose R-Jolad when they’re sick. Say patients: “There is no wast-
ing of time”; “They are friendly and have qualified doctors”; 
“They have reliable drugs.”
The hospital has had good years and bad years financially, but 
has always been self-sustaining, and Dr. Oladipo “is commited to 
sticking it out.” Given his success, Dr. Oladipo is often asked 
about expanding further or opening a new facility, but he cites 
access to affordable financing as a barrier: “I don’t know where 
to get it.”
Source: McKinsey survey; country interview.
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Ghana, for example, of 39 sampled medicines used 
to treat acute and chronic diseases, the public sec-
tor had less than 50 percent availability for 27 of 
the medicines while the private retail sector had 
less than 50 percent availability for only six.48 
Local sourcing of generic drugs can reduce the 
long and costly lead times often associated with 
purchasing pharmaceuticals. In Mozambique, for 
example, an average of nine months elapses from 
the moment a public international tender is con-
cluded until medicines arrive in the country. By 
contrast, working with local product suppliers, Af-
fordable Medicines for Africa (AFMA) is able to 
fulfill an order in 28 days across Africa. One rea-
son AFMA is able to reduce lead times so dra-
matically is because their manufacturing partners 
are willing to fill order sizes that are smaller than 
most major offshore suppliers usually accept. The 
results of AFMA’s reduced lead times are less 
product obsolescence and lower inventory costs.
Priate	Sector	Health	Care	Will		
Grow	Substantially	in	Some	Markets
The story of stagnant economic growth in Sub-
Saharan Africa is well known. Over the last 20 
years, real GDP per capita growth in the region 
has been only 0.2 percent per year on average,49 
roughly 30 times slower than growth in Asia.50 
Growth in health care expenditure has been cor-
respondingly sluggish. 
However, that story has begun to change. Since 
2001, Africa’s GDP as a whole has grown annu-
ally at five percent—faster than the global average 
of 4.2 percent. The IMF expects this performance 
to continue for at least the next five years as Afri-
can growth climbs to a projected 5.6 percent. In 
some large Sub-Saharan population centers such 
as Nigeria, and post-conflict areas such as Angola 
and the Democratic Republic of Congo, GDP per 
capita growth has exceeded five percent for each 
of the last five years. 51, 52
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Consistent with international trends, this growth 
in GDP will drive a greater demand for health care 
and an increase in per capita expenditure on health 
related goods and services (see Figure 1.9). 
Based on projected economic and population 
growth rates, the health care expenditure in Sub-
Saharan Africa is expected to grow from $16.7 
billion in 2005 to $35 billion in 2016 (see Annex 
6 for details), an annual growth rate of 7.1 percent 
per annum (Figure 1.10). 
This report also estimates that around $25–$30 
billion in incremental investment will be required 
for the physical assets (hospitals, clinics, distribu-
tion warehouses, etc.) needed to meet this in-
creased demand over the next ten years.
   Figure 1.10
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Will governments in Sub-Saharan Africa be will-
ing and able to provide the investment required? 
Perhaps, but history suggests that the private sector 
has a major role to play. In 2000, 53 Sub-Saharan 
African heads of state pledged to allocate 15 per-
cent of their national budgets to health care. This 
pledge was reaffirmed in the Gaborone Declara-
tion during the October 2005 session of the Con-
ference of African Ministers of Health in Botswana. 
However, according to the latest available figures 
for 2003, only one country (Liberia) has reached 
this level of expenditure, while 33 countries have 
not even reached ten percent.
In select countries where the environment is 
favorable to private sector participation in health 
	 The Business of Health in Africa  ( 	
Health policy makers will have to recognize 
the reality that private sector entities have a sig-
nificant role to play in health care. Many have 
concerns about private sector involvement in this 
field, and governments and policy makers must 
ensure that the sector is properly regulated to 
achieve high-quality health outcomes. 
Similarly, governments needing the support of 
the private sector to fund the expected growth in 
health care demand must create an environment 
supportive of significant private sector investment. 
Conclusion
The private sector has a positive role to play with-
in the broader context of Sub-Saharan African 
countries’ health care systems by expanding ac-
cess and improving quality and efficiency. Gov-
ernments, donors, and others in the international 
community need to reconsider the role of private 
sector entities in health care and engage with the 
private sector as a necessary part of an overall 
strategy for improving health care.
The next section of this report highlights how 
legitimate concerns about the role of the private 
sector in health care can be ameliorated through 
appropriate oversight and regulation; it also dis-
cusses implications for governments and policy 
makers. 
care, this report estimates that private sector enti-
ties have the potential to deliver between 45 and 
70 percent of the needed increase in capacity. This 
should not be surprising. As noted earlier in this 
report, in other markets such as India the devel-
opment of health care has been heavily under-
written by the private sector, and in China the 
government has openly acknowledged the need 
for private sector investment to supplement the 
public sector in building health care capacity. 
Overall, it is expected that the private sector 
will grow faster than the public sector in the next 
decade (Figure 1.11), and will require investments 
in the range of $11–$20 billion over the same pe-
riod to sustain this growth. 
For health care companies looking for markets 
in which to expand, and for investors looking to 
invest in health care businesses, this $11–$20 bil-
lion in private health care expansion represents a 
significant opportunity. These investment oppor-
tunities, and the challenges involved, are explained 
further in Section III.
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In order for the private sector to  
fulfill its potential for improving and  
expanding health care in Sub-Saharan  
Africa, five main imperatives have been  
identified. Together these imperatives  
create an agenda for policy makers,  
regulators, donors, and other stakeholders,  
aimed at the improvement of health  
care provision in Sub-Saharan Africa. 
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When appropriately regulated, private sec-tor enterprises can stimulate higher ef-ficiency and quality standards by com-
peting with each other and by complementing, 
and also providing competition to, public sector 
providers. Even those with concerns about the 
private sector in health care are increasingly rec-
ognizing the important role it can play as part of 
an overall health system.
However, in order for the private sector to ful-
fill its potential for improving and expanding 
health care in Sub-Saharan Africa, its shortcom-
ings must be honestly confronted and addressed. 
Consumers and patients must have confidence in 
the price, quality, and value of the care and prod-
ucts they purchase from the private sector. 
Regulation and oversight are at the heart of ef-
fective, high-quality private sector involvement in 
health care. In the United States, for example, 
there is a comprehensive framework for the regu-
lation of health care delivery. For pharmaceutical 
products, the high levels of oversight provided by 
the U.S. Food and Drug Administration and the 
European Agency for the Evaluation of Medicinal 
Products (EMEA) have been an important factor 
underpinning the success of the multinational 
pharmaceutical industry. In Colombia, major 
health reforms were introduced through Law 100, 
which extends universal health coverage for pub-
lic and private health services. As part of this re-
form, the Colombian Ministry of Health estab-
lished a registration system and later the Unified 
Accreditation System to improve quality and reg-
ulate the growing private medical sector. 
Even initial efforts at enhanced and targeted 
regulation could have large and immediate bene-
fits for the private health care sector in Sub-Saha-
ran Africa. If governments can then couple in-
creased oversight with other efforts to stimulate 
development of companies with high-quality 
practices, the result could be a more substantial, 
more formally structured, less fragmented, and 
higher-quality private sector that could foster im-
proved health outcomes within a mixed public-
private model. 
From interviews conducted as a part of this 
work, many ideas were generated, particularly 
from private sector representatives for what gov-
ernments, policy advisors, donors and others could 
do to encourage the development of a responsible 
private health sector.
Five main imperatives have been distilled from 
this long list of specific ideas. Together these im-
peratives create an agenda for policy makers, reg-
ulators, donors, and other stakeholders, aimed at 
the improvement of health care provision in Sub-
Saharan Africa, including through the private sec-
tor. These priorities include:
1. Developing mechanisms for creating and en-
forcing quality standards for health services 
and medical product manufacturing and distri-
bution;
2. Including as many of the population as possible 
in risk pooling programs; 
3. Channeling a portion of public and donor funds 
through the private health sector;
4. Enacting local regulations that are more en-
couraging of a private health care sector; and
5. Improving access to capital, including by in-
creasing the ability of local financial institutions 
to support private health care enterprises.
Section II:  Actions Needed to Enhance the Private  
Sector’s Participation in Health Care
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To be effective, this agenda must be targeted at 
the local level with specific intervention strategies 
that take local situations into account. The re-
mainder of this section of this report explains 
those imperatives further.
.	Deelop	and	Enforce	Quality		
Standards	
The quality of health care in Sub-Saharan Africa 
is highly variable and in many cases clearly sub-
standard. Counterfeit and poor quality drugs, un-
trained and under-trained providers, unhygienic 
facilities, and inadequate supplies and equipment 
are commonplace in both the private and public 
sectors. 
The reasons for these shortcomings are many 
and varied. They include lack of resources, insuf-
ficient training, corruption, and technically inade-
quate, opaque, and inconsistently monitored or 
enforced regulatory standards. As in all countries, 
the asymmetry of information in health care be-
tween providers and patients makes consumers 
vulnerable to low-quality providers. In Sub-Saha-
ran Africa, this lack of knowledge is compounded 
by limited access to care for many of the most 
vulnerable populations.
Beyond the obvious impact on the health of 
the population, the lack of transparent and en-
forced quality standards is a major barrier to the 
development of a more formal and higher-quality 
private sector in health. Reputable providers may 
find that they cannot recover the costs required to 
provide high-quality products and services in a 
market where unscrupulous or less competent 
providers hold a competitive advantage. Investors 
do not want to be associated with potentially low-
quality health care provision.
In interviews with entrepreneurs and business 
operators, the need for clearer—and more clearly 
enforced—quality standards, together with ac-
creditation of quality providers, was one of the 
most commonly cited barriers to a more vibrant 
and sustainable private health care sector in Sub-
Saharan Africa.
Improving quality standards is easy to applaud 
but hard to achieve. A plethora of quality-enhanc-
ing ideas have been tried in a variety of settings,53,54 
but few have been systematically evaluated and 
then replicated on a larger scale. An effort to ana-
lyze attempted interventions for malaria drug sell-
ers is a welcome start and offers a useful overview 
of the range of potential actions that can help to 
improve quality (see Figure 2.1). 
 National governments interested in enhancing 
the private sector’s contribution to health care 
should look for new approaches to regulating the 
industry while also seeking to foster initiatives that 
promote transparency and help give patients a 
voice. All stakeholders should explore financial or 
technical means of supporting and piloting quality-
enhancing initiatives for health care products and 
services for both the public and private sectors. 
The most effective interventions are likely to 
be designed around local institutions and incen-
tives, and all stakeholders should try to build on 
efforts that are already working in a local context 
(many of them collaborative rather than state 
run). The suggested interventions below give a 
broad idea of what is needed, but in all cases the 
local situation must be considered carefully to 
avoid the risk that increased government inter-
vention might simply increase bureaucracy and 
transaction costs.
In pharmaceuticals and medical products, im-
proving quality will require stakeholder support to:
• Strengthen national drug regulatory authori-
ties. All stakeholders should explore financial 
and technical means to strengthen the capacity 
of national drug regulatory authorities. Such 
bodies can achieve noteworthy improvements 
in quality. For example, Nigeria’s official drug 
regulatory authority, NAFDAC, reports reduc-
ing the incidence of counterfeit products in 
Nigeria from 40 percent to 17 percent between 
2001 and 2006.55 Support is also needed to in-
troduce good manufacturing practice (GMP) 
standards, to develop and qualify bioequiva-
lence testing laboratories, and to establish and 
maintain drug registration standards.56 
• Increase regional collaboration, mutual recog-
nition, and harmonization of regulatory stan-
dards. Regional standards and processes for 
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drug registration facilitate the entry of larger 
manufacturers with higher-quality products 
and enable facilities such as bioequivalence 
laboratories to be leveraged across the region. 
Some efforts in this direction have been started 
by the Ministries of Health of the Economic 
Community of West African States (ECOW-
AS),57 but the lack of mutually recognized cen-
ters of excellence makes the task particularly 
complicated. The international community 
can assist both financially and technically to 
bring regulators together on a regional basis 
around a harmonization agenda.
• Strengthen inspection and enforcement of ex-
isting regulations. While most nations have 
policies that aim to safeguard the quality of 
goods delivered to the public, efforts to moni-
tor and enforce these regulations are often 
lacking.58 Potential mechanisms to enhance this 
aspect of quality oversight include: creation of 
independent or semi-independent inspection 
bodies; enhanced training and incentives for in-
spectors; conducting surprise (rather than 
planned) inspections and continuing inspec-
tions beyond initial licensing or accreditation; 
publication of inspection findings; and creation 
of mechanisms to enable anonymous reporting 
of violations.59, 60, 61 Concentrating on informal 
drug sellers and counterfeit drugs would have 
the greatest development impact given the 
poor’s reliance on these services.
• Educate patients and care providers. Govern-
ments and the international donor community 
can support and expand initiatives to educate 
patients—as well as employees of hospitals, 
clinics, and pharmacies—on how to avoid 
counterfeit drugs and the dangers of informal, 
unregulated drug sellers. For example, consum-
Figure 2.1 
• Public regulations and enforcement practices  
may be inappropriate or have unintended 
consequences and deserve analysis and reform.
• Lack of access to capital can be a significant 
barrier to investing in quality improvements.
• Public oversight is often inadequate to ensure  
a high standard of care.
• Community involvement and provider self-
regulation can provide additional needed capacity 
in terms of monitoring and supervision. 
 
• Previous education of health care providers (formal 
or informal) may be absent, inadequate, or 
inappropriate, leading to adverse outcomes.
• Efforts to help correct these deficiencies may 
promote quality improvements.
• Information asymmetry is a challenge across the 
health care industry.
• Using market-related tactics and public education 
can help guide consumers toward high-quality 
products/services.
* Framework based on literature review of tactics used to improve quality of services provided by drug-sellers for malaria in Sub-Saharan Africa. 
Source: Goodman, unpublished.
Interventions to improve quality of health care services in Sub-Saharan Africa* 
Demand 
generation
Rationale Sample interventions
Creating an 
enabling 
environment
Quality 
assurance
Training  
and capacity 
building
• Changes in policy and regulations (e.g., updated 
standards, decentralized enforcement).
• Credit facilities for facility operators. 
 
• Franchising and outlet accreditation.
• Community accountability (e.g., involvement  
of community organizations).
• Involvement of provider associations.
• Public monitoring and supervision.
• Distribution of pre-packaged drugs and pooled 
procurement.
• Formal education (e.g., workshops, courses).
• Peer and in-shop education.
• Use of job aids and supportive instructional materials. 
 
• Formal education (e.g., workshops, courses).
• Peer and in-shop education.
• Use of job aids and supportive instructional materials.
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er awareness campaigns conducted in rural 
Zambia between 2000 and 2001 that educated 
families about correct chloroquine dosing led 
to a 60 percent improvement in anti-malarial 
dosing.62 Other steps, including packaging, 
branding, and labeling initiatives (including use 
of prepackaged drugs), can further help pa-
tients and care providers to identify potentially 
low-quality counterfeits. 
Improving the overall quality of medical care pro-
vider facilities will be particularly difficult given 
the fragmented, widely distributed, and essentially 
local nature of health care provision and will re-
quire sustained effort and enhanced regulatory 
oversight. An engaged community and more em-
powered patients will be important drivers behind 
higher-quality care. The international community 
can provide both financial and technical assistance 
to establish and scale-up local and regional initia-
tives to: 
• Establish standards of care and build regula-
tory skills through, for example, organizing re-
gional forums to share best practices, evaluate 
existing quality initiatives, and learn from fail-
ures. Not all efforts to establish standards of 
care will be led by government regulators. For 
example, in Nigeria the private sector is leading 
the creation of the SQHN (Society for Quality 
Healthcare in Nigeria), an organization aimed 
at establishing quality standards and bench-
marks for HMOs.
• Strengthen inspection and enforcement of ex-
isting regulations. As described above for phar-
maceuticals and medical products, efforts to 
monitor and enforce existing regulations are of-
ten lacking. Mechanisms, such as creation of 
independent or semi-independent inspection 
bodies, enhanced training and incentives for in-
spectors, and surprise inspections apply also 
in health services. In addition, encouraging 
involvement of professional associations by 
conducting peer reviews and peer reporting, 
publishing inspection findings, and creating 
mechanisms to enable anonymous reporting of 
violations could also be valuable in the provider 
setting.63, 64, 65 
• Compile and publish clinical performance 
data for both private and public provider fa-
cilities. Sub-Saharan Africa is a long way from 
having the information technology infrastruc-
ture or the clinical data available to undertake 
the sophisticated “league table”-type perfor-
mance tracking that is seen, with mixed results, 
in both the United Kingdom’s National Health 
Service and in the United States. Nevertheless, 
some level of transparency on clinical perfor-
mance, combined with the availability of the 
results of, and lessons learned from, the various 
quality initiatives around the region, could be a 
powerful force to improve quality.
• Provide education and technical support to 
providers, including hospitals, clinics, and phar-
macies, to help them improve the quality of 
clinical care and meet established clinical care 
standards. Training is needed in both the formal 
and informal private sector. The quality of 
medical schools is uneven and public efforts to 
provide post-graduate training and continuing 
education often fail to include private provid-
ers.66 Additional training is even more impor-
tant in the informal sector. Informal sector par-
ticipants are less likely to have adequate levels 
of education to begin with, and the poor peo-
ple that they serve are at a disadvantage in 
terms of education and purchasing power; they 
are, therefore, especially at risk. Though debate 
surrounds the effectiveness of specific inter-
ventions, some programs have achieved notable 
results. A pilot in the Kilifi District of rural Ke-
nya, for example, found that efforts to educate 
shopkeepers and community members were 
effective in improving anti-malarial dosing in 
young children.67 
• Foster community involvement in provider 
facilities by, for example, establishing govern-
ing or quality oversight boards for private sec-
tor hospitals drawn from the local community.
• Encourage franchising of high-quality provider 
organizations and implement performance 
contracts with service providers to create more 
standard levels of quality throughout broader 
networks.
• Enable legal redress by patients and families 
for harm done to patients. Conceptually, this 
has some appeal as a way of putting pressure 
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on providers. India experimented with this ap-
proach in their Consumer Protection Act of 
1986, with some documented improvements 
in quality, but with rather mixed results over-
all.68 Given that only a small percentage of the 
population will have the education and funds 
necessary to pursue this course, and that a ro-
bust justice system is a prerequisite for this 
mechanism to have any effect, the applicability 
of this idea to improve health care quality in 
much of Sub-Saharan Africa is likely to be lim-
ited, at least in the near-term. 
.	Foster	Inclusion	in	Risk	Pooling	
Arrangements
Risk pooling arrangements—be they government-
funded National Payment schemes,69 commercial 
insurance, or community non-profit mutuelles—
are critical to driving sustainable improvement in 
health care provision in Sub-Saharan Africa. 
Risk pooling is widely regarded as a better and 
more equitable method for financing health care 
rather than the out-of-pocket payments on 
which most of the Sub-Saharan African popula-
tion currently depends. Further, risk pooling ar-
rangements—and their ability to contract with 
provider organizations for the provision of care—
are a powerful force to encourage the develop-
ment of higher-quality, more organized private 
sector providers. 
For donors, risk pooling arrangements provide 
a means to aid the poorest of the population (for 
example, by subsidizing coverage for these groups) 
while encouraging sustainable improvements in 
health care provision by allowing the private sec-
tor to care for those able to pay for their services. 
For example, the Health Insurance Fund is a 
Dutch NGO financed by the Dutch Ministry of 
Development Cooperation. In a pilot program it 
is beginning to replicate in other countries, it aims 
to extend coverage to 115,000 people in Nigeria, 
with an emphasis on those in Lagos and the rural 
Kwara State who are not formally employed. It is 
likely that these farmers, market women, and their 
families would not otherwise be able to obtain 
health insurance coverage. Nigeria is the first 
country to benefit from this program, while other 
countries in Sub-Saharan Africa will follow.
Developing and regulating “insurance” markets 
is complex, and implementation of national pay-
ment systems may be beyond the reach of many 
governments. Further, there are low national so-
cial cohesion patterns in parts of Africa, and this 
may compromise the willingness of groups to en-
ter into risk pooling arrangements. However, by 
developing consistent health-financing systems, 
local governments, donors, and the international 
technical assistance community can together help 
to significantly expand the number of people cov-
ered by risk pooling arrangements, with substan-
tial benefits to health care. 
Risk Pooling—a Superior Way to Pay for 
Health Care
Today, Sub-Saharan Africa depends on out-of-
pocket payments as a means of financing about 
half of total health expenditure, and in some 
countries—such as Burundi, Democratic Repub-
lic of Congo, and Guinea—they account for more 
than 75 percent.70 Out-of-pocket payments have 
many drawbacks: they are the most inequitable 
form of health care financing, the poor pay a dis-
proportionate share of their income, and there is 
no opportunity for cross-subsidization between 
rich and poor or between the healthy and the un-
healthy. 
From a public health perspective, out-of-pock-
et payments fail to promote utilization of health 
care services for early detection and treatment of 
disease. For patients, they do not provide financial 
protection against the costs of serious illness, and 
payment is required at the time that care is deliv-
ered—the time when, due to illness, the patient is 
least able to pay.
Financing primarily through out-of-pocket 
payments is also a significant barrier to the devel-
opment of a higher-quality, formalized private 
sector. For providers, payments are unpredictable, 
making business planning and forecasting difficult, 
increasing risk, and decreasing the appetite of in-
vestors. From an investor perspective, payments 
typically go to small, poorly organized providers 
that are often of substandard quality, rather than 
the formal, established providers more suitable 
for capitalization. 
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Risk pooling arrangements are widely recog-
nized as far superior to out-of-pocket payments.71 
For the general population, these arrangements 
provide financial risk protection and can help to 
promote equity through cross-subsidization. The 
timing of payment is uncoupled from the timing 
of care delivery, increasing the patient’s ability to 
pay. Unsurprisingly, there is evidence that such 
risk pooling arrangements promote utilization of 
services and a healthier population. Figure 2.2 de-
scribes a recently implemented insurance program 
for pregnant women in Mauritania and demon-
strates the potential positive effect of risk pooling 
on utilization patterns and health outcomes. 
As well as benefiting the patient, the expansion 
of the number of lives covered by risk pooling ar-
rangements is a potentially profound force in de-
veloping a more structured, and higher-quality 
service provider system.
Risk pooling arrangements often include orga-
nized “contracting” functions that purchase health 
care on behalf of the individuals covered. For pri-
vate sector insurers, these contracting groups tend 
to purchase health care from private sector pro-
viders. If properly structured and professionally 
managed, contracting for a sizeable population 
can lead to better scrutiny of quality, promote 
greater efficiency, and, importantly, achieve the 
scale needed to help capture efficiency gains and 
encourage the development of organized provider 
networks.
This dynamic of large-scale purchasing foster-
ing the development of organized provider net-
works applies to government-funded health plans 
as well as the private market. However, this ben-
efit of risk pooling cannot be realized under 
national health payment plans that restrict mem-
bers to using only public health facilities. In addi-
tion, the lack of private contracting risks perpetu-
ating poor health care access for rural populations 
in areas where public sector providers often do 
not exist. A case in point is Tanzania, where the 
    Figure 2.2
Mauritania: Flat-fee coverage for obstetric care
Appointment attendance
Percent
No insurance Insurance
For a ~$15 fee, patients receive pre-,
ante-, and post-natal care, including:
• Medical consultations
• Diagnostic testing
• Medications
• Education
• Necessary emergency care
• Initial vaccinations
Maternal mortality was 747
(per 100,000 births) for those
without insurance and 100 for
those with insurance
83
50
21
31
81
98
Laboratory
Echo
Consultants
Note: Scheme initially piloted in two regions (Sebkha and El Mina) in November 2002 and has since been rolled out in additional areas; 
enrollment rates during pilot period exceeded 60 percent.
Source: Country interviews; McKinsey analysis.
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national risk pooling arrangement covers civil ser-
vants. Although initially supportive, unions are 
now protesting the plan on behalf of teachers in 
rural areas who have contributions deducted au-
tomatically from their payroll but are unable to 
make use of their benefits because there are no 
local public providers of an acceptable quality.
Help Is Needed to Expand Risk Pooling  
Arrangements
Many forms of risk pooling already exist in Sub-
Saharan Africa, but they cover only a very small 
proportion of the population. In a study of 12 pri-
marily West African nations,72 only two percent of 
the population was enrolled in community insur-
ance plans. Figure 2.3 below shows how risk pool-
ing—whether in the form of government social 
security programs or private sector insurance—cur-
rently accounts for only a small proportion of total 
health expenditure in the majority of Sub-Saharan 
African countries. The use of risk pooling is low in 
almost all countries in the region, even when com-
pared to other health care markets that are still in 
the developmental stages (such as China). 
More governments are considering national 
health insurance schemes but, as the examples of 
both Kenya and Uganda show, launching these ini-
tiatives presents a number of formidable challenges 
    Figure 2.3
Social security* and private prepaid** health care spending, 2003
Percent of total expenditure
23.0
0
0.1
0.2
0.2
0.2
0.4
0.9
1.0
1.0
1.1
2.4
3.0
3.8
4.6
5.0
5.1
5.3
6.7
6.9
7.5
8.3
8.4
8.6
9.1
13.5
14.9
24.1
26.1
49.5
Cameroon
Uganda
Mozambique
Chad
Guinea
Ethiopia
Burkina Faso
Guinea-Bissau
Malawi
Gabon
Seychelles
Madagascar
Tanzania
Niger
Nigeria
Benin
Mauritius
Togo
Côte d’Ivoire
Kenya
Rwanda
Swaziland
Senegal
Botswana
Zimbabwe
Mali
China
Namibia
Cape Verde
South Africa
* Includes schemes that are mandatory and government-controlled.
** Includes private insurance schemes, private social insurance schemes, commercial and non-profit (mutual) insurance schemes, HMOs, and other agents  
managing prepaid medical and paramedical benefits.
Source: World Health Report, WHO 2006.
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• Public system funded by general revenues
• Attempt to achieve universal coverage but 
often lack sufficient allocated funds from 
general ledger to do so.
• Though equity is theoretically superior to 
other models, management and efficiency 
are often lacking, especially in those 
systems in which care is delivered through 
public providers. 
• Parastatal or independent, non-profit 
insurance fund financed primarily by govern-
ment-mandated payroll contributions.
• Coverage linked to paying population (the 
formally employed) though may attempt to 
be extended, often with difficulty, to others 
(e.g., unemployed, informally employed) . 
 
 
 
 
 
 
 
• Classically for-profit, voluntary schemes 
funded by non-income-based contributions 
of individuals or employers or supported by 
donors.
• May provide primary coverage or exist 
alongside public payer systems.
• Open competition affords efficiency gains 
but adverse selection by insurers and 
reliance on private contributions tend to 
limit access and equity in favor of the 
healthy and rich populations.
• As a variation of the model, large employers 
who otherwise would have purchased 
coverage from external private insurers may 
form their own risk pool and self-insure.
• Typically non-profit, voluntary community or 
employment-based risk pooling prepayment 
schemes.
• Community solidarity and control are key 
elements.
• Take a variety of forms, including micro-
insurance.
• Though they offer coverage to typically 
uninsured populations, small risk pools and 
low-income of enrolled populations limits 
protection and sustainability.
Source: Gottret, 2006; Atim, 1998; Ndiaye, 2007; country interviews.
Models of risk pooling in Sub-Saharan Africa
Community 
health insurance
  Sub-Saharan Non-Sub-Saharan  
 Key characteristics Africa examples Africa examples
State-funded 
systems
Social insurance 
systems
Private  
insurance
• Ghana (2004): National Health Insurance 
Scheme (est. 2004) is a mixture of a 
state-funded and social-security system.
• Supported by consumption and pension 
taxes.
• Currently covers ~38 percent of the 
population but aims for comprehensive 
coverage.
• Implemented through public and private 
community mutuelles and private plans.
• Kenya: System initially established in 
1966 as universal, state-funded system, 
but underwent major reform in 1998 to 
transition to a social insurance scheme 
with mandatory coverage of all 
employed populations and voluntary 
enrollment for others; current enrollment 
~1.6 million.
• Many recently legislated plans, including 
Tanzania (1999) and Nigeria (2006).
• Nigeria (2005): currently rolled out to 
civil servants, with plans to ultimately 
achieve universal coverage.
• Uganda is in the process of designing a 
social insurance program.
• Most nations have very few private 
insurers who cater to the wealthy or 
foreign populations.
• Plans are more widespread in Namibia 
and Zimbabwe, though still cover a 
relatively small share of the population 
(Zimbabwe: six percent in 2002).
• Also common in South Africa. 
 
 
 
 
 
 
 
• Increasing prevalence in much of  
West, Central, and East Africa; coverage 
still <five percent of the population.
• Plans in parts of East Africa (e.g., 
Rwanda, Tanzania) vary from the norm 
in that they are initiated by governments 
rather than communities.
• United Kingdom.
• New Zealand.
• Sweden.
 
 
 
 
 
 
 
• Common in 
European Union 
nations (e.g., 
Germany, France) 
and Latin America 
(e.g., Argentina). 
• Republic of Korea.
 
 
 
 
 
 
 
 
• Chile, Singapore, 
United States, 
Uruguay. 
 
 
 
 
 
 
 
 
 
 
 
• Common across 
much of Asia  
(e.g., Philippines) 
and Latin America 
(e.g., Mexico).
• Precursor to social 
insurance systems 
in Germany, 
Japan, and 
Republic of Korea.
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(see sidebar). In both countries the government 
faced significant opposition to the introduction of 
such plans. The opposition came from diverse sec-
tors of the community, but in both cases the lack of 
private sector participation was a rallying point.
 Beyond national payment schemes, private 
sector arrangements—whether for-profit insur-
ance or community-based mutuelles—will be un-
likely to develop effectively without support, in-
cluding technical assistance, to create the right 
conditions for expansion. 
The number of community health insurance 
schemes has risen dramatically in recent years. In 
West Africa, for example, where a majority of 
schemes are based, there were 76 functional plans 
in 1997 and 626 in 2006.73 However, many of 
these are small-scale and their sustainability is 
uncertain. Individual countries have established 
public entities, such as Senegal’s Cellule d’Appui 
au Financement de la Santé et au Partenariat, re-
sponsible for organizing and supporting these 
various schemes with the aim of making them vi-
able. Mali has a private technical institution 
(UTM) that develops tools to train people regard-
ing community risk pooling schemes and provides 
training to help establish such schemes, although 
its financing as an NGO is not assured. 
Cultural barriers to saving for future health 
care needs must also be overcome, and trust in the 
entities managing the funds, whether public or 
private, needs to be built. In both Uganda and Ke-
nya, one reason for the opposition to the intro-
duction of national health insurance schemes was 
a lack of trust and a concern about corruption in 
managing the fund. Trust in a mechanism to pay 
for risks in the future is further undermined in 
Sub-Saharan Africa due to ethnic diversity, low 
national social cohesion, and low levels of solidar-
ity/identification between social groups, as well as 
civil strife and conflict in some areas.
In addition, better data concerning popula-
tion, health, and costs are needed to control for 
risk, set premiums, track outcomes, and contract 
with providers. Many countries lack population 
registries or death registries, and health statistics 
are not detailed enough to allow for actuarial 
analysis. Within a fully public provider system 
there is no transparency regarding the cost of ser-
vices, but purchasing—rather than simply subsi-
dizing—health care requires knowing how much 
one will need to pay.
Regulations that treat HMOs in the same way 
as auto or life insurance, or even fee-for-service 
health insurance, significantly inhibit the devel-
opment of these types of plans. Because HMOs 
provide the insured with services themselves, 
they tend to have far greater control over costs 
than traditional insurers—yet in many countries 
they are grouped with other insurers and are re-
quired to have the same minimum capitalization. 
In interviews conducted for this report with in-
surers, HMO executives, and entrepreneurs, cap-
italization requirements were cited as a signifi-
cant barrier to entering the market in Sub-Saharan 
Africa.
Finally, anything governments and external 
stakeholders can do to directly foster the develop-
Over the last several years, a number of nations in Sub-Saharan 
Africa have sought to develop national or social health insurance 
schemes but have faced objections from various interest groups 
regarding specific aspects of the plans’ designs:
• In Uganda, the government is in the process of establishing a 
social health insurance scheme. Though theoretically support-
ive of attempts to provide risk pooling and health care cover-
age to the population, a variety of employer associations, in-
surance companies, and private providers have joined forces to 
lobby against the government’s proposal that it manage and 
administer the plan. In response, the government is evaluating 
the potential solutions in which private sector players would 
have a role in managing the fund.
• Kenya’s government has similarly struggled with civil servant 
unions that object to their medical allowances being used as 
contributions to the social insurance scheme. A wide range of 
industry associations and trade and civil servant unions have 
raised other concerns. Beyond fears of under-representation, 
corruption, and inefficiency and debates over premium contri-
butions, stakeholders have also pointed to insufficient private 
sector participation for both insurers and providers, though 
the government provided assurances that the program’s ben-
eficiaries would be free to use accredited private sector provid-
ers (reimbursed at lower mission/public rates) and that insurers 
would be free to provide supplemental or complementary cov-
erage to those interested. 
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ment of organized, high-quality private sector 
provider networks would, in turn, benefit the ex-
pansion of large-scale private sector risk pooling 
arrangements. The extreme fragmentation among 
private sector providers today is, in itself, a barrier 
to entry for large-scale risk pooling entities. To op-
erate effectively, such entities need to drive effi-
ciency through their health purchasing, something 
which is difficult to do until consolidation into 
networks has commenced.
Agenda for Action
There is much that local governments, donors, 
and the international community can do to ex-
pand the number of individuals covered by risk 
pooling arrangements in Sub-Saharan Africa. 
Governments can:
• Develop coherent health financing systems 
that include the best mix of possible risk pool-
ing mechanisms (national payment plans as 
well as community and private plans);
• Allow private sector participation in national 
health payment plans, both by contracting with 
private care providers and sourcing some ad-
ministrative and other fund-management ac-
tivities from the private sector;
• Develop the capacity to promote, implement, 
and monitor community risk pooling schemes;
• Create incentives for people to enroll in private 
or community insurance where consistent with 
a coherent health financing system;
• Develop and make available to the private sec-
tor demographic and health data;
• Create health-specific capitalization require-
ments for HMO-style insurers; and
• Establish entities to support the develop- 
ment and expansion of community insurance 
schemes.
Donors can: 
• Channel some of their aid through private, 
public or community risk pooling organiza-
tions, for example, in the form of premium 
subsidies to expand coverage to the poorest 
members of the population. 
The International Community can:
• Support governments in developing the often 
complex regulatory frameworks required for 
effective operation of private sector risk pool-
ing arrangements; 
• Assist donors in designing aid approaches that 
help overcome cultural barriers to saving and 
insurance and encourage individual participa-
tion in risk pooling arrangements; and
• Develop in-field research to study the impacts 
of different plans on health outcomes, health-
system efficiency, and quality, in order to iden-
tify best practices and learn from failures.
.	Channel	Public	and	Donor	Funds	
Through	the	Priate	Health	Sector	
Risk pooling is just one way in which the public 
sector and/or donors can leverage the private sec-
tor to improve access to and quality of care. There 
are other mechanisms, which are explained below, 
which involve channeling some public or donor 
funds through the private sector to provide a base 
level of stable income so private sector entities 
can expand.
Governments
Around the world, governments are increasingly 
looking to leverage the capabilities of the private 
sector to meet public needs, and this is now as true 
in health care as it is in more traditional infrastruc-
ture such as transportation and energy. The evi-
dence—though not extensive—suggests that such 
arrangements for health care can have a positive 
impact. In a 2005 study74 of private sector con-
tracting arrangements in developing countries (in-
cluding one in Sub-Saharan Africa), the private 
sector performed better in terms of quality and 
coverage and in many cases provided services that 
were less expensive than the equivalent govern-
ment services.
Public and private sectors can work together in 
a wide variety of ways, as summarized in Figure 
2.4. Although, at present, very few of these ideas 
have been tried in Sub-Saharan African health care, 
there are some interesting examples represented—
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such as one in Lesotho—that could serve as models 
for others (see sidebar on page 28). 
There are many reasons why the private sector 
is not more extensively involved in public health 
priorities in Sub-Saharan Africa:
• Many governments do not have the capacity or 
capability to effectively procure, price, super-
vise, evaluate, or manage private sector con-
tractors;
• Many policy makers are unaware of the bene-
fits of partnering with the private sector or 
have an ideological opposition to private sector 
involvement in health care;
• Some countries have only limited private sec-
tor capacity and, where the private sector mar-
ket is small, prices are often high due to lack of 
competition; and
• Existing laws and regulations may make it diffi-
cult to reduce current public sector staff and re-
place them with private sector equivalents—even 
where hiring private contractors to handle ser-
vices such as cleaning, security, transportation, 
and catering would be far more cost-effective.
These barriers will not be easy to overcome, 
but governments could start immediately by ex-
amining their attitude towards private sector in-
volvement in health care and, importantly, articu-
    Figure 2.4
Source: Framework adapted from Marek, 2003; USAID, 2006; Loevinson, 2003; Harding, 2003.
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• Purchase of supplies or equipment from external private sources (e.g., 
NGOs, private clinics, etc.).
• Funds channeled to the private sector in exchange for provision of a 
single concrete episode of care, effectively subsidizing service provision 
(e.g., grants to NGOs for HIV/AIDS care, voucher schemes for maternal 
check-ups).
• Private sector delivers a defined set of services for public facilities, e.g.,
– Non-clinical support services (e.g., housekeeping, maintenance, 
catering, transportation, security, laundry, etc.)
– Ancillary clinical services (e.g., laboratory, radiology)
– Core clinical services (e.g., surgery, reproductive health care)
– Third-party administration
• Private sector delivers a set of predefined services for the public sector 
within private settings (e.g., immunization programs, nutrition programs, 
and consumer education campaigns).
• Private sector assumes management responsibilities (e.g., staffing and 
labor, supplies, ongoing training) for public facilities.
• Temporary operation and management of public facilities by private 
sector players; the private sector bears all risk and retains any profits, but 
does not enjoy ownership of facilities.
• Private sector provides capital investment for new or existing facilities 
and transfers ownership to the public sector after a specified period of 
time (e.g., build-operate-transfer).
• Sale of a public facility to the private sector (e.g., build-own-operate-
transfer) for ongoing operations and ownership.
Potential interactions between public and private health sectors
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lating where they would like to see it involved and 
what they plan to do to encourage participation in 
those areas. This level of transparency would help 
private sector organizations—and their inves-
tors—prioritize their efforts towards those coun-
tries and areas where the government is willing to 
engage them as partners in the development of 
health care services.
Donors
Although most donor resources for health in 
Sub-Saharan Africa are channelled through the 
public rather than the private sector (Figure 2.5), 
the breakdown varies a great deal by country.
In addition to variations between countries re-
garding where donors channel their resources, 
there are other differences in funding patterns. 
These differences correlate closely with donor 
size. Larger donors, including the major multilat-
eral and bilateral organizations and financing ve-
hicles, typically target the majority of their funds 
to the public sector, supplementing health and 
finance ministry budgets in individual Sub-Saha-
ran African countries. Two notable exceptions 
are the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR), which allocates large 
sums to the private sector for distribution of an-
tiretroviral drugs, and the Global Fund to Fight 
AIDS, TB, and Malaria (GFATM), which allows 
private sector enterprises to qualify as funding 
recipients. Other exceptions to this pattern in-
clude governments regarded as too corrupt, in-
competent, or distracted to handle international 
aid. In those cases donors have been known to 
channel a larger proportion of their money 
through the private sector (typically through 
NGOs). 
On the other hand smaller donors, which are 
usually dominated by private foundations and 
faith-based organizations, dedicate the majority 
(if not the entirety) of their funds to the private 
sector. They tend, however, to focus their dona-
tions on directly supporting private sector pro-
vider organizations (typically non-profit entities) 
rather than expanding the ability of the poor to 
pay for health care, for example, by subsidizing 
their participation in insurance or other risk pool-
ing mechanisms. 
With the exception of the distribution sub-sec-
tor, for-profit entities rarely participate in donor-
funded activities. Only in distribution is it com-
mon to see for-profit companies play a prominent 
role in such activities. For example, South Africa’s 
Fuel, Senegal’s Universat Logistics Company, and 
Kenya’s Shely’s Pharmaceuticals, Ltd., distribute 
medications, insecticide-treated malaria nets, and 
condoms for a small mark-up fee to end-users on 
behalf of donors and multilaterals. 
Given that some countries are believed to be 
reaching their absorptive capacity for additional 
donor funds, and that the private sector can be an 
efficient, equitable, and high-quality provider of 
health care services, the international community 
should consider:
• Earmarking a higher proportion of aid to fund 
private sector entities, particularly those that, 
increase the ability of the poor to pay for health 
care and, in so doing, foster the development of 
high-quality providers; 
• “Blending” aid money with some commercial 
financing in order to create and expand more 
sustainable private sector entities including 
health care social enterprises;
• Assisting local governments in expanding their 
ability to manage procurement and contracts 
with the private sector; and
A demonstration of the potential for broader engagement be-
tween the public and private sector is underway at the Queen 
Elizabeth Hospital in Lesotho. The Advisory Services Group of IFC 
is working with the government of Lesotho to contract the con-
struction and management of a 400-bed hospital and two associ-
ated clinics to the private sector. Historically, the private sector has 
been reluctant to bid for public management contracts in Sub-
Saharan Africa (outside of South Africa) because of two factors: 
1) the size of the facility may not be large enough to secure suf-
ficient financial interest; and 2) the risk that the government will 
not pay for the services rendered. Both of these risks are being 
addressed in this example. Expected annual turnover of the facil-
ity is in the range of $18–$20 million, which has garnered interest 
from a number of South African based operators. Secondly, the 
Lesotho government has been bonded by a partial risk guarantee 
from the World Bank, which guarantees the private sector pro-
vider payment through a unitary payment scheme over 17 years. 
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• Ways to reduce the risk for private sector enti-
ties in contracting with governments (as in the 
Lesotho example).
Employers
Because the formal economy remains small in 
Sub-Saharan Africa, employers tend to play a very 
limited role in total health expenditure, ranging 
from two percent in Kenya to 11 percent in Zam-
bia. When employers do participate in the health 
care system, their involvement can be both direct 
(operating their own clinics, for example) and in-
direct (purchasing health care services for their 
employees). Due to a growing awareness of corpo-
rate social responsibility, some companies have be-
gun to participate even more broadly. For example, 
in Ghana, AngloGold is financing and implement-
ing a malaria control program for its own workers 
and the communities in which they live.75 Several 
similar initiatives—such as the malaria control 
program of BHP Billiton in Mozambique76 and the 
HIV/AIDS monitoring and treatment program of 
Coca Cola,77 also in Mozambique—are present 
across Sub-Saharan Africa. When private sector 
employers do participate in health care provision, 
the private health sector is the recipient of the 
vast majority of the funds expended (Figure 2.6). 
Thus, employers, including multinationals, can 
clearly help the development of the local private 
health care sector by outsourcing the provision of 
health care for their employees. For example, 
Shell Nigeria, which traditionally managed its 
own clinics, is now in the process of contracting 
out services to a local integrated delivery network, 
an action that will help to build local capacity and 
broadly benefit the surrounding community.
.	Ensure	That	Local	Policies	and		
Regulations	Embrace	and	Foster		
the	Role	of	the	Priate	Sector
The ways in which local policies and regulations 
impede the development of the private sector in 
health care are myriad and often unintended. 
Modifying these policies and regulations can pro-
vide a rich opportunity for governments that are 
seeking to support the mobilization of a socially 
responsible private health care sector.
    Figure 2.5
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Detailed below are some of the more common-
ly encountered opportunities for reforms that 
would allow governments to either “get out of the 
way” or to actively create an enabling environment 
for private sector participation.
Cumbersome and Bureaucratic Regulatory 
Processes 
As is extensively described in the World Bank’s an-
nual Doing Business report, costly, slow and need-
lessly complex registration processes can impede 
new entrants in any business sector and choke off 
the growth of existing businesses. Interviews with 
health care business people for this report also 
highlighted a number of specific issues relating to 
the establishment of sound health care enterprises 
and access to quality drugs. In addition to address-
ing the need for accepted and enforced quality 
standards and HMO-specific capitalization rules 
(both already described elsewhere in this section), 
governments should seek opportunities to:
• Liberalize pharmacy chain ownership regula-
tions in order to allow development of chains 
and price competition. For example, in Senegal 
pharmacists can only own one pharmacy be-
cause the law requires them to be constantly 
present in their outlet. Similarly, diagnostic labs 
are limited in their development by the fact 
that only holders of a degree in biology can be 
equity holders in such businesses;
• Build regional credential recognition programs 
that will allow an easier flow of health care staff 
and providers between neighboring countries—
and allow local staff who have been trained 
overseas to return;
• Streamline the application processes for the es-
tablishment of country-specific health care 
non-profit organizations; and
• Develop common regional drug registration re-
quirements. For example, the Food and Drug 
Administration bodies of Ghana and Nigeria 
have started to cooperate informally so that 
when a drug is approved in one country, the 
approval process in the other country takes that 
approval into account.
Policies on Human Resources for Health 
There is a human resources crisis facing the health 
care sector in Sub-Saharan Africa, a crisis that acts 
as a major impediment to the development of 
health care in the region for both the public and 
the private sectors. The shortage of staff in public 
sector health care explains much of the reluctance 
expressed by public officials to support the growth 
of private sector providers who could lure away 
valuable staff. 
   Figure 2.6
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A case in point is Mozambique. With only 850 
physicians available to serve a population of 19 
million, health ministry officials are understand-
ably critical of for-profit and non-profit private op-
erations which attract scarce qualified staff away 
from public service positions. Similarly, in efforts 
to boost the provision of care for HIV/AIDS pa-
tients, some donors are competing with each other 
to attract medical staff to their programs, offering 
additional grants and more attractive benefits as 
incentives. 
It is therefore not surprising that many govern-
ments have regulations that require physicians, or 
at least some physicians, as well as nurses and 
pharmacists to practice only within the public sec-
tor. It is also clear that there are risks associated 
with dual (public and private) practice by health 
care professionals. Misappropriation of scarce pub-
lic resources (e.g., use of facilities and drugs), di-
version of patients away from public services,78 
reduced quality of care, and increased waiting 
times in the public sector are some of the more 
obvious possible concerns. 
Allowing part-time or after-hours private prac-
tice can, however, have benefits. Public sector wait-
ing times can be reduced, since patients who are 
willing and able to pay for their own care can be 
treated after hours; allowing health care profes-
sionals to supplement their incomes may enable 
the government to avoid losing skilled health 
workers; and formalizing the “dual practice” ap-
proach may help decrease the system of “unoffi-
cial” payments that is widespread in the public sec-
tor in many countries.
In Tanzania, ten to 15 percent of graduating 
doctors emigrate or leave medical practice and 
nurses commonly work in second jobs outside 
health care (typically in agriculture) in order to in-
crease their income. These figures demonstrate 
that permitting health care providers to supple-
ment their income by also working in the private 
sector health care market would be a more benefi-
cial approach than restricting work to the public 
sector market.
Therefore, although well-intentioned, regula-
tions that restrict the ability of health care profes-
sionals to participate in the private sector can have 
the perverse effect of exacerbating the human re-
source shortage in health care without producing 
any obvious benefits to the public sector. That said, 
governments’ ability to enforce these regulations 
appears limited, and many professionals do work 
actively in both sectors despite regulations forbid-
ding them to do so. For example, in Tanzania, 60 to 
80 percent of doctors employed in the public sec-
tor moonlight.79 And in Zambia, though junior 
doctors who work in the public sector are banned 
from also working in the private sector, it is com-
mon knowledge that many do so anyway.80 
Governments should consider:
• Re-examining health care staffing policies—
particularly those that restrict provider partici-
pation in the private sector, with an eye toward 
removing or modifying those policies that have 
had unintended and negative consequences. 
Policies that allow for the “safety valve” of pri-
vate sector participation and include controls 
concerning misappropriation of public funds 
are likely to have a positive impact on availabil-
ity of human resources for both the public and 
private sectors. For example, policies that allow 
public sector doctors to practice privately, per-
haps even using public facilities in exchange for 
a fee, will help to keep those doctors in the 
country and working in the health sector, and 
• Mobilizing the private sector to help meet hu-
man resource needs by allowing and, when pos-
sible, encouraging private sector training for 
health care professionals, including health care 
managers. For example, in Dakar, 150 out of 
250 nursing graduates each year are trained in 
one of the city’s 13 private nursing schools.
Tariffs and Other Barriers to Trade 
Policies that impede access to health supplies, or 
raise their cost, are a major concern for private 
businesses and patients alike. Burdensome customs 
processes often cause lengthy port delays that in-
crease costs to consumers. In some countries, tar-
iffs and import fees on medical goods are far more 
costly than those for non-health-related products. 
In Kenya, import agent fees, port and clearance 
charges, and import declaration fees account for 
21 percent of the final retail price of a typical med-
icine. Similarly, ten percent of private sector retail 
prices in Ethiopia, and 12 percent in Ghana, are 
attributable to non-freight costs of importation.81 
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Though these taxes raise public revenue and may 
encourage local manufacturing, they also raise 
drug costs, thus decreasing access to necessary 
treatments and supplies.
Non-customs regulations can also increase the 
cost of doing business for private sector enterprises 
and complicate access to affordable products. In 
Senegal, the fixed percentage-based product mark-
ups at pharmacies (23 percent) undermine retail-
ers’ incentive to substitute lower-cost generic 
equivalents for higher-priced brand-name drugs. 
In addition, inter-country differences in regula-
tions governing the transport and sale of medical 
products can disrupt established retail and distri-
bution patterns. This disharmony most severely 
limits product availability in the poorest countries, 
since producers may not be motivated to over-
come the import challenges of markets they regard 
as insufficiently profitable. 
In theory many of these regulations exist to 
support local manufacturers. However, in reality 
the benefit of such trade barriers does not bear up 
under closer inspection. In Nigeria and Ghana, im-
port barriers for selected products may protect the 
local pharmaceutical industry in the short-term, 
but in the long-term they limit incentives for qual-
ity improvements by reducing competition with 
foreign companies. In the Democratic Republic of 
Congo, while customs rates for final products and 
active pharmaceutical ingredients (API), are the 
same, taxes on packaging material exceed these 
rates. Because local material suitable for drug pack-
aging is largely unavailable, the effective tax rate 
for local formulations is higher than that for im-
ported products. 
In South Africa, a public tender system designed 
to support local industry often produces the op-
posite outcome. Out of ten total points, four are 
awarded to local suppliers, but these points are not 
weighted according to local value contribution. As 
a result, a small subsidiary of a foreign company 
with minimal local sourcing can achieve the same 
rating as a large local manufacturer that adds sig-
nificant value to the national economy. 
Governments should consider: 
• Taking a more nuanced view of import barriers. 
For example, when a government is aiming to 
support the development of the local pharma-
ceutical manufacturing industry, it should con-
sider also the downstream impact on health 
care of reduced competition from imported 
products. Under certain circumstances, authori-
ties should reduce barriers to importing health 
care products, particularly for those categories 
of products where local players don’t have the 
capabilities or the potential to develop a com-
petitive cost position; and
• Examining how customs clearance and other 
cargo-handling activities for health care prod-
ucts can be accelerated.
.	Improe	the	Ability	of	Local	Financial	
Institutions	to	Support	Health	Care	
Enterprises
A prime cause of the fragmented nature of the pri-
vate health care sector in Sub-Saharan Africa (as 
discussed in previous parts of this report) is the 
difficulty entrepreneurs and business operators 
face in securing financing from established finan-
cial institutions to expand their businesses or start 
new ones. This lack of access to formal financing is 
not unique to the private health care sector. Less 
than 25 percent of people living in developing 
countries have access to formal financial services. 
(By contrast, 90 percent of the residents of indus-
trialized nations have access to such services.82) 
Health care businesses in Sub-Saharan Africa 
tend to be small- and medium-sized enterprises 
(SMEs), and lack of access to capital is even more 
acute for SMEs. According to the 2005 World 
Bank’s World Development Report, small firms ob-
tain five percent of their financing through banks, 
while large firms rely on banks for 22 percent of 
financing needs. 
Limited lender experience and expertise is a 
part of the problem. While some investors have 
found success in the sector—local banks in Kenya, 
for example, originated over $30 million in health 
care loans in 2006 and are actively seeking addi-
tional investments83—a lack of banking know-how 
regarding SME lending combined with a lack of 
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knowledge about the health care sector, in general, 
leads to a perception of greater risk when evaluat-
ing loans to health care companies. Exacerbating 
the problem is that many health-related businesses 
are ill-equipped to provide the sort of financial in-
formation required by formal lenders. The result-
ing opacity of these businesses helps create the 
perception that SMEs are high-risk borrowers. 
The lack, or high cost, of financing has resulted 
in the continued fragmentation of the health care 
industry in Sub-Saharan Africa. That, in turn, 
causes inefficiency in operations due to lost econo-
mies of scale in procurement, systems, staffing, 
marketing, distribution, and administration. 
To tackle the problem, central banks and nation-
al governments in the region could consider man-
dating the expansion of bank lending to SMEs. In 
Nigeria, the central bank requires all Nigerian banks 
to set aside ten percent of their after-tax profit for 
equity investment in and the promotion of SMEs. 
Interventions of this kind, however, need to be 
carefully designed and monitored so as not to intro-
duce unintended distortions and incentives into 
the financial system.
The international community can take several 
steps to improve the availability of debt and equity 
financing to private sector health care entrepre-
neurs in Sub-Saharan Africa, such as:
• Educate local banks about the health care sec-
tor. Stakeholders such as development finance 
institutions (DFIs), bilateral donors, NGOs, and 
central banks should invest in technical assis-
tance education and training programs for local 
financial institutions, or at a minimum, should 
ensure that technical assistance is an element of 
existing financial sector programs. Training 
should focus on health care-specific risk assess-
ment, loan origination, and adaptation of lend-
ing products, with an eye toward development 
of sustainable capacity in health care expertise 
within institutions; 
• Encourage local banks and financial institu-
tions to lend to health care SMEs. A second 
cause of limited health care portfolios is a lack 
of long-term liquidity within local financial in-
stitutions. Investors should work with local 
banks to negotiate and invest in lines of credit, 
risk-sharing programs, guarantee facilities, or 
subsidized lending terms for health care specific 
portfolios. More immediately, bilateral and mul-
tilateral donors, foundations, and DFIs can 
channel investment through the small number 
of existing SME financiers, such as Business 
Partners and GroFin; and
• Develop equity-focused financing vehicles for 
health care enterprises. International stakehold-
ers should prioritize the development of equi-
ty-focused financing vehicles that can provide 
long-term capital to private sector health care 
businesses without the pressure of short-term 
returns on interest payments. Similarly, inves-
tors—such as DFIs, foundations, bilateral and 
multilateral donors—should be willing to col-
laborate to provide “patient capital” to catalyze 
entrepreneurial action and accelerate the 
growth of health care enterprises across Sub-
Saharan Africa.
Conclusion
Local governments, donors, and other stakeholders 
can all take action to mobilize and expand a high-
quality private health care sector in Sub-Saharan 
Africa, thereby improving health systems overall. 
Specific solutions will vary greatly depending on 
the local political and social context, the effective-
ness of local regulatory institutions, and the cur-
rent level of development of the formal private 
sector in health care. However, five imperatives—
developing and enhancing quality standards; in-
creasing the use of risk pooling arrangements; 
channeling more public and donor funds to pri-
vate sector entities; creating a regulatory frame-
work that is encouraging of private sector partici-
pation; and improving the ability of local financial 
institutions to support private sector health care 
enterprises—are common elements that stake-
holders need to emphasize.
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Political stability has dramatically improved in  
Sub-Saharan Africa in recent years. Concurrent  
with the increasing political stability is an  
improvement in the macroeconomic environment  
of Sub-Saharan Africa. Sub-Saharan Africa has  
achieved an average annual GDP growth rate  
of five percent over the last seven years, and this 
growth rate is forecast to increase throughout  
the remainder of this decade.
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Section III: The Case for Investing in the Private 
Health Care Sector in Sub-Saharan Africa
The poor investment climate in Sub-Saharan Africa has long discouraged entrepreneurs and investors. But today, numerous indicators, 
point to the development of a more attractive in-
vestment climate. This include dramatic increases 
in foreign direct and private equity investment and 
significant gains in stock market indices across the 
continent. To date, health care has not been a ma-
jor beneficiary of these positive investment trends. 
In spite of an oft-stated interest in investing in 
health care, most capital has instead gone into tele-
communications, financial services, oil, minerals, 
mining, and infrastructure.
This section of the report reviews the improve-
ments underway in Sub-Saharan Africa’s invest-
ment climate and summarizes the challenges par-
ticular to the health care sector. It also provides an 
assessment of the magnitude of health care invest-
ment opportunities available and highlights some 
potentially attractive health care business models 
for different types of investors. More detail on 
these business models, including case studies, are 
also provided in the Annexes to this report.
The	Inestment	Climate	in	Sub-Saharan	
Africa	is	Improing	Significantly
Political stability has dramatically improved in 
Sub-Saharan Africa in recent years, as Figure 3.1 
shows. The likelihood of continued stability has 
been strengthened by progress in establishing more 
resilient democratic structures and processes.
 According to the political freedom rating sys-
tem maintained by the U.S.-based non-profit orga-
nization Freedom House, over the past ten years 
three countries in the region have moved from 
“partly free” to “free,” and eight countries have 
moved from “not free” to “partly free”.84 In only 
three cases (Eritrea, Malawi, and Zimbabwe) have 
political freedom and civil liberties decreased. 
Corruption is still a major obstacle to invest-
ment, and the prospects for systemic reforms that 
could counter it vary considerably across the re-
gion. The institutions responsible for providing 
checks and balances across Sub-Saharan Africa 
generally lack both resources and political clout. 
New organizations, such as the Mo Ibrahim Foun-
dation, are raising awareness of good governance 
by providing a quantified list of Sub-Saharan 
countries ranked according to quality of gover-
nance. These organizations also raise awareness of 
the problem by conferring awards for excellence.85 
Civil society is also increasingly active and outspo-
ken concerning governance issues and corruption. 
Media in many Sub-Saharan African countries are 
independent and critical, and corruption is in-
creasingly debated publicly.
Concurrent with the increasing political stabil-
ity is an improvement in the macroeconomic en-
vironment of Sub-Saharan Africa. Sub-Saharan 
Africa has achieved an average annual GDP 
growth rate of five percent over the last seven 
years, and this growth rate is forecast to increase 
throughout the remainder of this decade. Over 
the same period, average inflation has dropped 
from 16 percent to less than eight percent. For 
many countries, these continental averages actu-
ally mask an even more compelling story. The 
combination of stable growth and reduced infla-
tion has been one of the most compelling macro-
economic factors influencing a positive invest-
ment climate.86, 87
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These improved political and macroeconomic 
developments have created an improved business 
environment. In 2007, according to the World 
Bank’s annual Doing Business report, Africa ranked 
third in the world (trailing only the Eastern Eu-
rope-Central Asia group and the OECD countries) 
in the pace of economic reform. In 2006, two-
thirds of Sub-Saharan African countries made at 
least one significant economic reform, and Tanza-
nia and Ghana ranked among the top ten reformers 
worldwide. Some countries have set ambitious 
goals. Mauritius, for example, wants to be a top ten 
worldwide country by 2009 when it comes to ease 
of doing business.88 
A concrete measure of the improving invest-
ment climate in Sub-Saharan Africa can be seen 
in the changing financial landscape in the region, 
especially in the rapid increase in the role of 
stock exchanges. In 1993 only ten stock exchang-
es operated in Sub-Saharan Africa, with a market 
capitalization of $175 billion. Today 19 stock ex-
changes are open for business, listing a total of 
about 800 companies, with a total market capi-
talization of about $1 trillion. The largest of these 
is Johannesburg (accounting for around $800 
billion of market capitalization), while start-ups 
like Uganda and Cameroon account for just un-
der $3 billion each.89 
Sub-Saharan African companies such as cable 
television network M-Net and beer giant SAB 
Miller have achieved impressive growth over the 
past ten years. The most notable case may be the 
incredible expansion of MTN, the South African 
cellular network operator, which has expanded 
throughout the continent and across all sectors of 
society.
Foreign investors have taken note of these 
changes. The net inflow of foreign investment in-
creased from $6 billion in 2000 to $18 billion in 
2005—an increase from less than one half of one 
percent to around two percent of global foreign 
investment.90 Close to half of the world’s major 
investment groups now express interest in the re-
gion,91 and several (including JP Morgan, Citibank, 
and AIG) have established specialized funds to 
focus on it. Large development finance institu-
tions such as IFC, FMO,92 DEG,93 NORFUND,94 
and OPIC95 have begun to focus on investment in 
Sub-Saharan Africa, and several of these are com-
mitting upwards of 20 percent of their portfolios 
   Figure 3.1
Indices of war and political conflict, Sub-Saharan Africa, 1994–2004
Percent
0
5
10
15
20
25
2000 20041994
Political instability
Wars
Source: International Monetary Fund.
	 The Business of Health in Africa  ( 	
to the region. Private equity flows to Sub-Saharan 
Africa have increased from a little under $100 
million in 2001 to over 2.3 billion in 2006. 
Figure 3.2 summarizes some of these positive 
changes in the investment landscape.
Health	Care	Represents	a		
Significant	Inestment	Opportunity	
Current consumer demand for health care ser-
vices continues to be unmet in most Sub-Saharan 
African countries. For example, every year 18,500 
wealthy Nigerians travel abroad to seek medical 
care.96 This supply gap applies to Sub-Saharan 
Africans with closer to average incomes as well. In 
Kenya at least five percent of the total stated de-
mand for health care is not satisfied due to limited 
access to services and products.97 Informal anec-
dotes gathered in the course of preparing this re-
port suggest that unsatisfied demand for health 
care is probably much higher.
As described earlier, in 14 Sub-Saharan African 
countries real GDP per capita has increased by 
more than five percent per annum for the past five 
years and is projected to grow at a similar rate for 
the next ten years. Increased incomes are already 
creating new opportunities. For example, Bridge 
Clinic, an ISO-certified facility in Lagos, Nigeria, 
that specializes in in-vitro fertilization, is planning 
to open a second location (in Port Harcourt) 
   Figure 3.2
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because it believes there will be sufficient patients 
in that area with the financial means to afford its 
services. The Reddington Hospital, also in Lagos, 
started in 2003 as a cardiac center to provide more 
affordable care for cardiac-related disorders that 
previously required treatment abroad. 
Further economic growth will fuel still greater 
demand for health care—and a greater need for 
capital investment in health care businesses to 
meet those demands. Merrill Lynch recently 
named health care as one of the top five sectors for 
investment in Africa, higher than infrastructure.98 
The biggest individual investment opportuni-
ties over the next decade will be found in building 
and improving the sector’s physical capacity. 
Around 550,000–650,000 additional hospital 
beds must be added to the existing base of 
850,000. An additional 90,000 physicians, about 
500,000 nurses, and 300,000 community health 
workers will be required over and above the num-
bers that will graduate from existing medical col-
leges and training institutions. Adding the demand 
for better distribution and retail systems and the 
need for pharmaceutical and medical supply 
production facilities to these numbers yields an 
estimate of $11–$20 billion in new investment 
needed by 2016. (See Annex 6 for details con-
cerning the methodology used to arrive at these 
amounts.) 
Health care provision accounts for roughly half 
of the current investment opportunity, with the 
remainder split across distribution and retail, 
pharmaceutical and medical product manufactur-
ing, insurance, and medical education. About 60 
percent of these opportunities could attract for-
profit investors, the remaining portion being 
equally spread between social enterprises and 
non-profit organizations (Figure 3.3).
The uses of investment funds will typically in-
clude refurbishment of existing assets, working 
capital increases, expansion of current capacity, 
service/product portfolio expansion, and new 
ventures. Expanding current capacity is the most 
common use of the projected investment across 
all sub-sectors. Working-capital funding is most 
relevant for distribution and retail enterprises, 
while financing for service and product-line ex-
pansion is needed primarily among insurance and 
manufacturing companies. 
Almost a quarter of these investment opportu-
nities are expected to have a project size larger 
than $3 million, a sum that is the typical mini-
mum threshold for direct investment by the tradi-
tional private equity players and large multilateral 
banks that have entered the region so far. The vast 
majority of investment opportunities (outside of 
the manufacturing sector) will be in SMEs, and 
some will require financing below $250,000. 
Innoatie	Business	Models	Can		
Delier	Returns	and	Significant		
Deelopment	Impact
The landscape of private health care in Sub-Saha-
ran Africa is as diverse as that of the continent it-
self. This report explores five different sub-sectors: 
health services provision, risk pooling, life scienc-
es, distribution and retail, and medical education. 
Together these sub-sectors represent an estimated 
cumulative investment opportunity for the pri-
vate sector of between $11–$20 billion over the 
next ten years. Each sub-sector provides its own 
unique range of financial and developmental op-
portunities. 
As private investors survey the health care 
landscape in Sub-Saharan Africa, they will find a 
confluence of sustained industry growth and op-
portunities for consolidation. These investors 
should prioritize the development of equity-fo-
cused financing vehicles that can provide long-
term capital without the pressure for early returns 
or interest payments to private sector health care 
businesses. 
“Angel” investors will find opportunities to en-
gage with some of the most innovative social en-
terprises in the world—enterprises that rely on 
new technology, experimental human resource 
approaches, or innovative business models. Invest-
ment in the region can deliver strong financial re-
turns while also addressing some of the most 
pressing health care needs in the world.
Investors who are interested in both financial 
returns and development impact (such as DFIs 
and foundations) should be willing to collaborate 
	 The Business of Health in Africa  ( 	
to provide “patient capital” willing to seek returns 
over the longer term. This approach is expected to 
provide financial returns as well as accelerate ac-
cess to health-related goods and services across 
Sub-Saharan Africa. 
Finally, donors have a key role to play, using 
subsidized investments to finance those opportu-
nities that are not quite financially viable but that 
show crucial promise in the development of a 
sustainable, high-quality, and responsible private 
health sector in Sub-Saharan Africa. 
Just as there is no single kind of investor, there 
is no single best investment opportunity. Howev-
er, given the breadth and diversity of the private 
health care landscape in Sub-Saharan Africa, in-
vestors should be able to find an opportunity that 
is right for their individual needs and goals. 
The five sub-sectors and their key segments are 
illustrated in Figure 3.4 along the dimensions of 
financial viability, individual project size, and total 
market opportunity. It is important to stress that 
this illustration (as well as those that follow it for 
each sub-sector) represents the range of well-op-
erated businesses and organizations observed dur-
ing the development of this report. They are in-
tended to give a sense of the opportunities 
available and to illustrate the main differences be-
tween the sub-sectors. Individual enterprises that 
fall outside the ranges shown are also likely exist, 
but the volume of available opportunities outside 
of these ranges is not expected to be significant. 
Each of these sub-sectors is explored in more 
depth below. An even fuller description of each 
(including market trends, successful business 
models, and case studies) can be found in An-
nexes 1–5. 
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Provision
As discussed earlier in this report, provision is the 
largest private health care segment in Sub-Saha-
ran Africa and holds significant potential for finan-
cial returns and development impact. The private 
sector share of provision varies significantly by 
country, and this variation is primarily driven by 
individual government perspectives on the role 
that should be played by paid health care services. 
Regardless of the social and political context, over 
time the limited capability of the public sector to 
fully satisfy the anticipated continued rapid in-
crease in demand is expected to drive an increase 
in the private sector’s share in most countries. 
The majority of private health care provision is 
for-profit. Within provision, business models typi-
cally fall into four broad categories: inpatient care 
(including primary care), outpatient care, preven-
tative care, and diagnostic services. Inpatient care 
is by far the largest of these categories in financial 
terms, at 65 percent of total provision expendi-
ture. Specific investment models within these four 
segments are illustrated below (Figure 3.5). 
High-end clinics that target growing middle- 
and upper-income populations in urban centers 
can deliver net profits of up to 30 percent. These 
clinics provide the high-quality care that attracts 
patients and the well-equipped environment that 
attracts medical and nursing staff. An expected in-
crease in the number of patients able to afford 
these services, as well as increasing acceptance of 
local treatment among patients, makes prospects 
for growth impressive. Examples include the Tan-
zania Heart Institute in Dar es Salaam, Lagoon 
Hospital in Lagos, Bridge Clinic in Abuja, and 
Nyaho Medical Clinic in Ghana.
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Investment opportunities in private health care in Sub-Saharan Africa
Not viable
High
Low
Viable ongoing
operations (i.e.,
not including
setup cost)
Fully viable
$0.25–1m $0–0.25m $1–3m
Fi
n
an
ci
al
 v
ia
b
ili
ty
Individual deal sizeSmall Large
Size indicates relative 
size of total market 
opportunity
Health services
provision—Inpatient
>$3m
Health services
provision—
Prevention
Pharmaceuticals
and medical
products
Health services
provision—
Outpatient
Medical
and nursing
education
Retail
Health services 
provision—Diagnostic 
services
Distribution
Risk pooling
Note: Chart is illustrative and represents the range of well-operated businesses and organizations observed during the development of this 
report. Intended to provide overview of the opportunities available and the differences between the sub-sectors. Individual enterprises may 
fall outside the ranges shown.
Source: McKinsey analysis.
	 The Business of Health in Africa  ( 	
At the other end of the spectrum are high-vol-
ume, low-cost hospitals. These tend to be located in 
high-density areas and target low-income groups 
requiring basic medical care. Since the services avail-
able are limited, patient throughput is extremely 
high (up to 100 patients per day per doctor). A 
typical revenue range for such businesses is $1–$5 
million per year. Examples include R-Jolad Hospital 
in Nigeria, Selien Hospital in Tanzania and the 
Nsambya Hospital in Uganda. Because they provide 
health services to a very large population, these hos-
pitals have significant development impact. Addi-
tionally, the high productivity of their medical per-
sonnel helps to make the services affordable.
These examples of both high-end clinics and 
high-volume, low-cost hospitals are only two of 
the many promising investment models to be 
found in this sub-sector. Figure 3.6 provides a 
brief description of some other possibilities. A 
more comprehensive description of opportunities 
in provision, including further detail on each of 
the models below and specific case examples, can 
be found in Annex 1. 
Risk pooling
As discussed in Section II, risk pooling mechanisms 
are critical to driving sustainable improvement in 
health care provision in Sub-Saharan Africa. Risk 
pooling is a better way to pay for health care than 
the out-of-pocket payment systems on which most 
of the Sub-Saharan African population currently 
depends. Further, because they are able to contract 
directly with provider organizations, risk pooling 
arrangements are a powerful force for encouraging 
the development of higher-quality, better orga-
nized private sector providers. 
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Risk pooling can take many forms. It is still in 
its nascent stages in Sub-Saharan Africa, but evi-
dence exists of its appeal. Private insurance ac-
counts for 20–30 percent of health care expendi-
ture in Namibia. In West and East Africa, there are 
as many as 600 distinct community-based health 
insurance schemes, covering over 1.5 million peo-
ple. Nigeria recently approved a compulsory na-
tional health insurance scheme for civil servants 
and the formal sector that is to be implemented 
by private enterprises with the goal of eventually 
extending coverage to the entire population. 
Overall, risk pooling arrangements are expected 
to present a $1.4–$2.5 billion investment oppor-
tunities in Sub-Saharan Africa over the next ten 
years. 
Specific investment models within risk pooling 
are illustrated in Figure 3.7. 
Integrated HMOs, which typically provide ba-
sic insurance coverage coupled with selected pre-
ferred providers, are currently emerging through-
out the region. These usually involve a capitation 
model or in-house provision of care. By provid-
ing in-house health services (generally primary 
care), these HMOs can control claims costs and 
fraud more efficiently. Although cost contain-
ment can make insurance affordable, the main 
development impact is the creation of incentives 
to catalyze the development of a larger provider 
network. Currently this model is best developed 
in Namibia, Nigeria, and Zimbabwe. 
    Figure 3.6
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Microinsurance is still rare across Sub-Saharan 
Africa. However, creating incentives for custom-
ers to buy health insurance packaged with tradi-
tional microfinance products could spur the 
growth of this market and extend health care cov-
erage within poorer segments of society and rural 
populations. Plans including basic coverage for 
common or catastrophic conditions could be sold 
by microfinance corporations and linked to prod-
ucts like loans. While current examples of such 
models in Sub-Saharan Africa are primarily social 
enterprises accepting below-commercial returns, 
Grameen’s experience in Bangladesh suggests that 
margins can be high. 
Figure 3.8 provides a brief description of busi-
ness models in this sub-sector. A fuller description 
of the opportunities available, including further 
detail on the business models and specific case ex-
amples, can be found in Annex 2.
Life sciences
Overall, life sciences represent a $1.6–$2.9 billion 
investment opportunity over the next ten years, 
with the largest segment being generic manufac-
turing. The four life science segments explored in 
this report are generic drug manufacturing, medi-
cal supplies manufacturing, infectious disease in-
novation (based outside of Sub-Saharan Africa), 
and South African-based life sciences innovation. 
Of note, the majority of investment opportunities 
in life sciences are expected to be in excess of $3 
million, significantly higher than the smaller-scale 
projects that are more common in the other sub-
sectors. 
The estimated 2006 pharmaceutical market in 
Sub-Saharan Africa was $3.8 billion, but local 
manufacturers account for only 25–30 percent of 
that. Medical supplies and devices account for an 
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additional $2.1 billion, but less than ten percent 
of that is locally produced. 
Specific investment models in life sciences are 
illustrated in Figure 3.9 
More than 70 percent of Sub-Saharan Africa’s 
estimated $1 billion in annual pharmaceutical 
production is concentrated in South Africa, 
where Aspen Pharmacare, the only vertically in-
tegrated manufacturer in the region, is the clear 
leader. Together Nigeria, Ghana, and Kenya rep-
resent about 20 percent of Sub-Saharan Africa’s 
pharmaceutical production. Overall, 37 Sub-Sa-
haran African countries have some pharmaceuti-
cal production. Local manufacturers currently 
capture only a small share of the donor market in 
Sub-Saharan Africa (estimated to amount to a 
total between $750 million and $1 billion), pri-
marily because donors require product prequali-
fication from more stringent regulatory bodies 
like the WHO or the United States Food and 
Drug Administration. As of April 2007, only two 
Sub-Saharan African manufacturers99 had WHO 
prequalified products. 
It is important to note that Sub-Saharan Afri-
can manufacturers generally produce at a cost 
disadvantage to large Asian generic manufactur-
ers due to a variety of factors, including scale, an 
expensive asset base coupled with older technol-
ogy, higher financing costs, and lack of integra-
tion with API production. Despite this cost dis-
advantage, Sub-Saharan African manufacturers 
sold $1 billion of generic pharmaceuticals in the 
region last year.100 There is mixed evidence re-
garding whether or not local production is pref-
erable to importation. A 2003 WHO study of 
anti-malarials, for example, found no consistent 
quality differences between locally produced 
and imported products.101
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Figure 3.10 provides a brief description of in-
vestment models in life sciences. A fuller descrip-
tion of possible opportunities, including further 
detail regarding these models and specific case ex-
amples, can be found in Annex 3.
Distribution and retail
Distribution and retail represents a $1.6–$2.8 bil-
lion investment opportunity for the next ten years, 
with 80 percent of the investment potential to be 
found in the development of distribution infra-
structure (warehouses, trucks, supply chain man-
agement information systems, etc.). The retail 
sector, while significantly smaller, is the most prof-
itable segment within health care across most of 
Sub-Saharan Africa, with net margins of up to 50 
percent. Across Sub-Saharan Africa, hospitals and 
clinics often depend on their pharmacies to cross-
subsidize their businesses. For example, in one Ke-
nyan outpatient clinic, 70 percent of the clinic’s 
profit came from its pharmacy. 
The counterfeit drugs epidemic (and the health 
risks they represent) in Sub-Saharan Africa makes 
distribution and retail extremely sensitive compo-
nents of the health care sector. In Kenya, a survey 
by the National Quality Control Laboratories 
(NQCL) and the Pharmacy and Poisons Board and 
based on a random sample of 116 anti-malarial 
products found that almost 30 percent of those 
drugs in the country were counterfeit.102 One of 
the factors allowing for the prevalence of counter-
feit products is the often enormously fragmented 
supply chain that feeds both the public and pri-
vate sectors. In Uganda there are over 100 official-
ly registered importers/distributors, and 12–14 
“industry leaders.” In Nigeria, there are 292 licensed 
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medical importers and 724 licensed medical dis-
tributors. One leading manufacturer reported sup-
plying a complex network of more than 100 out-
sourced or owned distributors. 
Specific investment models in distribution and 
retail are illustrated in Figure 3.11. 
Aside from pharmacies attached to public hos-
pitals and clinics, most formal outlets are private, 
single-outlet operations. For example, over 1,500 
retail outlets are legally registered with the Phar-
macists Council of Nigeria, but the only retail 
chain is Mediplus, with ten outlets. This situation 
offers significant opportunities for consolidation. 
In South Africa, where retail margins have been 
stringently regulated in recent years, the sector is 
shifting rapidly toward major chains, which com-
pensate for lower margins with volume. Although 
there are only a handful of pharmacy chains in the 
remainder of Sub-Saharan Africa, those that do 
exist are extremely successful, in some cases show-
ing growth rates of over 100 percent a year. This 
opportunity varies significantly by country due to 
government regulations that restrict the develop-
ment of pharmacy chains in many areas.
Given the relatively low volume of medical 
products that flow through formal distribution in 
some countries, successful distribution companies 
have chosen to operate across sectors, delivering 
soft drinks and consumer goods as well as phar-
maceuticals. Though these distribution approach-
es have limitations for some categories of product 
(for example, vaccines requiring temperature-
controlled distribution), they are adequate for the 
vast majority of over-the-counter medicines. These 
are often the products with the lowest margins, 
and, therefore, they benefit the most from a lower-
cost, shared transportation platform. Depending 
on the region in which they operate, businesses of 
this kind can have from $1–$15 million in annual 
revenues. Because they increase the accessibility 
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and availability of drugs, the development impact 
of investing in such models is significant. By en-
abling low-volume distribution of pharmaceuti-
cals, these models also reduce both stock-outs and 
obsolescence. 
Figure 3.12 provides a brief description of sev-
eral possible investment models in distribution 
and retail. A fuller description of the opportuni-
ties, including further detail on the models and 
specific case examples, can be found in Annex 4. 
Medical and nursing education
As mentioned in Section II, Sub-Saharan Africa 
has the lowest availability of qualified health care 
human resources in the world. This situation has 
seen little improvement in the last 40 years. (In 
comparison, countries like India and Morocco 
have seen physician and nurse densities increase 
by 200 to 400 percent). Unfortunately the exist-
ing capacity for medical and nursing education 
remains woefully inadequate across many emerg-
ing economies. The WHO estimates that the larg-
est relative shortage in health service staff (doc-
tors, nurses and midwives) is in Sub-Saharan 
Africa where an increase in the order of 140% is 
required to meet the threshold standard per 1,000 
population.
The availability of skilled human resources is 
one of the most significant barriers to the growth 
of health care provision across Sub-Saharan Afri-
ca. The estimated shortage of health care profes-
sionals is in the order of 4.3 million globally with 
an uneven distribution between geographic and 
economic regions. Therefore, the development 
impact of expanding the capacity for medical and 
nursing training institutions is clearly significant. 
In many countries in Sub-Saharan Africa, pub-
lic teaching institutions for health professionals 
   Figure 3.11
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Source: McKinsey analysis.
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are oversubscribed by students possessing the re-
quired entry qualifications. For example, in Ghana 
public nursing schools have the capacity to accept 
only 40 to 50 percent of qualified applicants—de-
spite a serious shortage of nurses. Research under-
taken for the WHO in 2006 indicates that the 
African Region has the lowest number of profes-
sional training institutions for medical education 
(66 as compared to the next lowest region of the 
Eastern Mediterranean with 137 and the Ameri-
cas with 441). The African Region also has the 
second lowest density of nursing and midwifery 
training institutions with just 288 (compared to 
1,338 in the Europe Region).
The World Health Report 2006 suggests that 
there has been significant growth in private sector 
provision, albeit from a very low base. Neverthe-
less, the role of the private sector in the African 
Region has been limited to date.  
There are a number of reasons for this includ-
ing:
• government regulations which have tradition-
ally restricted the role of the private sector in 
medical and nursing education;
• the difficulties facing potential schools in part-
nering with approved local teaching hospitals, 
which are usually public institutions;
• the high capital investment costs relating to 
medical education; and 
• in some cases, the limited spending power of 
potential students.  
Evidence from developing countries elsewhere 
(e.g., in Egypt and India) indicates that private 
medical and nursing schools can be financially vi-
able—and that they can play an important role in 
the supply of qualified health care staff.  
   Figure 3.12
Promising investment opportunities in retail and distribution
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• Serves as a platform for expanding
reach of drug outlets to rural regions. 
• Efficiency gains allow for lower prices
and increased affordability.
• Mediplus (Nigeria), Vine
Pharmacy (Uganda).
• 0.5–3.0 • 0.3–1.0
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• Significantly increases access to essential 
drugs in remote regions.
• ADDO (Tanzania). • 0.3–2.0 • 0.3–1.0
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system.
• Increases access to drugs in 
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• PHD (South Africa), MDS
Logistics (Nigeria).
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Source: Country interviews; McKinsey analysis.
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Countries like Ghana, Senegal, Tanzania, and 
Uganda, tend have more open policies regarding 
the participation of the private sector in educa-
tion, and therefore may be best suited to the de-
velopment of private sector models for profes-
sional health education.  
In the short term, nursing schools would ap-
pear to offer the more attractive investment op-
portunity—as regulations tend to be less restric-
tive than medical schools, and set-up costs are 
lower, thus leading to more affordable courses. For 
example, private institutions in Ghana currently 
charge about $2,500 for annual tuition—repre-
senting a 50 percent premium over government 
schools. Still, such fees are low enough that the 
potential wages offered by local employers can 
quickly pay off the debt. In countries with more 
restrictive regulations the provision of specialist 
or post-graduate nursing courses may offer an 
early opportunity—as regulations tend to affect 
undergraduate courses.
Private medical and nursing education could 
represent a total investment opportunity of $1.1 
to $1.9 billion over the next decade. Medical edu-
cation in particular is asset intensive and it is like-
ly that more than half of the potential investments 
would require more than $3 million. Considering 
the barriers to entry, established private hospitals 
which can achieve local accreditation as training 
institutions are clearly best suited to take advan-
tage of such opportunities. Of course, private hos-
pitals around the world commonly establish pri-
vate training institutions, especially for nursing 
staff, in order to source qualified staff for their 
own needs.
Specific investment models in medical and 
nursing education are illustrated in Figure 3.13. 
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Figure 3.14 provides a brief description of some 
existing models in medical and nursing education 
in Sub-Saharan Africa. A fuller description of op-
portunities, including further detail on these mod-
els and specific case examples, is available in An-
nex 5. 
Conclusion
The sheer size of the health care challenges facing 
Sub-Saharan Africa often obscures the remark-
able opportunities that lie beneath the daunting 
statistics. 
Improved political and economic conditions 
across Sub-Saharan Africa are creating new in-
vestment opportunities and growing economies in 
the region will create increasing demand for health 
care goods and services. 
   Figure 3.14
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addresses the critical reason for
resource shortage. 
• Hubert Kairuki (Tanzania). • 1.0–5.0 • 2.0–10.0
Schools for 
nurses, midwives, 
lab technicians
• Expands the overall capacity 
of the health care system 
within a country.
• Institut Santé Service (Senegal).
• Central University College
(Ghana).*
• 0.3–2.0 • 0.3–2.0
Distance learning 
for nurses
• Provides access to education 
to students in rural areas and
helps them avoid the cost of
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* Medical education program planned to be launched in September 2007.
 Source: Country interviews; McKinsey analysis.
Of the estimated $11–$20 billion in private in-
vestment needed to meet health care demand 
over the next decade, health care provision ac-
counts for roughly half, with the remainder split 
across distribution and retail, pharmaceutical and 
medical product manufacturing, risk pooling, and 
medical education. About half of these invest-
ments will be attractive to fully for-profit entities, 
the remaining portion of private sector invest-
ment being equally spread between social enter-
prises and NGOs. 
The unfulfilled economic potential in health 
care means that with relatively minor policy and 
attitudinal changes potential investors of all kinds 
will find numerous opportunities to reap returns. 
Just as importantly, those changes and the result-
ing investments will have a transformational im-
pact on the development of the region and the 
health of its people.
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Conclusion
As much as $30 billion in new investment over the next decade will be required to meet the region’s health care demands, and up to two-thirds of that may have 
to come from the private sector. Fortunately, increased political stability has led to 
improved economic prospects in the region. Vibrant local stock markets and an influx 
of new foreign investors attest to the increasing role of the private sector across all 
economic activities in Sub-Saharan Africa, and health care is no exception.
The private sector already accounts for a remarkable share of the region’s health 
care. Private parties financed roughly 60 percent of all health expenditure—pre-
dominantly in the form of out-of-pocket payments by individuals, and about 50 
percent of that went to private providers. But private health care will require sup-
port and increased supervision if it is to continue to play the important role that it 
currently plays. 
	 The Business of Health in Africa  ( 	
This report identifies a number of significant im-
pedments or barriers to the further development 
of a sustainable and socially responsible private 
health sector, integrated into the broader strate-
gies and systems developed by the governments 
of Sub-Saharan Africa. To help knock down these 
barriers, it advocates:
 Developing and enforcing quality stan-
dards through both government and self-
regulation to foster the development of a 
more formal, sustainable and higher-qual-
ity private sector;
 Fostering risk pooling programs to improve 
the financing of health care;
 Using the private sector to deliver services 
by encouraging the public sector and donors 
to more closely engage with that sector;
 Modifying local policies and regulations to 
support and mobilize the private sector by 
streamlining bureaucratic processes, liberal-
izing human resource regulations, and re-
ducing tariffs and other import barriers; and
 Improving access to capital from financial 
institutions by educating local banks about 
the true risk profile of the health care sector, 
using international financial backing to en-
courage local financial institutions to lend to 
health care enterprises, and developing 
equity-focused financing vehicles for health 
care enterprises.





Even before those initiatives are tackled, the esti-
mated $11–$20 billion in private investment 
needed to support the expected growth in health 
care spending in Sub-Saharan Africa over the next 
decade will provide opportunities that yield both 
financial return and health impact for investors of 
all kinds.
This report was based in large part on inter-
views with many innovative, principled, and so-
cially minded entrepreneurs who are dedicated to 
building strong health care enterprises in Sub- 
Saharan Africa. Their enthusiasm and commit-
ment coupled with appropriate policy changes by 
donors, governments and the investment commu-
nity can create a private sector that is a robust and 
integrated component of a broader health sys-
tem—one that can help  provide the region’s in-
habitants with the healthier future they have so 
long deserved.
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Annex I:  Examples of Successful Business  
Models in Health Services Provision
Current private sector participation in health services provision varies widely by country (Figure A1.1). The capabilities of the public 
sector and the attitude of the population toward 
it are generally the primary drivers of such vari-
ability. In some countries, access to public health 
services is considered a right and the utilization of 
paid services is heavily resisted. Government’s 
view of the role of the private sector in provision 
of health services also varies widely. 
The public-private mix and the composition of 
the private sector in terms of financial objectives 
have even higher variability when each of the four 
components of health services provision (outpa-
tient care, inpatient and specialty care, preventive 
medicine, and diagnostic services) are examined, 
as shown in Figure A1.2. 
For-profit involvement in outpatient services 
ranges from 84 percent of private outpatient rev-
enues in Kenya103 to only 15 percent in Tanza-
   Figure A1.1
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Source: National Health Accounts, WHO; McKinsey analysis.
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nia.104 Traditional healers are also extremely active 
in the outpatient sector. For example, they ac-
count for up to 30 percent of the private activity 
in Ethiopia.105
Inpatient services follow a similarly diverse 
pattern. In Nigeria, for-profit businesses garner 72 
percent of the expenditure on private inpatient 
services, which accounts for about half of the total 
market.106 Conversely, in Mozambique, only ten 
percent of the already small private sector partici-
pation (eight percent of the market) goes to for-
profit players.107 
Across the continent the participation of the 
private sector in preventive services (vaccination 
and prenatal being the most-often used services) 
is limited. The highest market shares are 45 per-
cent in Nigeria108 and 30 percent in Uganda.109 
Elsewhere, the private sector participation in these 
activities is less than 20 percent. FBOs and NGOs 
are the main providers of private activity, often in 
partnership with the public sector.
While diagnostic services are often offered only 
at large hospitals, various examples of outsourced 
specialized providers with profitable business 
   Figure A1.2
Provision of health services in selected countries
Private sector
participation
• Smallest participation of private sector across 
continent: the Ministry of Health operates 
5,000 total facilities nationwide, equivalent 
to 85 percent of total provision. Large 
presence in rural communities, with health 
posts not staffed by a health professional.
Mozambique
Private sector
structure
Nigeria
• Private sector participation is among
highest (~58 percent), dominated by
the for profit segment. Share of the
private sector is set to grow relatively
to the overall growth in the market.    
• Limited access anywhere to highly specialized 
services.
–No dialysis facilities in the country.
–Cardiac surgery provided in one private 
  facility only; most patients flown to Portugal. 
For-profit clinics account for only ten percent 
of the small private sector (eight percent), 
largely covered by FBOs and other NGOs 
(45 percent).
•
Inpatient and
specialty care
•
•
72 percent of all private hospital 
revenues (half of total in the sector) 
are absorbed by the private, for-profit 
sector.
Specialists frequently serve at both 
public tertiary care centers and 
separate private practices.
•
•
•
44 percent of private activity (41 
percent of market) is for-profit.
Two tertiary referral hospitals are 
faith-based.
Specialty services extremely limited, 
many patients are flown to India for 
specialty services (e.g., surgery, dialysis, 
transplants, etc.).
• Private sector unable to afford CT/MRI and 
use public equipment.
FBO inpatient practices cover large portion 
of  basic lab services (45 percent of private 
contribution).
Diagnostic
services
• Approximately half of modern 
diagnostics (e.g., mammogram, CT, 
MRI) are in the private for-profit sector.
• No known private sector diagnostics.
South African-based company 
provides some services.
•
•
Tanzania
• Private sector participation is relatively 
modest at 33 percent with proportional 
participation within the for-profit, social, 
and non-profit sectors. The private sector 
is expected to grow in share as the 
economy liberalizes further. 
Outpatient
•
•
Common specialists (e.g., cardiology, surgery) 
with private practices account for about 20 
percent of overall private outpatient sector.
Traditional healers play a significant role 
(13 percent of the private activity).   
• For-profit activities dominate this 
space with 65 percent of the private 
sector share (covering 52 percent of 
the market).
• Primary-care provision is 30 percent 
private in rural areas and 40 percent 
private in urban areas.
Social enterprises cover 45 percent of 
private activity.
•
Preventive
• Private sector participation in preventive care 
is limited to FBOs, NGOs, and the informal 
segment. They constitute about 13 percent 
of overall prevention and are expected to 
grow at the same rate as the public sector.
• Ministry of Health involves private 
sector in preventive health strategies 
(e.g., distributes free vaccines to 
private clinics) but only social enterprises.
No activity of for-profit segment in 
this area.
•
• All social enterprise facilities participate 
in public vaccination program, yet 
private share of prevention is only 
10 percent.
90 percent of prenatal care is public.•
Source: Ministries of Health; National Health Accounts; country interviews; McKinsey analysis.
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models do exist. In Uganda, up to 50 percent of 
diagnostic services are supplied by private enter-
prises, and more than half of them operate on a 
for-profit basis.110 
Regardless of the social and political context, 
the limited capability of the public sector to sat-
isfy the rapid increase in demand for health ser-
vices will, in most cases, drive an increase in the 
private sector’s market share.
Empirical evidence (detailed in Annex 6) sug-
gests that health care provision will attract about 
50 percent of the total projected private sector 
investment opportunity, or about $5.6–$10.2 bil-
lion (Figure A1.3). Nearly two-thirds of this will 
be for inpatient care, about 30 percent for outpa-
tient care, and less than ten percent for preventive 
care, diagnostic services, and auxiliary services. 
Most of the investment opportunity will be in 
SMEs, with nearly two-thirds being in projects 
with sizes below $250,000, a quarter between 
$250,000 and $3 million, and just over ten per-
cent being greater than $3 million. 
Innoatie	Strategies	Exist	and	Will	
Represent	the	Basis	for	Competitieness
While health-service provision remains a chal-
lenging sector, successful innovative business 
models have overcome some of the barriers that 
have historically crippled this area. Investing in 
such opportunities could deliver significant finan-
cial returns in addition to making a fundamental 
contribution to the development of the region.
The following are some of the approaches that 
have worked well and that will likely be replicated 
in existing or new businesses:
   Figure A1.3
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• Innovative utilization of medical personnel. 
The lack of specialized resources can signifi-
cantly constrain the delivery of services; it is 
necessary to develop innovative models to over-
come this problem, especially in rural areas. Use 
of ophthalmic officers instead of fully qualified 
surgeons for common eye procedures, use of 
nursing attendants instead of qualified nurses, 
and even in some cases the involvement of fam-
ily members are typical solutions, albeit non-
optimal, to such shortages. Such solutions also 
keep costs down and therefore allow facilities 
to serve the lowest quintiles of the population.
• Sharing of managerial resources. Another way 
to overcome the lack of human resources and 
to reduce overhead costs involves resource-
sharing initiatives, which a number of facilities 
have adopted. In the case of the Biruh Tesfa 
project in Ethiopia, for instance, 92 reproduc-
tive health and family planning clinics share 
equipment and pharmaceutical procurement, 
technical support, and financial management 
and control.
• Cross-subsidization. Health providers that ca-
ter to a broad range of target population groups 
across urban/rural or rich/poor divides can of-
fer a tiered pricing system that allows more af-
fluent patients to subsidize other patients in 
need. At the same time, treating both types of 
patients makes it possible to spread the fixed 
cost over a larger volume.
• Establishment of outsourcing contracts or gov-
ernment concessions. Health services provid-
ers that can guarantee consistent quality should 
be able to establish outsourcing agreements 
with governments for specific services where 
public resources may be constrained (as in the 
case of nutrition services in Senegal). In other 
situations (as in the case of hospital concessions 
in South Africa), the partnership is set up in 
the form of a concession.
• Creation of a reputation for quality through 
franchising. In an environment where people 
travel long distances for health care, sometimes 
by-passing “free” public facilities in doing so, a 
reputation for quality and reliability is a key 
condition for success. The establishment of 
franchises can allow a set of facilities to share a 
common, highly-controlled supply chain, thus 
guaranteeing the origin of pharmaceuticals and 
medical supplies.
• Procurement pooling. Given that the expendi-
ture in pharmaceutical and medical products is 
in some cases up to two-thirds of the total op-
erating cost for facilities, an effective procure-
ment strategy is a major key to success. Pro-
curement pooling can deliver significant savings 
due to increased purchasing power.
Examples	of	Successful	Business	Models	
The investment themes described in Figure A1.4 
are examples of business models that effectively 
utilize the innovative strategies discussed above, 
achieving financial success and having an enor-
mous development impact.
The likelihood of an investment’s success will 
significantly depend on the target country. Different 
countries will present different market opportuni-
ties (both in terms of expected market growth and 
competitive scenarios), and investment climates re-
main significantly heterogeneous across the region.
Detailed descriptions of these models follow.
Small, High-End Centers
High-end hospitals serve both middle-class and 
wealthy patients in cities across Africa. While the 
very wealthy may travel abroad for elective medi-
cal procedures, high-end hospitals serve the emer-
gency and general health needs of these popula-
tions in addition to the health needs of the 
moderately wealthy. High-end hospitals generally 
depend on a mix of company membership plans, 
individual pay-per-service fees, and private insur-
ance programs for their revenue. High-end hospi-
tals provide the high-quality care that attracts pa-
tients and the well-resourced environment that 
attracts medical staff. Notwithstanding these ad-
vantages, these hospitals still often cite recruitment 
and retention of top doctors as a key limitation. 
There are numerous examples of high-end 
hospitals across Sub-Saharan Africa, including 
both commercial and social enterprise models. 
Examples include the Tanzania Heart Institute 
in Dar es Salaam, Lagoon Hospital in Lagos, 
Bridge Clinic in Abuja, and Nyaho Medical 
Clinic in Ghana. Figure A1.5 below presents 
another example of a high-end hospital, Lister 
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Hospital in Accra. Lister Hospital is a two-year-
old, for-profit, 25-bed hospital and in-vitro fer-
tilization center. Notably, Lister Hospital has a 
large patient base. Having achieved early suc-
cess, Lister seeks to expand both its facilities 
and its patient base. 
Network of Primary and Secondary Care 
Clinics
The Christian Health Association of Kenya has 
been successfully coordinating the operations of a 
network of 363 facilities (24 hospitals, 43 health 
centers, and 296 dispensaries) since the 1930s. 
Across the continent other FBOs have tackled the 
issues of limited demand in low population den-
sity regions, scarcity of management resources, 
and limited purchasing power by forming inte-
grated networks of clinics. 
For-profit models, often based on a franchising 
model, have developed more recently. Each facility 
is operated independently, typically attracting rev-
enues of $20,000–$300,000 per year. Initial capi-
tal, technical assistance, and management talent are 
provided by a central agency that is also responsible 
for procuring equipment, purchasing drugs and 
supplies, and enforcing process standards. Other 
forms of for-profit networks include large chains of 
clinics with similar operational characteristics. 
Being part of a network allows management 
to spread overhead costs over a large revenue 
base and to share managerial resources across the 
network. The increased scale also allows the pro-
vider to offer a large set of specialized services, 
often including dental or maternity services, rely-
ing for these on shared medical personnel across 
hospitals. 
   Figure A1.4
Development impactExamples
Revenue range
$ million
Setup cost
$ million
Promising investment themes in health services provision
Hospitals with cross-
subsidization model
•• • 0.2–2.0 • 0.2–1.5
Network of primary and 
secondary care clinics
•• • 0.01–0.3 
per clinic
• 0.02–0.6
per clinic
Large diagnostic
laboratories
•• • 0.5–3.0 • 1.0–3.0
Hospitals offering 
in-house insurance
•• • 0.3–5.0 • 0.5–3.0
High-volume, low-cost
hospitals
•• • 1.0–5.0 • 0.5–3.0
Specialized doctors
covering network of
hospitals
•• • 0.1–1.0 • 0.2–2.0
Small, high-end centers
• Allows the retention of high-
quality, specialized resources in 
the country.
Improves access within rural 
regions, providing quality care  
to underserved populations.
Increases accessibility to health 
care services to regions without 
established insurance systems. 
Increases access to standardized 
services within a larger population 
base.
Extends affordable care to larger 
population base, especially the 
poor.
Improves the overall efficacy of 
treatment by supporting the 
diagnostic phase.
Provides access to specialized 
resources in rural areas.
Increases access to specialty 
care across the region.
• Tanzania Heart Institute (Tanzania), 
Lagoon Hospital (Nigeria), Bridge 
Clinic (Nigeria), Lister Hospital (Ghana).
Christian Health Association (Kenya), 
Biruh Tesfa (Ethiopia), Clinic Africa 
(Uganda).
Kadic Hospital (Uganda), AAR Clinic 
(Uganda), Selian Lutheran Hospital 
(Tanzania).
R-Jolad (Nigeria), Nsambya Hospital 
(Uganda), Selian Lutheran Hospital 
(Tanzania).
International Hospital (Kampala), CCBRT 
(Tanzania).
Bio24 (Senegal), Radmed Diagnostic 
Center (Nigeria).
Tsilitwa (South Africa).
N/A (potential model yet to be piloted).
• 0.2–10.0 • 0.5–3.0
Telemedicine
•• • 0.1–1.0 • 0.3–1.0
Source: Country interviews; McKinsey analysis.
	 The Business of Health in Africa  ( 	
These models can effectively reach under-
served rural populations; additionally, high opera-
tional efficiency and standardized processes can 
improve the quality of care. A reputation for qual-
ity often helps these networks to generate addi-
tional revenues through increased volumes and/or 
premiums. 
Figure A1.6 shows highlights of the business 
model and the financials for Clinic Africa, an inte-
grated network of clinics in Uganda. Another ex-
ample is the Biruh Tesfa project in Ethiopia; start-
ed in 2000, it has expanded at an impressive rate 
and currently operates 92 clinics. The Mucas Hos-
pital in Nigeria is a group practice combining sev-
eral general practitioners and specialists that is 
based on this same model.
 Hospitals Offering In-House Insurance
Section II of this report discussed the fact that the 
establishment of risk pooling mechanisms signifi-
cantly increases the financial viability of health-
service provision facilities. Given the limited pres-
ence of health financing vehicles in Sub-Saharan 
Africa, some providers have set up their own in-
house insurance schemes. 
These businesses increase the accessibility of 
health care to segments of the population that 
would otherwise be unable to afford specialized 
services. At the same time, risk pooling allows en-
terprises to be profitable, especially if they man-
age to attract a base of at least 20,000 members, 
guaranteeing them a revenue range of at least 
$500,000 per year.
Figure A1.5 
Source: Country interviews; McKinsey analysis.
Case study, small high-end hospital: Lister Hospital, Ghana 
Lister Hospital is an upscale, 25-bed private hospital in Accra
A large, up-scale hospital Planning to expand
Hospital profile
• Opened in 2005.
• 25 bed in/outpatient facility with a separate in-vitro 
fertilization center.
• 10,896 patients currently registered. Some regulars, 
some one-time only. 
• National Health Insurance Coverage is too low ($2 per 
doctor consultation) and therefore not accepted.
Lister had support at start-up
• Total start-up cost was ~$2.7 million, funded by four 
shareholders.
• Suppliers credit has largely been used for equipment 
purchase since then. 
• Government was supportive of Lister and readily 
accredited the facility after it was operational.
Lister Hospital plans to expand
• Seeks to grow direct employer accounts, which 
currently only account for 10 percent of patients.
• Plans to expand its facilities:
Invest in Intensive Care Unit (ICU).
– Build full Emergency Room (ER);
– Improve equipment:  
mammogram & cat scan; and
– Build bigger pharmacy.
Lister faces some challenges as it grows
• Financing
 Available local bank rates are high, therefore 
Lister is also exploring international and 
development financiers.
• Medical personnel 
 Attracting and retaining medical personnel 
who have practiced in first-world medical 
facilities and/or have opportunity to leave  
is a challenge.
• Client base
  Direct employer accounts are important  
to sustainability and growth, but there is 
strong competition for them among  
private hospitals.
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Some in-house schemes may need reinsurance 
or subsidies from donor agencies to protect them 
in case of catastrophic conditions or epidemics, 
yet the model is fundamentally viable, as shown 
by the example of Kadic Hospital in Uganda (de-
scribed in Figure A1.7). While its current profit-
ability is limited, Kadic could significantly increase 
its margins if it doubled its capacity, a prospect 
that is in line with forecasted demand.
Another example is the AAR Clinic in Kampala 
(200 patients/day and 30,000 members). Selian 
Lutheran Hospital in Tanzania, a FBO, relies on 
in-house insurance for only part of its catchment 
population. Further applications of this model are 
currently present in the Democratic Republic of 
Congo, Nigeria, and Uganda across the for-profit 
and social enterprise segments. 
Countries like Cameroon, Chad, Sierra Leone, 
and Sudan, where coverage by risk pooling ar-
rangements is very small, are likely candidates for 
future successful implementations of this model, 
provided capital is made available. 
Urban clinics are quickly profitable
• Profit margin about five percent for 
urban clinics with $30,000 in revenues.
• Rural clinics not yet sustainably 
profitable.
• Typical clinic requires about $15,000  
of seed capital from NGO, mostly  
for facility, working capital, and 
equipment.
Rapid expansion: Five clinics in 1.5 years
• Have demonstrated profitable urban 
model and ability to open new clinics.
• Have not yet demonstrated  
self-sustainable rural model.
Historical 
growth
Profitability
Figure A1.6 
Source: Country interviews; McKinsey analysis.
Case study, primary care clinic network: Clinic Africa, Uganda 
Clinic Africa is a fast-growing network of primary-care clinics in Uganda. With demonstrated profitability at urban clinics, Clinic 
Africa’s challenge is to build profitability among its rural clinics as it continues growing aggressively.
Description Key investment considerations
Future growth 
prospects
Goal of 100 clinics in region
• Financing demand for continued 
rapid growth, potentially from donor 
to NGO or private investor to clinics.
• Strong urban growth opportunity. 
• Rural growth requires one of the 
following:
– Develop independently profitable 
model
– Expand rural network as social 
enterprise, subsidized by NGO 
funding and urban network 
profits
• Two-year old clinic network that opened  
five clinics (three urban, two rural) and served 
over 5,000 largely poor patients in its first  
1.5 years.
• Clinics are centrally owned but individually 
operated by local physicians: 
– NGO oversees expansion and quality- 
control for network; and
– Physicians retain most profits (small portion 
of urban clinics’ profits are paid to cover  
in-country NGO operations).
• Urban clinics are profitable within three to  
six months while rural clinics unable to 
generate similar profitability.
• Typical facility characteristics:
– Three to six physicians
– 2,600 pharmacy visits 
– 1,500 outpatient visits
– 1,400 laboratory tests
– 500 inpatient stays
	 The Business of Health in Africa  ( 	
High-Volume, Low-Cost Hospitals
Hospitals located in high-density areas often use a 
low-cost, high-volume business model that allows 
them to target low-income groups needing basic 
interventions. The throughput of patients is ex-
tremely high (up to 100 patients per day per doc-
tor), since the set of services provided is limited; 
the typical revenue range of such businesses is $1–
$5 million.
In a few cases, a variation of this business 
model exists in the form of specialized care: by 
focusing on a single type of service (e.g., cataract 
surgeries, heart conditions), hospitals can achieve 
high efficiency levels and maximize the utiliza-
tion of their personnel. These hospitals have sig-
nificant development impact as they can provide 
health services to a very large population; addi-
tionally, the high productivity of the medical 
personnel and the resulting possibility to contain 
prices significantly impacts the affordability of 
the services.
Figure A1.8 shows the details of the business 
model and the financials for R-Jolad, a successful 
high-volume hospital in Nigeria that is mentioned 
in Section I. Other examples of this model are the 
Selien Hospital in Tanzania and the Nsambya 
Hospital in Uganda (350 beds).
In general, countries that have adopted a na-
tional health insurance scheme (Ghana, Namibia, 
Nigeria, and Senegal) are favorable environments 
• Five percent net margins.
• $800,000 revenues.
• Costs evenly split between 
COGS and OPEX.
• In-house insurance provision 
supported historical growth 
by funding demand with a 
secure revenue stream.
Historical 
growth
Profitability
Figure A1.7 
Source: Country interviews; McKinsey analysis.
Case study, provider with in-house insurance: Kadic Hospital, Uganda 
Kadic Hospital is a 32-bed private hospital with approximately five percent profit margins serving middle-income patients in 
Kampala. It also serves low-income patients, primarily through outreach programs. Kadic first established an in-house insurance 
program to help patients finance health care at a time when most patients had no external source of insurance.
Hospital care
• 24-hour outpatient services in addition to  
inpatient services.
• 85 permanent medical, support, and allied medical 
staff plus 40 part-time consultants in various specialties.
• Currently 60 percent of hospital patients have some 
form of health insurance, increasingly from outside 
sources.
In-house insurance
• Kadic offers schemes for families, schools, and 
corporations.
• Creation of own membership model was necessary due 
to lack of health insurance companies at the time of 
establishing the hospital. Today, however, the hospital is 
developing relationships with external health insurance 
companies to slowly replace in-house membership 
model.
• Membership costs $15 per year and covers outpatient 
services and two days of hospitalization.
• Co-payments and additional charges (e.g., for drugs) 
also apply for members of in-house insurance scheme.
• Currently about 6,000 members contributing  
10 percent of hospital revenue through membership  
premiums.
A hospital with in-house insurance Key investment considerations
Future growth 
prospects
• Reduce in-house insurance 
for groups with more 
efficient external alternatives.
• $1.1 million investment to 
double capacity. 
• Kadic faces competition from 
other hospitals for growing 
middle-class demand, 
including five new hospitals 
being built in Kampala 
targeting middle- to high-
income patients.
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for this model, since such schemes favor providers 
that are able to contain prices. 
Hospitals with Cross-Subsidization Models
The limited size of the patient base that can af-
ford top-quality treatment in Sub-Saharan Africa 
significantly hinders the growth of the for-profit 
private sector. However, many facilities have start-
ed to use cross-subsidization business models to 
overcome this constraint. Differential pricing 
structures enable hospitals to successfully cater to 
the needs of diverse segments of the population 
and spread the elevated fixed-cost structure of the 
operation over a large set of customers.
Clients with the ability to pay higher prices 
receive a higher level of service, which generally 
includes nicer waiting rooms, private rooms, and 
an appointment reservation service. Conversely, 
poorer clients pay a reduced price, in some cases a 
fee that only covers the cost for provision of the 
service, and receive a more basic service while re-
ceiving the same quality of medical care. 
Figure A1.9 shows some highlights of the busi-
ness model and the financials for a facility based 
on cross-subsidization in East Africa.111 Examples 
of cross-subsidization models currently in opera-
tion are either for-profit or social enterprises (of-
ten FBOs). The size of such businesses is typically 
Balanced revenue streams with 
high single-figure net margins
Gradual self-sustained growth from  
small clinic to major hospital
• Single-physician primary clinic in 1982. 
• 150 bed, 250 patient per day outpatient 
hospital with 12 consulting rooms.
Historical 
growth
Profitability
Figure A1.8 
Source: Country interviews; McKinsey site survey; McKinsey analysis.
Case study, high volume hospital: R-Jolad, Nigeria 
R-Jolad is a financially sustainable social enterprise in Lagos providing 200–250 patients a day from mixed income levels with good 
quality health care. In the words of one patient, “They offer on-time services, are friendly, and have qualified doctors.”
• Non-profit, but fully self-sustainable  
full-service hospital and clinic in Lagos.
• High primary care volume: also has medical 
specialists and surgical suites.
• 17 full-time generalist physicians;  
12 part-time consulting physicians.
• Fees: primary care 100–400N/consult;  
500–700N/visit for labs/drugs.
• Five percent bad debt.
• Small fixed margin on drugs and laboratory 
tests.
• No history of donor or public funding; 
rarely takes small (~$75K) short-term loans 
from local banks to finance growth.
• R-Jolad draws patients from a range of 
income levels:
Description Key investment considerations
Future growth 
prospects
140 percent revenue growth through  
higher-end 30-bed expansion
• $1.1 million investment in new hospital. 
• Projects $3.3 million revenues. 
• Key constraint is access to affordable long-
term financing (current available rates are 
22–25 percent for five-year loan).
> $930 
per annum
$739–$930 
per annum
< $730 
per annum
43%39%
17%
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within the range $0.3–$2 million. The level of 
cross-subsidization determines the profitability of 
the overall operation. Lastly, in some cases, cross-
subsidization takes place through the intervention 
of donors, as is the case with the Hope Ward at 
the International Hospital in Kampala.
Diagnostic Labs
Because screening for HIV/AIDS, TB, Sexually 
Transmitted Diseases (STDs), and other condi-
tions is absolutely essential to planning treatment, 
diagnostic services are a fundamental component 
of the health care sector. Most labs across Sub-
Saharan Africa attract revenues between $500,000 
and $3 million, and most operate at capacity with 
high profit margins. Their expansion is often lim-
ited by the scarcity of technical personnel and 
capital resources.
In the case of the example in Figure A1.10, a 
successful lab in Senegal achieved a net profitabil-
ity of 14 percent by catering to individuals, private 
clinics, and even public facilities.
Diagnostic labs improve access by extending 
services that are underrepresented across Sub- 
Saharan Africa. This improves the overall efficacy 
of treatment and delivers significant positive 
health outcomes.
In other situations, diagnostic labs serve entire 
regions; satellite facilities collect samples and 
transport them to the central lab, where the few 
specialized technicians process them.
Figure A1.9 
Source: Country interviews; McKinsey analysis.
Case study, cross-subsidization: private specialized hospital, East Africa 
This private hospital in East Africa offers high-quality outpatient and inpatient services for eye and orthopedic consultation and surgery. 
A social enterprise, it is committed to serving primarily low-income populations, but seeks to grow its service to higher-income patients 
to build profitability.
I. A commitment to serve the poor
Hospital committed to serve their general 
patient base even if it means turning away 
wealthy patients.
II. Quality that attracts the wealthy, too
High quality standards and good reputation  
for specialized care attracts all patients, 
including the wealthy. However, the hospital 
lacks capacity to meet the demand for its 
higher-priced private services.
III. Price differentiation on comforts, not 
medical care
Medical care for private and general patients 
are identical. Price differentiation is based on 
comfort levels (non-emergency waiting times, 
private rooms, food choice).
IV. Facing a growth imperative
• Unstable break-even margins at present.
• Excess demand from wealthy patients.
• Has acquired land and is training doctors 
for expansion.
A valued hospital needs to grow The cross-subsidization solution
I. The hospital offers a differentially priced menu of services…
2Normal
15Fast-track
25Fixed appointment
35General ward
85Private room
115VIP room
III. …it can improve the sustainability of all its operations.
II. …so by growing its high-income patient base only slightly…
Consultation cost ($) Bed cost ($)
3
7
96 1Current
90 3Planned      
General Private VIP
10
–2  to 2Current
Planned      
Net margins (percent)
(percent)
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Telemedicine
Telemedicine offers a solution to the lack of doc-
tors in rural areas. Many small and rural towns 
across Africa are served by small clinics staffed 
only by a nurse, with the nearest fully qualified 
doctor ten or more miles away. That makes the 
doctor inaccessible to a sick patient for whom the 
journey may be too arduous or expensive. 
As detailed in Figure A1.11, in Tsilitwa, a town 
in South Africa’s Eastern Cape, a government-
sponsored telemedicine project offers a solution. 
Tsilitwa’s single clinic serves 10,000 patients but 
has no doctor. The closest doctor-staffed hospital 
is over ten miles away, with no direct transporta-
tion connecting the towns. South Africa’s Center 
for Scientific and Industrial Research and re-
searchers from the University of Cape Town’s 
computer science department have equipped 
Tsilitwa’s clinic with wireless Internet equipment 
with which nurses can send pictures to doctors 
remotely and speak with them in real time. The 
set up uses a wireless local area network (LAN), a 
computer with a Web camera, a VoIP-enabled 
phone, and specialized software. 
The telemedicine project improves patient 
health outcomes while saving them time and 
money. Many patients who could not or would 
not make the journey to see a doctor now have 
the benefit of a doctor consultation. Patients do 
not have to waste time and can avoid the costs 
associated with transportation and additional con-
sultations. 
The Tsilitwa’s Telehealth Project is a non-com-
mercial venture, and telemedicine in Sub- 
Saharan Africa has yet to demonstrate its commer-
cial viability. The primary challenge to commercial 
viability is the high cost of telecommunications. 
However, the use of Web cameras and VoIP- 
Figure A1.10
Key investment considerations
Multiple revenues streams fuel robust profitability
• ~14 percent net margins.
Source: Country interviews; McKinsey analysis; company website.
Bio24 seeks affordable financing to grow
• Plans to expand into larger facility to be able to 
absorb additional business (currently at capacity).
• Seek debt financing of $1.4–$1.8 million to set up 
larger facility and expand business but local lending 
rates are expensive at ~20 percent per annum.
Future growth 
prospects
Profitability
Private insurers: 23%
Employer health 
plans: 18%
Clinics: 7% Research 
centers: 2%
Individuals
and hospitals:
50%
Sources of revenue 
Percent
Case study, diagnostic laboratories: Bio24, Senegal
Bio24 is a profitable diagnostic laboratory in Dakar operating at capacity and interested in expanding. Its services are in high demand by 
insurers, health providers, research centers, and individuals in both the public and private sector. 
Description
• For-profit single-owner organization, 
started in 1994 as spin off from a 
university.
• Obtained ISO 9000 certification  
in 2001.
• Currently employs 47 people.
• Services: medical analyses,  
reproductive analyses, assisted 
fertilization.
• Exclusive providers of 24/7 services 
(not available in public sector);  
therefore utilized by public hospitals 
during off-hours and for specialized 
analyses.
• Bio24 develops additional services 
and revenue streams, such as house 
calls to pick up samples for testing.
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enabled phones, which are cheaper than tradition-
al telephone communication, and the increasing 
penetration of wireless connectivity throughout 
the continent, bodes well for health entrepreneurs 
who seek to develop scalable telemedicine. Sec-
ondary challenges include constraints on doctors’ 
time and clinic staffs’ varying capability to use 
technology effectively.
Specialized Doctors Covering a Network  
of Hospitals
Most hospitals across Sub-Saharan Africa are un-
able to offer specialized care. This is due to a short-
age of skilled specialists, high capital expenditures 
for equipment, and, especially in rural areas, lack of 
sufficient demand to absorb the fixed costs. A busi-
ness model that includes a group of specialists that 
moves across a large network of hospitals with spe-
cialized equipment could prove financially viable. 
For example, a group of orthopedic surgeons could 
share equipment and conduct operations in hospi-
tals throughout East Africa. Rural hospitals could 
book patients in blocks for a given week when the 
surgeons are scheduled to be there. Typical size 
range of such businesses is $0.1–$1 million.
Given the relatively well-developed road infra-
structure in Southern Africa (Botswana, Namibia, 
and South Africa), this model has a better chance 
of success in that region. These models have the 
potential to extend specialized care to under-
served regions. They could also be combined with 
a cross-subsidization model to serve the poorer 
sections of society at a cheaper rate than richer 
segments. While no examples of this model have 
yet been found on the ground, industry experts 
believe it has significant potential.
 
• Profitability: While the model has not demonstrated financial 
sustainability, it can be cross-subsidized with other services at the 
hub. Funding has thus far come from a combination of government, 
donors, and private enterprises. 
• Development impact: 
– The Tsilitwa Telehealth Project serves 10,000 people in the rural 
Eastern Cape of South Africa.
– There is one clinic and no doctor at the clinic in Tsilitwa, so this 
service gives patients access to doctors for which they would 
otherwise travel at least ten miles.
– This model makes health care cheaper by avoiding additional 
transportation and consultation costs.
– This model makes health care more responsive since patients do 
not have to waste time traveling or in waiting rooms.
– This model improves health care quality since it enables nurses to 
more easily consult a doctor.
• Growth opportunities: 
– Expand network to additional rural areas as possible given growth 
in rural tele-connectivity across the continent.
– Financial sustainability will be challenging to achieve on a 
commercial basis given the costs of technology and doctors’ time. 
Growth and health objectives may best be accomplished through 
a wholly or partially-subsidized model.
Figure A1.11 
Source: Country interviews; McKinsey analysis.
Case study, telemedicine: Tsilitwa Telehealth Project, South Africa 
The Tsilitwa Telehealth Project is a government-sponsored program that allows rural nurses to consult remotely with doctors on 
challenging cases by speaking and sending pictures through wireless telephony.
• Initiative: The telehealth project in 
Southern Africa uses a system in which a 
nurse can send live pictures of a patient 
over a wireless network to a remote doctor 
while speaking on a VoIP-enabled phone.
• Implemented by: The wireless network, 
including VoIP was set up by the govern-
mental telecom authority.
• Local context: Village lies over 10 miles 
from the nearest hub, which is a small 
town 20 miles north of a regional hub.
Description Impact and Outlook
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Annex 2:  Examples of Successful Business Models in 
Risk Pooling Arrangements
As described in detail in Section II, risk pool-ing arrangements in Sub-Saharan Africa can be found in discrete regional and popula-
tion niches. Private schemes are predominantly 
found among the wealthy, foreigners, and/or em-
ployees of large corporations. For example, in 
Namibia and Zimbabwe—two of the more de-
veloped insurance markets—private insurance 
accounts for 20–30 percent of health care ex-
penditure even though it covers only three to 
seven percent of the population. An additional 
core of risk pooling arrangements is concentrated 
in employer-managed health plans, which are in-
creasingly common even among small enterprises. 
Employers outsourcing the administration of their 
medical plans to separate insurance companies 
and workplace clinics also represent an emerging 
trend in the development of health insurance and 
HMO industries in Sub-Saharan Africa.
In West and East Africa, community-based 
health insurance schemes (a term that includes a 
diverse array of risk pooling arrangements with 
varying degrees of sustainability) are widespread; 
as many as 600, with over 1.5 million beneficia-
ries, have been launched in Francophone Africa 
in the past 20 years. 
Many countries have sought to implement so-
cial security systems, but success has been restrict-
ed by the limited size of the formally employed 
population. Micro health insurance, health savings 
accounts, or health credits all play a minimal role 
in Sub-Saharan African society, where low levels 
of social cohesion due to ethnic diversity under-
mine trust in the willingness of other groups to 
pay for future risks. Nevertheless, these mecha-
nisms present long-term growth opportunities, 
especially given a considerable cultural shift to-
ward pre-paid mechanisms.112 
Figure A2.1 shows the large variability in the 
development of the health financing industry 
across three sample countries. 
Although the market is nascent, some govern-
ments are starting to view private risk pooling ar-
rangements as a potential mechanism to extend 
health care to the broader population. For example, 
Nigeria, the continent’s most populous nation, has 
recently approved a compulsory national health in-
surance scheme to be implemented by private en-
terprises with the ultimate goal of extending cover-
age to the entire population. Also in Nigeria, 
bilateral donor funds are passing through a private 
HMO to subsidize basic health care insurance to 
115,000 people in two poor target groups.
Overall, we estimate that risk pooling arrange-
ments will represent about 13 percent of the pro-
jected cumulative investment demand in private 
health care, or about $1.4–$2.5 billion. About 80 
percent of this is estimated to consist of investment 
opportunities below $3 million (Figure A2.2). 
Focused	Strategies	Are	Being	Tested
In these nascent markets, the challenge for new 
companies is twofold: how to reach minimum 
economic scale as fast as possible, and how to 
finance operations during the initial money-losing 
phase. 
The following are some of the strategies that 
have been shown to work well; companies that 
adopt them can be attractive investment oppor-
tunities.
• Access to large and randomly selected groups. 
The size of the population pool is key. A risk 
pooling scheme requires a minimum of 20,000 
people. With this size, unsystematic risk can be 
diversified within the insured population as a 
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whole so that it is not necessary for every prod-
uct to be profitable in order for the overall plan 
to be viable. With more than 100,000 lives, a 
scheme can optimize individual risk pools for 
each plan, making each product profitable on 
its own, or it can offer more extensive coverage, 
covering, for example, chronic diseases, as well 
as products for higher-risk groups. An addition-
al condition for the success of this strategy is 
that the population must be randomly selected 
in order to avoid the adverse selection issues 
that a voluntary scheme naturally incurs. Given 
the size and nature of the populations compos-
ing public workforces, outsourcing agreements 
with governments that cover a group of em-
ployees are a natural opportunity for programs 
of these kinds.
• Vertical integration. Integrating the risk pool-
ing mechanism with service provision signifi-
cantly increases the likelihood of financial via-
bility, since the possibility of fraud is reduced 
   Figure A2.1
Risk pooling arrangements in selected countries
Nigeria
•
•
Legislation for compulsory HMO 
membership for the formally 
employed sector expected to be 
passed in 2007.
Health insurance funds provide 
subsidies to poor.
• Private insurance accessible 
primarily to the rich and employed, 
mostly through employer benefits.
Only one company, UNIC, with 
20,000 covered lives.
Government has contracted HMOs to 
provide risk pooling to government 
employees.
Experimental of donor insurance 
subsidies for the poor through private 
HMO.
•
•
Rapid recent buildup of public 
National Health Insurance Coverage, 
now covering 38 percent of population.
Insurance pay-out terms lower than 
most private providers will accept, 
so mostly used for public providers.
•
•
Private insurance also available, 
though generally limited to rich.
Employer-based insurance programs 
also exist. 
•
•
Wide variety of health insurance 
models in Senegal, with most of them 
not-for-profit or public.
Bulk of people with insurance are 
covered by compulsory employee 
programs (50/50 employer-employee), 
of which there are about 120 in Senegal.
• Employer programs.
• Micro insurance schemes.
•
•
•
•
HMOs.
• Private indemnity insurance.
• Microinsurance.
• HMOs.
Ghana Senegal
Industry
structure
Areas of 
growth
•
•
•
Long-standing private insurance history, 
though programs focus on small, 
high-income, more easily managed 
groups.
Seven private insurance companies 
average 1,500 beneficiaries, cover one 
percent of beneficiaries, but represent 
31 percent of expenditures.
Lack of volume results in expensive 
premiums.
Private sector
participation
Source: Ministries of Health; country interviews; McKinsey analysis.
    Figure A2.2
Risk pooling investment opportunity, 
cumulative 2007–2016
Percent, $ million
30
70
0
By financial
objective
For-profit
Social 
enterprise
NGO/
non-profit
80
20
By individual
project size
>3.00
0.25–3.00
1,400–2,500 1,400–2,500 
Source: Ministries of Health; National Health Accounts; country 
interviews; McKinsey analysis.
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and direct access to data on the covered lives 
allows for optimization of each plan. 
Seeral	Successful	Business	Models
Figure A2.3 illustrates selected examples of busi-
ness models that effectively leverage the strategies 
discussed above; these models can help business 
to achieve financial success while also having sig-
nificant development impact.
A detailed description of these models follows. 
Indemnity Insurance as Part of  
General Insurance
Indemnity insurance is a classic fee-for-service in-
surance model that generally targets the employed 
segment of the population. Several large general 
insurers in the region are considering extending 
their service lines to include indemnity health in-
surance. This model would charge a fixed fee pre-
mium based on subscriber’s risk profile and could 
be available for groups or individuals.
Given the large customer base that most of 
these insurance companies already have, offering 
an indemnity health insurance product would be 
a natural product line extension. The extensive 
databases these payers maintain regarding their 
customers—including which products they pur-
chased and their creditworthiness—means that 
cross-selling can be tailored and focused. The life 
insurance information contained within these da-
tabases can be used to price premiums. In fact, 
several organizations have already started offering 
indemnity insurance across Sub-Saharan Africa.
Investments in this sector could fund capital 
expenditures in new equipment, skill enhance-
ment, and marketing efforts. Some investments 
could also fund acquisitions of the indemnity arms 
of other companies. In the Sub-Saharan African 
context, opportunities in this area typically have a 
revenue basis of $1–$5 million.
The key drivers of profitability are operational 
scale and insured population demographic make-
up. Most companies aspire to make the bulk of 
their profits on investment earnings from premi-
ums while only breaking even on medical costs. 
Kenya and Tanzania have seen the growth of orga-
nizations using this model over the last few years. 
    Figure A2.3
Development impactExamples
Indemnity
insurance within
general insurance
•
•
Creates an insurance culture.
If properly scaled and managed, 
can force efficiency gains within 
the network of service providers.
• Strategis (Tanzania), UNIC 
Health (Nigeria), GLICO 
(Ghana), CFC Life (Kenya), 
The Cooperative Insurance—
CIC (Uganda).
Promising investment themes in risk pooling arrangements
HMOs integrated 
with service 
providers
•
•
•
Increases accessibility to health care 
services to broader population.
Risk pool sharing makes health care 
more affordable.
Acts as a catalyst in building a provider 
network of both private and public clinics.
• Hygeia (Nigeria).
• Total Health Trust (Nigeria).
Micro health 
insurance associated 
with microfinance 
institutions
•
•
•
Provides financial protection for 
low-income groups.
Establishes an insurance culture across 
rural and underprivileged segments.
Catalyst for growth of providers within 
these segments.
•
•
N/A in Sub-Saharan Africa.
Application potential for 
Grameen Kaylan (Bangladesh) 
model.
• 1.0–5.0
Annual revenues
$ million
• 0.5–15.0
• 0.5–5.0
• 2.0–4.0
Setup cost
$ million
• 1.5–7.0
• 1.0–2.0
Source: Country interviews; McKinsey analysis.
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Life insurance companies, specifically, have broad-
ened their product portfolio by offering indemni-
ty coverage. Uganda is also well positioned to see 
this model flourish given the relatively large num-
ber of general insurance companies there. Con-
versely, countries with established national health 
insurance schemes (like Namibia, Nigeria, Sene-
gal, and Zimbabwe) may not be favorable markets 
for this business model.
Figure A2.4 shows the key features of this busi-
ness model and the financials for private insurance 
in Tanzania.
Integrated HMOs
Several health insurers are starting to offer a range 
of medical services themselves. These models pro-
vide broad insurance coverage with restricted pro-
vider choice. This usually involves a capitation 
model or in-house provision for care. By providing 
in-house health services (generally primary care), 
insurers can more efficiently control claims cost 
and fraud. Furthermore, additional availability of 
information can allow rigorous case management.
The market for these financing vehicles is grow-
ing significantly, although setbacks have occurred 
• Four year old company with 2005–2006 subscriber growth of  
~50 percent.
• Past growth driven by corporate accounts (first multinational 
corporations, then local companies).
,
• Growth targets of doubling underwriting in 2007 and 50 percent 
growth in 2008.
• Strategis has tendered for new Dutch Health Insurance Fund contract 
to insure large, generally non-wealthy population.
• Corporate insurance continues to offer near term growth with good 
margins.
• Retail growth opportunity in medium-term, given growth in 
employed families seeking quality care. 
– Currently <ten percent retail, with 30 percent target
– First local company with individual risk assessment capability for 
retail underwriting. Able to partner with affinity groups and banks 
for retail volume.
• Key growth challenges include:
– Competition from new entrants for both subscribers and 
personnel.
– Uncertain regulatory environment: New legislation expected on 
HMOs may have consequences for registered insurers.
– Uncertain impact of National Health Insurance Fund’s aspiration of 
growing coverage to 45 percent of Tanzanian lives by 2015.
Figure A2.4 
Source: Country interviews; McKinsey analysis.
Case study, private insurance: Strategis, Tanzania 
Tanzania’s leading private insurer, Strategis has experienced rapid growth from corporate subscribers, and has set aggressive growth 
targets for underwriting large insurance funds, more local companies, and individuals.
• Strategis offered the first private health 
insurance in Tanzania. It designs, under-
writes, and sells medical insurance to:
– Companies
– Affinity groups
– Families and individuals
– Travel cover (in/out)
• Three percent profit before tax, almost 
exclusively from underwriting given limited 
investment income opportunities.
– Currently > 90 percent corporate, plan 
to increase retail to 30 percent.
• Network of > 100 contracted private 
providers throughout the country.
• Quality standards part of provider contract, 
but hard to enforce if no alternative 
provider is available.
• Expatriate management provided through 
AMSCO project (funded by UN and IFC).
• 30,000 of Tanzania’s 60,000–70,000 
insured lives.
Tanzania’s leading private insurer… … Strategis has experienced rapid growth from corporate 
subscribers…
…and has set aggressive growth targets for underwriting large 
insurance funds, medium sized enterprises and individuals.
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in some East African countries. In countries with 
compulsory schemes or tax incentives, this indus-
try is projected to grow. The model is relatively 
well-developed in Namibia, Nigeria, and Zimba-
bwe. Other countries have smaller enterprises but 
are looking to expand. So far, individual HMOs 
have not been able to grow their revenues over 
$15 million in Africa.
Health insurance usually operates with high 
loss ratios and low reserves; however, with limited 
investment income opportunities, a profit margin 
needs to be generated through underwriting. Con-
tainment of medical costs within a member popu-
lation is an important key to profitability. The re-
cent failures of some HMOs in Kenya that lacked 
in-house care provision indicate that vertically in-
tegrating primary care may be a critical element 
of success. The prevalence of vertical integration 
financing opportunity could be higher in coun-
tries like Namibia and Zimbabwe, where several 
large HMOs are already active.
Although cost containment through in-house 
managed care can make insurance affordable, the 
main development impact is the creation of incen-
tives to catalyze the creation of a larger provider 
network. Integrated HMOs are also central to es-
tablishing an insurance culture across the region.
Figure A2.5 shows the key features of this busi-
ness model and the financials for such an integrat-
ed HMO in Nigeria. While this initiative is still 
not making a profit, it is expected to rapidly 
achieve break-even status followed by sustained 
profitability once subscriptions peak.
Urban clinics are quickly profitable
• Current five percent EBITDA margins. 
• Projecting ten percent EBITDA driven by 
improved cost efficiencies.
Significant recent growth
• Leading company in this sector in Nigeria, with 
29 registered HMOs, the company has grown 
significantly over the past three years, powered 
by the establishment of Nigeria’s National 
Insurance Fund.
Historical 
growth
Profitability
Figure A2.5 
Source: Country interviews; McKinsey analysis.
Case study, integrated HMO: Nigeria 
Large Nigerian HMO with more than 170,000 members and over 200 providers, the company is in the midst of a growth phase. 
• Part of larger hospital group.
• Operating as HMO since 1986,  
separate entity since 2005.
• 170,000 members in 2006:
– 70,000 from large corporations
– 100,000 from federal government
– 400 individual members 
• As of 2007 subsidized poor populations 
added as target group.
• Contracted network of 200+ providers in 
85 cities/towns, including selected public 
clinics.
• Working with overseas hospital group to 
optimize hospital operations.
• Recipient of grant from Global Fund for 
HIV/AIDS program and supported by 
Dutch Health Insurance Fund and 
PharmAccess Foundation. 
• Starting its own quality assessment 
agency for its external providers.
Description Key investment considerations
Future growth 
prospects
Continued rapid growth in the near future
• 150 percent subscribers growth in 2007:
– 125,000 paid by the Dutch Health  
Insurance Fund
– 120,000 police 
– 10,000 corporate 
– Additional retail subscription through local 
banks
• Future success will require:
– Improving cost efficiency without  
compromising quality of care.
– Investing in underwriting capabilities to 
support retail profitability.
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Micro Health Insurance
Microinsurance remains rare across Sub-Saharan 
Africa, but creating incentives for customers to buy 
health insurance along with traditional micro- 
finance products could create an excellent oppor-
tunity to spur the growth of the market and ex-
tend health care coverage within the poorer 
segments of society and rural populations. 
Plans including basic coverage for common or 
catastrophic conditions would be sold by the mi-
crofinance corporation and would be linked to 
products like loans. Combining insurance prod-
ucts and loans could yield cost synergies by reduc-
ing the transaction costs of separately offering 
loan and insurance products.
In Sub-Saharan Africa, the expected scale for 
such vehicles is $0.5–$5 million. Profitability is 
tightly linked to administration costs and default 
rates; these can be significantly reduced if linked 
to other microfinance products such as loans. In 
addition, products with higher cost sharing with 
customers can further increase margins. 
Most examples of microinsurance available to-
day involve social enterprises that are ready to ac-
cept sub-commercial rates of return on their busi-
nesses. In Bangladesh, where such models are 
significantly more developed, micro health insur-
ance achieves up to 39 percent profit (Figure 
A2.6). This model must be built on the existing 
infrastructure of a microfinance institution to am-
ortize enrollment and premium collection costs. 
Extending customer reach through financing 
pools such as farmers’ associations is critical to the 
success of these models.
Given the aggravated financial risk of insolven-
cy that could be brought on by an epidemic, the 
need to subsidize catastrophic coverage is acute 
within this sector. Governmental and donor sup-
Sample financials 2004
Income statement
Figure A2.6 
* Excluding grant funding of additional $126,015.
 Source: NGO website; country interviews; McKinsey analysis.
Case study, microinsurance: Grameen Kaylan, Bangladesh 
Grameen Kaylan is a micro health insurance scheme created by the Grameen Bank, recipient of the 2006 Nobel Peace Prize. It offers 
pre-paid insurance to all Grameen Bank employees and borrowers, as well as the poor close to any of its clinics. 
• Health program initiated in 1993.
• Ten clinics and $40 million endowment fund for start-up of 
operations.
• Upgrade of facilities and expansion financed by grants from 
International Labor Organization.
• Six health centers financed by donations from Stitching.
• Out of 2.5 million microfinance clients, 58,000 subscribe to 
voluntary health insurance.
• Pre-paid insurance card valid for 12 months.
• Insurance coverage includes:
– Free check-ups
– Pregnancy cost
– Limited hospitalization
– Discounts for drugs and diagnostic services
• Network of about 50 doctors in 29 rural health centers.
• Providers available for non-members who pay more.
Grameen Kaylan offers pre-paid insurance for  
the poor…
…in a financially successful model
Revenues
• No. covered lives
• Revenue
Costs
• Claims
• Administration
• Commissions
Operating income
• Depreciation
• Taxes
Operating margin
290,000
$ 338,005
$ 5,164
$ 38,611
$ 163,687
Non notable
Non notable
39%*
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port would be essential to manage and subsidize 
this risk. Microinsurance products provide a sig-
nificant level of financial protection for low- 
income groups. Furthermore, they establish a 
platform for more evolved health care products 
across communities. This, in turn, stimulates de-
mand among the poor and acts as a catalyst for 
overall growth of provision in this segment.
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Annex 3:  Examples of Successful Business Models in  
Life Sciences Manufacturing and Innovation
The estimated 2006 pharmaceutical market in Sub-Saharan Africa was $3.8 billion, of which local manufacturers produced 25–30 per-
cent. Medical supplies and devices accounted for 
an additional $2.1 billion, but less than ten per-
cent of that was locally produced. 
Two additional components of the life sciences 
are relevant to Sub-Saharan Africa’s health sector. 
One is the innovation taking place in the region, 
primarily in South Africa, where companies like 
Bioclones—which develops novel formulations for 
erythropoietin (EPO), a hormone used to treat re-
nal failure—are contributing to the establishment 
of a sustainable innovation sector. The other is 
research that is undertaken outside Sub-Saharan 
Africa but which is aimed at addressing health 
burdens that are relevant to Sub-Saharan Africa—
such as The Foundation for Innovative Diagnos-
tics (FIND), which has developed rapid tubercu-
losis diagnostics.
Provided that manufacturers will be able to 
withstand the pressure of competition from im-
ports, life sciences across the region (including 
South Africa) is expected to account for 14 per-
cent of projected cumulative health care invest-
ment opportunities, or about $1.6–$2.9 billion. 
Generic pharmaceutical manufacturing will be 
the largest single component, representing 40 per-
cent of the projected investment in this sector. 
Most of the investments in this sector are likely to 
be greater than $3 million.
Innovation represents most of the remaining in-
vestment opportunities, while medical supplies 
and devices manufacturing will absorb not more 
than three percent of the projected investment 
volume. The investment potential in clinical re-
search organizations (CROs) is even smaller, but 
could potentially present some attractive knowl-
edge-transfer opportunities for investors looking 
for smaller opportunities. Most CRO opportuni-
ties are expected to be below $250,000.
Overall, most of the investment opportunities 
in life science are large; two-thirds are expected to 
be greater than $3 million and one-third is ex-
pected to be between $250,000 and $3 million; a 
negligible component will be below $250,000 
(see Figure A3.1).
Following is a description of key industry dy-
namics and promising investment opportunities 
in these four areas.
   Figure A3.1
Life sciences investment opportunity, 
cumulative 2007–2016, including 
South Africa
Percent, $ million
64
35
1
By individual
project size
>3.00
<0.25
3
21
36
40
By sub-sector
Medical 
supplies
manufacturing
South African
life sciences
innovation
Infectious 
disease 
innovation
Generics 
manufacturing 0.25–3.00
1,600–2,900 1,600–2,900 
Source: Ministries of Health; National Health Accounts; country 
interviews; McKinsey analysis.
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Pharmaceutical	Manufacturing
More than 70 percent of Sub-Saharan Africa’s es-
timated $1 billion in annual pharmaceutical pro-
duction is concentrated in South Africa, where 
Aspen Pharmacare, the only vertically integrated 
manufacturer in the region, is the clear leader. Ni-
geria, Ghana, and Kenya together represent about 
20 percent of Sub-Saharan Africa’s pharmaceuti-
cal production (see Figure A3.2). Of these three 
countries, only Kenya produces significant vol-
umes for regional export—between 35 and 45 
percent of Kenyan manufacturers’ revenues come 
from exports to other Eastern African Commu-
nity (EAC) and Common Market for Eastern and 
Southern Africa (COMESA) countries.
Overall, 37 Sub-Saharan African countries 
have some pharmaceutical production, with 34 
having capacity for formulation and 25 limited to 
packaging or labelling. Only South Africa has a 
limited degree of API production. Most produc-
tion outside South Africa is of non-complex, high-
volume, essential products, such as basic analge-
sics, simple antibiotics, anti-malarial drugs, and 
vitamins.
Local manufacturers currently capture only a 
small share of the donor market in Sub-Saharan 
Africa (estimated to amount to a total between 
$750 million and $1 billion), which is mostly fo-
cused on treatments for HIV, TB, and malaria. Do-
nor-funded contracts generally require product 
prequalification from stringent regulatory bodies 
such as the WHO or the United States Food and 
Drug Administration (FDA). As of April 2007, 
only two Sub-Saharan African manufacturers113 
had WHO prequalified products, and only 11 of 
   Figure A3.2
Estimated pharmaceutical market and generics manufacturing in Sub-Saharan Africa
44
28
28
100% = 3,800
SSA Pharmaceutical
market
Local generics
Imported generics
Imported originators
735
25
36
9
12
14
22
56
56
1,072
South Africa
107Nigeria
Ghana
Kenya
Senegal
Côte d’Ivoire
Tanzania
Uganda
Rest of Anglo/Lusaphone
Rest of Francophone
SSA
Breakdown of estimated ex-factory 
pharmaceuticals market in SSA, 2006
Percent, $ million
Breakdown of estimated ex-factory local generics 
manufacturing by country, 2006
$ million
89%
Of 46 SSA countries, 37 have pharmaceutical industries, with 34
doing formulation, 25 doing packaging/labelling, and just 1* doing
limited API production
* South Africa’s Fine Chemicals Corporation (owned jointly by Aspen Pharmacare and  India’s Matrix) is the only API producer in SSA. 
Source: Country interviews, BMI South Africa Pharmaceuticals and Health Report Q4 2006; Global Insight; IMS; Company annual reports; African Union  
Draft Pharmaceutical Manufacturing Plan; McKinsey analysis.
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the 248 WHO prequalified HIV, TB, and malaria 
medicines were produced by these two Sub-Saha-
ran African manufacturers. While several manu-
facturers in the region are seeking prequalifica-
tion, it is a difficult process for most of them—it 
requires renovation of production facilities, famil-
iarity with qualification requirements and pro-
cesses, and a dossier of product efficacy and safety 
tests that meets with regulatory bodies’ require-
ments. Given the prevalence of small manufactur-
ers in the region, the above requirements repre-
sent too high an economic burden, and at the 
same time often exceed the limited technical ca-
pability of the management teams.
Sub-Saharan African manufacturers generally 
produce at a cost disadvantage to the large Asian 
generic manufacturers (Figure A3.3). One key 
disadvantage is scale. Although conversion cost 
scale efficiencies generally plateau around 1.0–1.5 
billion tablets in blister packaging per year, pro-
duction at most Sub-Saharan African formulation 
sites is far below that level. For example, it is esti-
mated that a third of the 30–40 percent cost dis-
advantage that a leading Ghanaian manufacturer 
suffers versus high-scale Indian manufacturers is 
attributable to scale.
Other causes of production cost disadvantage 
include a more expensive asset base (partially re-
lated to less-optimized process design), often cou-
pled with obsolete technology, financing costs, 
and lack of integration with API production. In 
some cases, for example South Africa, labor costs 
are significantly higher than in India. In other situ-
ations, lower labor productivity leads to higher 
labor costs even where employee wages in com-
parable roles are close to those in Asia. Finally, 
   Figure A3.3
Estimated representative production cost structure for a bottle of 100 simple analgesic tablets* 
Indexed to Nigeria ex-factory production cost = 100 
Production scale**
Indexed to Nigeria = x 
x
x
4x
10x
10x65
75
90
100
100Nigeria
South Africa
Tanzania
India
Ghana
–35%
* Costs include both raw materials (API, non actives, and packaging) and conversion.
** Relative volumes based on manufacturing plants with estimated production of 1.2 billion tablets for South African facility vs.  
     500 million for Tanzanian facility, 120 million for Nigerian facility, ~120 million for Ghanaian facility, 1.2 billion for Indian facility.
Source: Ghana Ministry of Health; Energy Information Administration 2006 Industry Electricity Prices; country interviews; McKinsey analysis.
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regulation can work against local production, as in 
the Democratic Republic of Congo, where high 
import duties on packaging materials result in a 
higher overall tax on production for local manu-
facturing than on importing.
Freight costs do not go very far to close the gap 
between low-cost imports and locally manufac-
tured generics, since they only account for approx-
imately 12 percent out of 35 percent of the cost 
disadvantage (or four percent of the ex-factory 
cost of local manufacturers). 
Moreover, given import difficulties and the 
fragmentation of distribution networks, shipping 
to other markets in Sub-Saharan Africa can be 
more expensive than Asia-to-Africa shipping, 
thus significantly limiting export opportunities. 
Intra-African imports are often subject to the 
same import tariffs as intercontinental ones, and 
manufacturers report that even when there are 
favorable trade terms between countries, they of-
ten do not actually enjoy the benefits (tax breaks), 
since they either don’t extend to pharmaceuti-
cals or are misapplied. 
Despite this cost disadvantage, last year Sub-
Saharan African manufacturers sold $1 billion of 
generic pharmaceuticals in the region.114 In most 
countries, local producers benefit from regulatory 
support in one or more of the following forms: (1) 
preference policies for public tenders (price ad-
vantage); (2) tax benefits on raw materials, inter-
mediates, and final products; and (3) import bans 
on selected essential medicines (for example, in 
Ghana and Nigeria, import is banned for the sev-
en largest volume products).
In general, these protectionist policies aid the 
domestic competitive position of Sub-Saharan 
African pharmaceutical manufacturers. As local 
manufacturers increase their production capabili-
ties, it is plausible to anticipate that governments 
will extend this support to new products or seg-
ments of the supply chain. However, whether 
these policies will improve access to more afford-
able drugs or create the right incentives to im-
prove drug quality is debatable. 
Over the past decade, key stakeholders in the 
Sub-Saharan African pharmaceutical industry 
have debated whether the establishment of local 
manufacturing has a beneficial role to play in in-
creasing the accessibility to and quality of drugs. 
In many instances there is a perception that local 
manufacturing improves production quality over-
sight and security of supply. However, evidence of 
this is mixed. A 2003 WHO study of anti-malarial 
drug quality in selected Sub-Saharan African 
countries acknowledged that it is easier to exer-
cise oversight over local producers than foreign 
producers. However, no consistent quality differ-
ences between locally and imported products 
were found.115
Separate research found that, although over 90 
percent of counterfeit products in Nigeria with an 
identified source were imported, 44 percent of 
banned products come from unidentified sourc-
es.116 Any effort to limit the tragically high preva-
lence of counterfeit and substandard products in 
Sub-Saharan African markets would certainly 
serve both patients’ and legitimate manufactur-
ers’ interests.
Some stakeholders express concern regarding 
security of supply for HIV, TB, and malaria 
(ACTs) treatments given patients’ vulnerability to 
shortages in product availability. Supply interrup-
tions that might occur if product supply was not 
able to respond immediately to demand—for ex-
ample, as a result of a surge in global demand for 
such drugs—could theoretically cause supply in-
terruptions and be disastrous for patients requir-
ing these remedies. To put some quantification 
around this concern, if the percentage of HIV-af-
fected Indian population under ARV treatment 
were to increase from its 2005 levels of seven per-
cent to 50 percent, the worldwide demand would 
grow by an estimated 25 percent.117 
API supply appears to be the key potential 
vulnerability, and this would not be addressed 
unless Sub-Saharan African manufacturers were 
able to develop greater control over their API 
supply. While it would be hard for Sub-Saharan 
Africa to develop a competitive API industry 
(given scale and expertise disadvantages), a via-
ble alternative seems to be increasing the local 
formulation of final products to a size where it 
would be possible to acquire an offshore API 
source; this is the case for Aspen Pharmacare, 
which recently acquired API production facili-
ties in both South Africa and India.
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Notwithstanding the debate about the benefits 
of local production, there is a clear mandate from 
Sub-Saharan African governments and regional 
bodies to support the development of pharma-
ceutical manufacturing in Sub-Saharan Africa. 
This is made explicit in the African Union’s 2007–
2015 health strategy, which stated that “African 
Union Member States need to embark on local 
production of pharmaceuticals and other health 
commodities.”
Key Investment Opportunities
Successful local companies have adopted some or 
all of the following strategies to increase their 
competitiveness: 
• Establish scale and invest in quality certifica-
tion. The opportunity to build scale is impor-
tant to the growth and future competitiveness 
of Sub-Saharan African manufacturers. Likely 
future opportunities include: 
 – The growth of domestic generic pharmaceu-
tical markets; domestic industry consolida-
tion; and greater access to regional and even 
global markets. In addition to revenue growth 
opportunities, there are productivity gains to 
be garnered from increased manufacturing 
scale. Furthermore, large-scale manufacturers 
are better able to support the costs and ad-
ministration needs associated with certifica-
tion and maintenance of quality standards.
 – Expansion of product portfolios. Larger-scale 
manufacturers are more likely to obtain 
WHO prequalification and, therefore, be-
come able to locally produce more ARVs, TB 
drugs, ACTs, and drugs for the treatment of 
the region’s growing non-communicable dis-
ease burden (hypertension, heart disease, 
cancer, etc.) in addition to the low-complex-
ity, high-volume drugs local manufacturers 
often have the capability to manufacture at 
this time.
 – Aggregation of country markets into regional 
markets. This would create significant scale 
opportunities for Sub-Saharan African man-
ufacturers (see Figure A3.4, where the po-
tential opportunity created by regionalizing 
markets according to current regional trade 
community memberships is estimated). 
• Secure contract manufacturing, product li-
censing, or other technology-transfer-based 
relationships with multinational companies. 
Sub-Saharan African manufacturers can derive 
significant advantages from partnerships with 
multinational companies, including leading 
South African manufacturers. Contract manu-
facturing or licensing arrangements offer local 
firms the opportunity to expand product port-
folios, increase market share, and develop com-
petencies. There are multiple local firms that 
have tie-ups/joint ventures with either niche 
multinational companies or Indian manufac-
turers (especially in South Africa) who could 
help improve the viability of local manufactur-
ing. For example, the Cipla-Medpro relation-
ship has facilitated technology transfer and cost 
effective manufacturing.
Typically, foreign manufacturers’ criteria in as-
sessing local partners for contract, license, or joint 
venture relationships are the prospective local 
partner’s production capability and standards, 
market access and position, and management pro-
fessionalism. 
An example of a successful generics manufac-
turer is detailed in Figure A3.5.
Manufacturing	of	Medical	Supplies
The overwhelming majority of Sub-Saharan Afri-
ca’s estimated $2.1 billion medical supplies mar-
ket is imported. This lack of local manufacturing 
is generally linked to the lack of scale for com-
modity supplies, the production complexity of 
specialized devices, and the established expertise 
or proximity to raw materials (such as latex) of 
other production sites.
However, there is a case for local manufactur-
ing for the following categories of goods:
• Bulky products. For items such as furniture for 
hospitals and clinics, local manufacturers would 
have a significant distribution and cost advan-
tage over imports. 
• Products that make use of locally available raw 
materials. Vertical integration efficiencies and 
the lack of tariffs on local raw materials would 
allow viable production of goods such as gauz-
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es and dressings. For example, cotton is grown 
in Uganda, Senegal, and Mozambique, and 
manufacturing finished cotton products would 
be a natural vertical integration opportunity.
• Products that require customization. Items 
such as prosthetics and eyeglasses typically re-
quire proximity to users. 
• High-value products and products in high- 
tariff categories. For example, Disa Vascular in 
South Africa can supply the local market with 
high-quality coronary stents, relying not only 
on state-of-the-art technology but also on its 
protection from import duties.
In addition, the availability of existing capacity 
favors the production of goods with low manufac-
turing complexity and/or those that are related to 
an existing industry, such as textiles. Three large 
product categories that fit the above criteria are 
mosquito nets—the current shift is toward long-
lasting insecticide treated nets (LLINs)—medical 
gauzes, and medical furniture. 
As shown in Figure A3.6, in 2007 LLINs repre-
sent a global market of $150–$300 million, of 
which about two-thirds is concentrated in Sub-
Saharan Africa.118 Medical gauzes, wadding, and 
dressings represent an estimated $90–$120 mil-
lion annual market in the region. Medical and 
dental furniture represent an estimated $80–$120 
million annual market. 
   Figure A3.4
National market sizes, 2006 
$ million
South Africa
Local production* Imports Local production* Imports
Nigeria
Côte d’Ivoire
Ghana
SADC
662 1,971
101 405
11 176
50 167
687 2,230
76 597
153 587
37 375
13 160
17 115
8 81
33 53
2 18
Rest of 
COMESA** 
and CEMAC
Anglo/
Lusaphone 
ECOWAS
Francophone 
ECOWAS
Kenya
Senegal
Uganda
Tanzania
Average 
of other 
37 countries
Regional market sizes, 2006
$ million
Evaluation of scale effects of regionalization of pharmaceutical production 
In addition, large manufacturers could afford the investment and time required to
undergo WHO certification and access donors’ markets
 * Domestic production for domestic market. Excludes intra-African exports, e.g., Kenyan production exported to other African countries.
 ** Includes Tanzania. Excludes COMESA countries that are also in SADC. 
 Source: Country interviews, BMI South Africa Pharmaceuticals and Health Report Q4 2006; Global Insight; IMS; Company annual reports; African Union  
   Draft Pharmaceutical Manufacturing Plan; McKinsey analysis.
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Figure A3.5 
1. Swipha is a top-three Nigerian manufacturer…     …with distinctive quality…  …that is poised for growth.
Estimated share of Nigerian manufacturing     Quality certification Growth opportunity
Percent 
* Excluding estimated 25 percent of products (by value) imported in final product form from Roche (Swipha), 33 percent from Cipla for Evans, 25 percent from  
Aventis for May & Baker. GlaxoSmithKline is Nigeria’s largest pharmaceutical company, but locally manufactured value is less than those listed above.
Source: Country interviews; company business plan; McKinsey analysis.
Case study, certified generics manufacturer: Swipha, Nigeria
Swipha is a leading generics manufacturer in Nigeria with good quality that is poised for growth. Swipha is investing in growth, but still 
has a lot of room for growth in order to become a continental leader. 
• Large market opportunity.
– Nigerian pharmaceutical market 
~$400 million.
– ECOWAS pharmaceutical market 
~$1 billion.
• Strict quality standards creates growth 
opportunities.
– Key concern for MNCs considering 
contract manufacturing is quality.
– Nigerian regulator intends to 
increase local GMP requirements. 
The only Nigerian  
manufacturer with  
ISO 9000 certification. 23
16
13
12
Evans*
Swipha*
May &
Baker*
Emzor
2. Swipha is investing in expansion but still has a lot of room to grow in order to become a regional leader.
210140
~ 3,000
Swipha
Phase II
Aspen
Pharmacare
13x
Swipha
Phase I
Estimated tablet capacity (million/yr.)
• Swipha just finished 50 percent 
expansion of tablet capacity and  
40 percent liquid capacity.
• Swipha plans additional 50 percent 
expansion of tablet capacity.
• Swipha plans to expand regionally 
first by participating in Ghanaian 
public tenders.
• Top 20 global generics  
manufacturer.
• Owns API manufacturing plants in 
South Africa and India.
• Products pre-qualified with 
multiple stringent regulators 
(WHO, USFDA, etc.).
• Expanded businesses in United 
Kingdom, Australia, and recently 
United States.
• Employs > 2,500 people.
The LLINs case example below (Figure A3.7) 
shows the challenges of investing in LLINs as well 
as the potential opportunities. 
Innoation
In 2006, South Africa spent 0.9 percent of its $250 
billion GDP on research and development across 
industries. In comparison, India’s spending in re-
search and development is 1.2 percent of GDP, or 
$9.5 billion, and the amount for the United States 
is 2.7 percent of GDP, or $350 billion.
Private sector investment in biological, medi-
cal, and health sciences accounted for less than 10 
percent of that value in South Africa.119 Not sur-
prisingly, there is only one biotech-focused ven-
ture capital firm in the country, Bioventures, with 
just $11 million under management. 
Limiting factors for the development of early 
stage biotech venture capital funds have been:
• Few exit opportunities. There are no later stage 
venture capital firms to fill the developmental 
funding pipeline and private equity firms are 
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not interested in such early entrepreneurial 
models or in risky biotech investment. In addi-
tion, in recent years major device and biotech 
companies (usually the larger exit opportunity) 
have been less acquisitive of new ventures.
• A limited pipeline. Venture capital firms would 
have to reach down further into basic research 
to “pull up” very early stage companies, and 
therefore would end up holding investments 
for a very long time.
• Lack of experience. Few funding sources un-
derstand the sector well enough to feel com-
fortable investing in it.
On the other hand, about 51 biotech compa-
nies are active, engaged in first-, second-, and 
third-generation technologies.120 
Although small by global standards—private 
sector life sciences innovation outside large com-
panies spending in clinical research currently 
receives an estimated $50–$60 million—South 
Africa’s emerging life sciences innovation sector 
has a strong base. The nation is politically stable 
and enjoys the subcontinent’s highest rating for 
ease of doing business.121 The country has strong 
communication, research, and physical infrastruc-
tures, and it is endowed with one of the world’s 
highest rates of biodiversity per unit area.
   Figure A3.6
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$ million Suitability for local production 
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and infrastructural demands of production.
Attractiveness depends on specific instrument; sub-categorization
necessary.
High complexity of production.
Potentially attractive.
Attractive opportunity given size of the product and ease of 
manufacturing. Currently done by A to Z Textiles in Tanzania.
Simple product but highly dependent on availability of high-
quality latex.
Simple moulded production but few opportunities for 
competitive advantages.
Bulky product lends SSA distribution cost benefit.
Potentially attractive.
Extension of existing, well developed, cotton and 
textile industries.
Complexity of production may make unattractive.
Evaluation of opportunities for local manufacturing of medical supplies
* All figures, except mosquito nets, are imports with estimates extrapolated from Comtrade medical supplies import data to countries with 65 percent of total 
2007 Sub-Saharan African health care spending and estimating that imports represent 95 percent of SSA  medical supplies. LLIN sizing based on Roll Back 
Malaria projection of 42 million nets demanded in 2006, assuming 70:30 (30m:12m) LLIN : conventional net split, at $5/net pre-distribution price based on 
producer interviews and net prices quoted on Roll Back Malaria website data.  Price encountered ranges from $4 to $6, pre-distribution. 
Source: Comtrade; Rollback Malaria; McKinsey analysis.
	 The Business of Health in Africa  ( 	
South Africa also has strong academic and re-
search institutions with expertise in the biomedi-
cal sciences and a track record of medical device 
innovation. Historically, however, intellectual 
property (IP) has generally been sold off-shore or 
simply not been commercialized. Hence research-
ers lack experience commercializing IP.
On the basis of the above, access to capital 
from financiers with investment experience in in-
novation would address a critical need in the sec-
tor’s development. 
The sector’s need for capital extends along the 
developmental pipeline, from pre-clinical work to 
commercialization of both APIs and intermediate 
or finished products.
Figure A3.7 
A large market… …and a challenging market
• Estimated $120–$250 million per annum 2007 market in 
SSA, based on 30–50 million nets at $4–5/net ex-factory.
• LLINs have lower life-time cost to user ($5.33) than regular 
insecticide treated nets (ITNs) that last fewer washes ($8.33).*
• 10–20 percent margins.
* Rollback Malaria estimate based on three year lifespan (estimate of seven washes/year), and re-treatment of ITNs every six months.
Source: Country interviews; Rollback Malaria; McKinsey analysis.
Case study, medical supplies manufacturing: long lasting insecticide treated nets (LLINs)
LLIN manufacturing illustrates some of the opportunities and challenges for supplies manufacturing in Sub-Saharan Africa. There is 
currently one LLIN manufacturer in Africa, Tanzania’s A to Z Textiles, making three–four million nets per annum.
• Challenging business environment given price variations 
between countries, nascent distribution systems, need to sell 
on credit, higher up-front user cost than insecticide treated 
nets (ITN), risk of counterfeits.
• Slow registration process (both WHOPES & in-country) vs. 
conventional nets that do not require registration.
• Market for LLINs is currently >90 percent public/donor 
funded, and not yet a developed or sustainable private 
market.
Africa already produces textiles and bed nets… …although it is at a cost and technical disadvantage  
 to Asia
• Africa has local textile manufacturing.
• Textile manufacturers have experience with mosquito net 
production (but not LLIN production).
• Cost leaders are Bangladesh, Vietnam, and China.
• Technical leaders are Thailand and China.
A bulky product means a freight advantage… …which helps, but does not achieve cost parity
• Bulky product may offer distribution cost savings if  
manufactured locally.
• Distribution costs estimated at only five percent of total cost 
for nets with stenting technology. The key cost considerations 
are in yarn, stitching, stenting, chemicals, and financing.
There may be preference for local supply… …and that will require building sustainable private  
 markets
• With a high malaria burden, Africa has an interest in ensuring 
a stable LLIN markets, including supply.
• Potential for preferential status as a local producer when  
competing for tenders, especially if channeled through 
government procurement.
• Local supply would support the development of sustainable 
markets needed to reach more people.
• Developing competitive local supply requires a long-term  
co-investment by local manufacturers and foreign technology 
owners.
• To build a rationale for long-term co-investment, donors, 
governments, and suppliers need to collaborate to develop 
sustainable private LLIN markets.
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With other imperatives for public spending in 
South Africa, including other urgent health needs, 
future growth in research and development in-
vestment may need to come largely from the pri-
vate sector. In 2006, South Africa’s Ministry of 
Finance increased tax deductions for private re-
search and development from 100–150 percent, 
signalling strong support for private sector-led in-
novation. That support builds on a public invest-
ment in 2003 in biotechnology regional innova-
tion centers to support the commercialization of 
life sciences research. 
Additionally, South Africa enjoys a strong rep-
utation for clinical research, with a $10 billion 
global industry that grew a remarkable 15 percent 
from 2005–2006.122 With a strong laboratory in-
frastructure, a diverse native patient population, 
reliable ethical standards, and lower costs than 
similar research in the Western world, the country 
is an attractive base for clinical research. At pres-
ent South Africa absorbs an estimated three per-
cent of the global market (400 studies in Africa, of 
8,000 globally123). 
External investment opportunities in clinical 
research organizations are, however, limited. 
With an estimated capital investment of only 
$30,000–$60,000 to set up an out-patient clini-
cal research site, the need for external financing 
is particularly low.
The key driver of public support for life sci-
ence innovation in South Africa is the aspiration 
that local innovation will generate solutions to lo-
cal health burdens. Public funding and research 
institutions are seeking to prioritise initiatives that 
address key health burdens, such as HIV and TB, 
or that develop innovations related to key indus-
Figure A3.8 
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Source: Country interviews; McKinsey analysis.
Case study, biotech innovator: Disa Vascular, South Africa 
Disa Vascular is a South African biotech company that develops coronary stents. With strong academic backgrounds but minimal prior 
commercial experience, Disa’s founders have developed market-ready innovations with limited external funding.
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trial sectors, such as mining and agriculture. Entre-
preneurs, on the other hand, are primarily guided 
by the market opportunity for their products 
(both domestic and global) and the research inter-
ests of product innovators. 
For now, the best opportunity for commercial 
investors may be in late-round funding given the 
dearth of venture capital, greater public participa-
tion in early stages of funding, and the long time to 
exit. The current landscape shows that investors 
prefer innovations that are cheap to develop and 
quick to commercialize, such as medical devices 
and innovative formulations of existing drugs.
Figure A3.8 shows the investment opportunity 
associated with Disa Vascular, a South African 
biotech company producing coronary stents.
Commercialization	of	Infectious	and	
Neglected	Disease	Research
Sub-Saharan Africa stands to benefit greatly from 
the development and commercialization of infec-
tious disease medicines and products. The region 
bears a disproportionate share of the world’s in-
fectious disease burden (Figure A3.9).
Africa bears 88 percent of malaria’s health bur-
den, 76 percent of HIV’s health burden, and 58 
percent of the overall HIV, TB, and malaria, 
neglected disease burden. The bulk of this is bur-
den is found in Sub-Saharan Africa. Investing in 
solutions to these diseases, no matter where the in-
novation is based, is key to addressing the most im-
portant problems in Sub-Saharan African health.
   Figure A3.9
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A significant opportunity to make a dramatic 
and positive impact on health care in Sub-Saharan 
Africa lies in financing the commercialization of 
infectious and neglected disease products that are 
developed at a global level. Although there are sev-
eral sources and models of innovation for such 
products, commercial/non-profit product develop-
ment partnerships (PDPs) are the clear leaders in 
this area.
The prototypical model for a PDP centers on a 
non-profit, donor-funded organization that man-
ages a portfolio of partnerships with multiple 
commercial companies and research institutions, 
all focused on developing a drug, vaccine, diagnos-
tic, or other product for a specific disease. For ex-
ample, the Malaria Vaccine Initiative (MVI) is a 
donor-funded organization that is partnering with 
companies such as GlaxoSmithKline, Shanghai 
Wanxing Bio-pharma, and GenVec, and research 
institutions such as La Trobe University in Austra-
lia and the International Center for Genetic Engi-
neering and Biotechnology in India to develop a 
malaria vaccine (Figure A3.10).
MVI provides its partners with financial and 
technical support and, in exchange, requires that 
they commit to preset, low “cost-plus” prices for 
the public sector of poor nations. The commercial 
or institutional partners own the IP that is devel-
oped by the partnership and are free to pursue 
commercial pricing in wealthy nations, as well as 
in the private sector of poor nations.
Figure A3.10 
Malaria Vaccine Initiative (MVI)
• Donor funded (Bill & Melinda Gates  
Foundation).
• Focused on single disease (malaria) and product 
type (vaccine).
• Currently managing ten active projects with  
18 partners.
Source: Country interviews; MVI web site; McKinsey analysis.
Case study, product development partnerships: Malaria Vaccine Initiative (MVI)
MVI provides financial 
investment and technical 
support
Partners commit to low 
prices for products to 
public sector of poor, 
highly burdened countries
Potential Investor Role
• No clear role with non-profit initiative. • Finance production in developing markets.
• Get involved in late-stage clinical trials.
• Technical assistance with commercialising product 
and market execution in Sub-Saharan Africa.
Research partners
• Develop and own IP.
• Produce for global market in pursuit of 
commercial interest, potentially cross- 
subsidising between markets to support  
low prices in poor markets.
• Late-stage clinical trials can be barrier if clear 
upside potential of product does not exist.
• Initiatives may require ongoing donor support 
during commercialisation phase (until 
economic sustainability is established).
• MVI partners include (non-exhaustive list): 
– GlaxoSmithKline Bio (Belgium)
– Shanghai Wanxing Bio-pharma (China)
– GenVec (U.S.)
– International Centre for Genetic 
Engineering and Biotechnology (India)
– La Trobe University (Australia)
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Commercial partners often also see their in-
vestment in neglected disease research as part of 
their commitment to corporate social responsibil-
ity. There are similar partnerships pursuing malaria 
drugs (e.g., the Medicines for Malaria Venture); 
diagnostics (e.g., the Foundation for Innovative 
New Diagnostics); and other products (e.g., Net-
Mark, which focuses on developing affordable and 
easily transferable LLIN technologies). 
Investing in the commercialization of APIs, 
pharmaceuticals, and products developed by 
PDPs could entail financing some of the costs of 
Phase 3 clinical trials, as well as costs related to 
commercialization (such as manufacturing and 
product registration), provided that the products 
had significant market potential in wealthier 
countries (making the opportunity appealing 
from a financial standpoint).
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Annex 4:  Examples of Successful Business Models in 
Distribution and Retail
The challenge posed by the epidemic of coun-terfeit drugs—and the health risks they rep-resent—in Sub-Saharan Africa makes distri-
bution and retail industries an extremely sensitive 
component of the health care sector. In Kenya, a 
survey by the National Quality Control Laborato-
ries (NQCL) and the Pharmacy and Poisons 
Board, and based on a random sample of 116 anti-
malarial products, found that almost 30 percent 
of the drugs in the country were counterfeit.124 
Some of the drugs lacked the necessary active 
pharmaceutical ingredients, contained the wrong 
ingredients, or were useless preparations. Aside 
from the obvious immediate threat this presents 
to the patient, an even larger issue is associated 
with the potential increase in resistance rates that 
such counterfeits can cause. These outcomes make 
such practices absolutely damaging. 
According to the Kenyan Association of the 
Pharmaceutical Industry, counterfeit pharmaceuti-
cal products account for approximately $130 mil-
lion annually in sales there;125 in Nigeria, the largest 
market in the region, 17 percent of the drugs in 
circulation are still fake despite recent focused ef-
forts undertaken by the National Agency for Food, 
Drug Administration, and Control (NAFDAC). 
There are several forces driving the demand for 
counterfeit and substandard drugs; the financial 
inaccessibility of basic medicines and limited 
physical access are the obvious ones. If affordable 
quality drugs were available at reliable retail out-
lets, or if drug coverage could be fostered, the 
market for drug peddlers would diminish. 
In addition to the above, however, one of the 
key root causes of the prevalence of this problem 
in Sub-Saharan Africa is the difficulty in utilizing 
an enormously fragmented supply chain that feeds 
both the public and private sectors. 
In Uganda there are over 100 officially regis-
tered drug importers/distributors, and 12–14 “in-
dustry leaders” In Nigeria there are 292 licensed 
medical importers and 724 licensed medical dis-
tributors; one leading manufacturer reported sup-
plying a complex network of both outsourced and 
owned distribution that involves more than 100 
distributors.
The regional exception to this fragmentation is 
Francophone West Africa, where four major dis-
tribution companies serve the region, largely us-
ing France as an operational hub. Naturally the 
landscape is also fundamentally different in coun-
tries with higher public participation in the indus-
try. In Tanzania and Mozambique, for example, 
most distribution is carried out by quasi-govern-
mental companies that dominate the market, 
making quality control significantly easier to en-
force.
In addition to fragmentation, the large role of 
informal channels (where quality is by nature 
harder to control) make the situation more chal-
lenging; for example, 60 percent of the secondary 
distribution in Nigeria takes place in informal 
markets, which also supply a large proportion of 
formal retailers. Pharmacists often prefer to pick 
up goods from the marketplace at a discount rath-
er than having them delivered through formal dis-
tribution channels. 
The lack of transportation infrastructure in the 
region also significantly hinders the growth of dis-
tribution businesses in general. The poor state of 
roads and ports raises capital costs and reduces as-
set life. Other infrastructural shortcomings, such 
as an inconsistent electricity supply, make the es-
tablishment of cold chains for vaccines and other 
sensitive drugs difficult. Also, low point-to-point 
volumes limit the investment return from build-
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ing direct distribution capabilities within or be-
tween countries and create the need for hub-and-
spoke models. Most distribution companies either 
focus on specific product lines or specific geo-
graphic regions. Most established enterprises make 
net margins of seven to 20 percent and importers 
can make net margins of up to 30 percent (de-
pending on the drug) if they integrate import and 
distribution. 
Retail is the most profitable segment within 
health care across most of Sub-Saharan Africa. 
Net margins can vary between five and 50 percent 
depending on the country. In Tanzania, where 
there are no margin limitations and there is limit-
ed competition in retail due to the small number 
of pharmacy authorizations granted, retailers have 
a gross margin of 80–100 percent, depending on 
the product.
In Senegal, by contrast, gross retail margins are 
set by regulation to 23 percent and, without any 
incentives to promote cheaper drugs, pharmacists 
actively push more expensive branded products.
Across Sub-Saharan Africa, hospitals and clin-
ics often depend on their pharmacies to cross- 
subsidize their business. For example, in one 
Kenyan outpatient clinic, 70 percent of the clinic’s 
profit comes from its pharmacy. 
Aside from pharmacies that are part of public 
hospitals and clinics, most formal outlets are pri-
vate, single-outlet operations. For example, over 
1,500 retail outlets are legally registered with the 
Pharmacists Council of Nigeria, but the only retail 
chain is Mediplus, with 10 outlets. This scenario 
offers significant opportunities for consolidation. 
In South Africa, where retail margins have been 
stringently regulated in recent years, the sector is 
shifting rapidly toward the existence of major 
chains because they are able to compensate for 
lower margins with volume. In the remainder of 
Sub-Saharan Africa, only a handful of chains are 
in operation; however, those that do exist are ex-
tremely successful, in some cases showing growth 
rates of over 100 percent a year.
Given the significant regulatory and infrastruc-
tural differences between the region’s nations, the 
opportunity for growth through consolidation is 
country-specific. For example, in Uganda each 
pharmacist can operate a maximum of only two 
retail outlets. Given the shortage of qualified phar-
macists, there are only 250 retail pharmacies in the 
country. Similarly, Senegalese law limits pharmacy 
ownership to a single pharmacist. So, it is not pos-
sible to own a pharmacy chain in that country. In 
other areas, the ability to consolidate pharmacies 
to create chains may be limited less by regulation 
than by the infrastructure complexities of manag-
ing a geographically dispersed business.
Figure A4.1 shows the difference in industry 
landscape in three representative countries.
Distribution	and	Retail	Will	Present	
Inestment	Opportunities	of	Oer		
$	Billion
It is estimated that distribution and retail will at-
tract about 14 percent of the projected cumula-
tive investment demand, or about $1.6–$2.8 bil-
lion (see Figure A4.2). Nearly 80 percent of 
investments will finance the development of dis-
tribution infrastructures (warehouses, trucks, and 
supply chain management information systems), 
with the vast majority of the opportunity concen-
trated in the medium-sized enterprises range (87 
percent of investments in distribution will be in 
the range of $0.25–$3 million). Within retail, 
where the remaining 21 percent of the opportu-
nity will lie, most of the investment will finance 
SMEs with project sizes below $250,000. 
Successful	Strategies	Exist	and		
Will	Represent	the	Basis	for		
Competitieness
Entrepreneurs and business managers have devel-
oped many strategies for success in this challeng-
ing environment, and they will represent the basis 
for competitiveness either on a country or a re-
gional basis.
• Forward or backward integration. Distribution 
is a business that presents opportunities for in-
tegration worldwide. However, in the case of 
Sub-Saharan Africa, experience with integra-
tion has so far been very limited (with the ex-
ception of Francophone Africa), mostly due to 
limitations in access to capital. In the vast ma-
jority of cases, products go through a national 
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importer/distributor, who then sells to a pri-
mary distributor, who again sells to a local 
wholesaler. In numerous situations the number 
of steps in the supply chain is even greater, and 
this obviously creates a significant amount of 
inefficiency in terms of assets and inventory 
management. 
• Leveraging the informal network of non-phar-
macy drug outlets. In spite of extreme frag-
mentation, the informal network as a whole 
offers a capillary infrastructure and the possi-
bility to access rural areas where the formal 
sector would not be able to compete due to the 
limited scale of the market. Leveraging this 
network—with the necessary control mecha-
nisms—can be a major source of competitive-
ness. For example, in Senegal some pharmaceu-
tical distributors have partnerships with local 
redistributors, shipping parcels of products via 
the informal network of buses that covers the 
rural regions of the country.
• Guarantee of quality through scale or fran-
chise. In today’s market, a guarantee of quality 
is a more significant strategic advantage than it 
was in the past. Initiatives such as the consum-
er awareness campaigns launched by NAFDAC 
    Figure A4.1
Uganda
Distribution
Nigeria
• Potential for regional integration of 
distributors due to moderate domestic 
consolidation, the requirement to import 
through other countries from being 
landlocked, presence of large export-
oriented manufacturers in neighbouring 
countries, and regional trade policies of 
COMESA and EAC.
Opportunities
• Vertical integration between 
manufacturing and distribution, 
or between retail and distribution 
for high population density areas. 
Rural distribution opportunities by 
combining medical product distribution 
with other goods or with transport 
services.
• Significant investment required to 
enter market as a distributor. 
Possibility of network of separately 
owned pharmacies to jointly invest 
in distribution company given high 
degree of industry organisation 
among pharmacies.
Senegal
Industry
structure
• 10–20 percent estimated net margins. 
Distribution largely controlled by 8–12 
companies; landlocked country means 
imported products often come through 
neighbouring countries first.
•
• Reported margins low at 2–10 percent, 
depending on volume and region.
Largely private and highly fragmented 
(290 registered importers and 720 
registered distributors); fragmentation 
stimulates competition but introduces 
supply chain weaknesses resulting in 
obsolescence and counterfeit leakage.
•
• Distribution gross margins capped 
at 18 percent by law, often 15 
percent after discounts.
Consolidated among three major 
distributors with a  fourth smaller one. 
Regulatory requirements for distributors 
to serve all retail outlets raises costs 
of entry.
•
Retail
• Consolidation of pharmacies, employing 
at least one pharmacist for every two 
pharmacies;  demand exists for additional 
outlets but growth is limited by shortage 
of qualified pharmacists.
Opportunities
• Consolidation of outlets into 
pharmacy chains is a significant 
opportunity, further improved by the 
high geographic concentration of 
existing outlets in urban centers, 
(Lagos state has 30 percent of total 
national outlets, Abuja has 11 percent).
• Limited opportunity given the 
regulatory limitations on scale.
Industry 
structure
• Fragmented market with ~35 percent 
margins make retail lucrative and allow 
room for competitors to harvest volume 
at lower prices.
Shortage of pharmacies despite high 
margins due to limited number of qualified 
pharmacists and law prohibiting pharmacists 
from operating more than two pharmacies.  
•
• 15–25 percent price mark-ups.
Highly fragmented (1,500 registered 
retailers and estimated 6,000–10,000 
hawkers) with a few nascent chains 
(<ten outlets generally).
•
• Retail gross margins capped at 
23 percent by law.
Highly fragmented; law prohibits 
chains of more than one pharmacy.
and proscribes a maximum permitted 
number of pharmacies in a given area.
•
Distribution and retail in selected countries
Source: Ministries of Health; National Health Accounts; country interviews; McKinsey analysis.
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have significantly altered the attitude of Sub-
Saharan African consumers toward quality. 
Creating a controlled supply chain and a brand 
associated with product quality can be a major 
source of competitiveness. High-quality dis-
tributors with geographic breadth also offer 
significant value to donors who procure in bulk 
and seek private sector distribution partners to 
cover whole countries or regions. For example, 
the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR) has chosen to dis-
tribute products regionally through a company 
that has high-quality and information-tracking 
capabilities and distribution hubs in Southern, 
West, and East Africa. One consortium is in the 
process of launching a single quality-oriented 
brand sourcing products exclusively from high-
quality producers.
Examples	of	Successful	Business	Models
The investment themes described in Figure A4.3 
are selected examples of business models that ef-
fectively utilize the innovative strategies discussed 
above, achieving financial success but also having 
a significant development impact.
The likelihood of an investment’s success will 
significantly depend on the country that it tar-
gets. This will be true both because different 
countries will present different market opportu-
nities (both in terms of expected market growth 
and competitive scenario) and because the in-
vestment climate remains significantly heteroge-
neous across the region.
   Figure A4.2
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Pharmacy Chains
Pharmacy chains or consolidation within the re-
tail segment can create financial returns—pro-
vided that the legislative framework does not 
give incentives to distributors to push higher-
value products because of higher fixed distribu-
tion margins—via efficiency gains in purchasing, 
consolidated operations, resource sharing, and 
quality controls. Some pharmacy consolidations 
have paid back their investment within 18–24 
months through efficiency gains. Furthermore, 
these businesses have established a reputation 
for quality and built a brand that attracts talent 
from universities.
Other existing pharmacy chains in Sub-Saharan 
Africa have less than $3 million in revenues.
The development benefit of retail consolida-
tion can come from improved product quality 
due to increased supply chain management capa-
bilities and better aggregate information for de-
mand forecasting. Additionally, a large pharmacy 
chain can use its profitable operations as a plat-
form to penetrate rural markets or markets for the 
poor.
Provided that the legislative framework is 
structured to avoid giving distributors and retail-
ers incentives to promote the use of more expen-
sive products, pharmacy chains, with their more 
efficient cost structures, can support reduced pric-
es for patients.
    Figure A4.3
Promising investment themes in retail and distribution
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• Efficiency gains allows for lower
prices and increased affordability.
• Mediplus (Nigeria), Vine
Pharmacy (Uganda).
• 0.5–3.0 • 0.3–1.0
Multi-sector
distribution platforms
• Broadens access within rural regions.
Profit maximization strategies also
expand portfolio of drugs being made
available.
•
• Increases overall capacity of
distribution system.
• Nufaika (Tanzania), Great
Brands (Nigeria).
• 1.0–15.0 • 1.5–7.0
Pharmacy accreditation
programs for informal
retail operators
• Significantly increases access to
essential drugs in remote regions. 
• ADDO (Tanzania). • 0.3–2.0 • 0.3–1.0
Multi-brand vertically
integrated platforms
• Expands overall capacity of
distribution system.
Increases access to drugs in rural
areas.
•
• PHD (South Africa), MDS
Logistics (Nigeria).
• 3.0–10.0 • 1.0–3.0
Supply chain 
management 
programs for donors 
or governments
• Relieves burden on public sector
and helps improve efficiencies
across system.
• MEDA voucher program
(Tanzania), Village Reach
(Mozambique). 
• 0.3–1.0 • 0.3–1.0
Development impactExamples
Annual revenues
$ million
Setup cost
$ million
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Figure A4.4 shows the details of the establish-
ment of a successful pharmacy chain in Uganda.
Multi-Sector Distribution Platforms
In some countries, the volume of drugs that flows 
through distribution channels is too small to sus-
tain pharmaceutical-only operations. Distribution 
companies that operate across sectors—such as 
those that distribute soft drinks and consumer 
goods—have demonstrated a financially viable 
operation model.
It is important to notice that this model cannot 
be extended to all types of drugs throughout the 
supply chain because several prescription drugs 
require very stringent transport conditions in or-
der to avoid cross-contamination, not to mention 
those that require a refrigerated supply chain 
(typically vaccines).
Nevertheless, this opportunity applies to the 
vast majority of over-the-counter (OTC) drugs, 
which are often also the drugs with the most lim-
ited margins and, therefore, those that would most 
benefit from a shared transportation platform.
These integrated enterprises combine drugs 
and medical supplies with existing distribution 
platforms to achieve scale. Trucks carrying sup-
plies of consumer goods now also carry pharma-
ceutical products—loads which on their own 
might not have been able to fill a truck. This in 
turn reduces the cost of transportation and builds 
efficiencies within the supply chain. 
Depending on the regions where they operate, 
businesses of this kind can have sizes between $1 
million and $15 million in revenues.
The example detailed in Figure A4.5 has a net 
profit of three percent. 
    Figure A4.4
Vine Pharmacy is building a profitable chain… …and projects to grow at 23 percent per annum over the next  
three–five years.
• Started in late 1999, added approximately one  
outlet per year.
• Average payback for initial investment on each 
pharmacy has been between 12–18 months.
• Total staff of ~15 people.
• Expansion to date has been largely internally financed.
Sample financials 2006
$ million
Operations  Assets
• Sales 1.1 • Stores 5
• Cost of goods 0.5 • Employees 15
• Operating Expenses  0.2 • Debt 0
• Net profit 0.4
• Vine Pharmacy plans to expand to 12 stores by 2012.
• Availability of trained staff is an inhibitor to growth.
+23%
1.1
1.9
2008 20102006
2.5
Revenue growth projections
$ million
Source: Country interviews; McKinsey analysis; company website.
Case study, pharmacy chain: Vine Pharmacy, Uganda
Vine Pharmacy is a growing pharmacy chain in Uganda with five outlets in urban Kampala and Entebbe.
	)	 The Business of Health in Africa
Because they increase the accessibility and 
availability of drugs, the development impact of 
investing in such models is significant. By enabling 
low-volume distribution of pharmaceuticals, these 
models improve the frequency of distribution, 
thereby reducing both stock-outs and obsoles-
cence. 
Multi-Brand Vertically Integrated Platforms
A profitable distribution business can also be built 
through vertical integration across portions of the 
life sciences supply chain. 
Historically, in Sub-Saharan Africa products 
are imported through a national agent, often ex-
clusive, who then sells to a primary distributor, 
taking charge of the distribution of the product to 
a network of regional warehouses. From the ware-
house, the product is sold to a local wholesaler 
who then distributes to the network of pharma-
cies and hospitals in its region of coverage. In nu-
merous situations the number of steps in the sup-
ply chain is even higher than this, a situation that 
obviously creates a significant amount of ineffi-
ciency in terms of capital asset and inventory 
management.
Once developed, a distribution infrastructure 
that covers the entire supply chain will easily at-
tract pharmaceutical manufacturers. Without so-
phisticated, large-scale, or reliable national distrib-
utors, many of these producers across Sub-Saharan 
Africa have historically taken it upon themselves 
to secure the distribution of their own products. 
However, for many of these companies, distribu-
tion is not a core competence, and they are more 
Figure A4.5 
1. One of East Africa’s largest distributors
Source: Country interviews; McKinsey analysis; company website.
Case study, multi-sector distributor: Nufaika, Tanzania
One of East Africa’s largest integrated distributors, Nufaika combines pharmaceutical distribution with other consumer goods.
3. Profitable and growing
Primary hub
Secondary hubs
Spokes
TANZANIA Dar es Salaam Revenue growth projections
$ million
6.3 8.4
13.82.9
9.2
2005
4.5
12.9
2006
9.2
23.0
2007
Pharma
FMCG
+58%
2. A mix of pharmaceutical and consumer goods
• Pharmaceuticals
• Personal hygiene (soaps, diapers, toothpaste, etc.)
• Food
• Cosmetics
• Robust IT backbone for tracking inventory.
• Management team has deep and international 
experience.
• Total staff of 100 people.
Sample financials 2006
$ million
Operations  Assets
• Sales 12.9 • Trucks 45
• Cost of goods 11.1 • Branch offices 9
• Operating expenses 1.4 • Stock offices 18
• Net profit  0.4 (3%)
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than willing to outsource it and reap the benefits 
of an overall cheaper chain. In the example in Fig-
ure A4.6, Fuel Africa not only covers the entire 
supply chain for pharmaceuticals distribution, but 
also distributes on behalf of numerous suppliers, 
with the effect that its economies of scale become 
more and more important, to the point that con-
sumer prices for the products it distributes can go 
down by 15–30 percent (vs. similar figures for ex-
clusive distributors or direct distribution).
Additionally, improved supply chain control 
can increase the quality of products in the market 
while reducing stock-outs. 
Businesses of this type are typically large (in 
the context of Sub-Saharan Africa), in the range 
of $3–$10 million in revenues.
Pharmacy Accreditation Programs for Informal 
Retail Operators
Because they allow access to treatment in areas 
and conditions where no formal commercial en-
tity could operate at a profit, distribution models 
that leverage existing physical infrastructures and 
consumer habits to distribute drugs in remote ar-
eas have an enormous development potential.
An accreditation and training program enabling 
small rural shops to sell essential drugs is a busi-
ness model that has significant development im-
pact that can also be financially sustainable. Given 
high retail margins, charging fees for a 40-day 
training program that allows regular shop owners 
to sell essential medicines is a viable business 
Figure A4.6 
Regional distribution model
* The United States President’s Emergency Plan for AIDS Relief.
   Source: Country interviews; McKinsey analysis.
Case study, vertically integrated distributor: Fuel Africa, Sub-Saharan Africa
Fuel Africa is a subsidiary of South African Fuel Group. It distributes medical products across Sub-Saharan Africa, with hubs in South 
Africa, Kenya, and Ghana. It estimates reducing consumer prices by 15–30 percent for imported pharmaceuticals.
Integration Key success factors
Vertical
• Provides procurement, importing, 
primary warehousing, and primary 
bulk-distribution logistics services;  
integration allows Fuel to reduce both 
importer and distributor mark-ups.
• Tight operational coordination with 
secondary/final-mile distribution 
partners through information tracking 
systems and capability support 
improves supply chain management.
Horizontal (future potential)
• Currently solely pharmaceutical and 
medical products distribution.
• Product and service expansion 
possibilities include “pharmacies in a 
box,” distribution of other products 
through pharmaceutical distribution 
infrastructure, and on-site medical 
suppliers servicing/rentals.
Scale
• Hub-and-spoke model aggregates 
volumes to solve problem of low  
intra-Africa point-to-point volumes.
• Volume growth and lower mark-ups 
increase competitiveness over time.
• Infrastructure investment enabled by 
multi-year, large-volume PEPFAR* 
commitment; additional opportunity 
to add volumes from other sources. 
Quality reputation
• South Africa parent company with 
high-quality standards and supply 
chain capabilities.
Management
• Parent company with logistics 
expertise as well as experience 
operating in Sub-Saharan Africa.
Innovation resource use
• Seek to partner with local distributors 
for last-mile distribution, potentially 
providing SME loans and capability 
development for partners.
Nairobi,
Kenya
Tema,
Ghana
Centurion,
South Africa
• Regional hubs aggregate volume.
• Replace local primary wholesalers, but 
outsource final-mile to local SMEs.
• Provide high-quality inventory 
management to improve efficiency 
and reduce obsolescence.
• Reduce mark-ups by providing logistics 
service only, but not assuming 
ownership for inventory. This lowers 
working capital needs.
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model. This has been implemented in Tanzania 
through the ADDO scheme on a pro-bono basis 
(Figure A4.7). However, regular retail shop own-
ers have demonstrated a willingness to pay for this 
training in order to enter the lucrative retail drug 
market. 
These models have revenues in the range of 
$0.3–$2 million.
These business models dramatically increase 
access to drugs for remote populations by increas-
ing the number of medical outlets available. In ad-
dition, training programs for small retailers can 
improve their awareness of counterfeit and sub-
standard products, thus enlisting them as key 
agents in improving product quality.
Supply Chain Management Programs for 
Donors or Governments
The voucher program described in Figure A4.8, 
which administers (as a social enterprise) the dis-
tribution of LLINs on behalf of donors, is one of 
the several examples of private sector initiatives 
that provide health services on behalf of govern-
ments and donors.
Governments that find themselves unable to 
address all their capacity shortfalls often look to 
the private sector to support the growth in de-
mand. These models are usually based on a fixed 
margin structure. Hence, their financial viability is 
often linked to operational effectiveness, and 
therefore, to their capability to deliver positive 
health outcomes.
Figure A4.7 
ADDO addresses a key local health challenge…
Source: Country interviews; “Strategies for Enhancing Medicines to Africa” web site; McKinsey analysis.
Case study, solutions to localized conditions: Accredited Drug Dispensing Outlets (ADDO), Tanzania
ADDO is a donor-supported initiative led by the Tanzanian Food and Drug Authority to train and license small, privately operated retail 
outlets in rural and poor areas to sell a set list of essential medicines, including selected prescription drugs.
…with an innovative model that relies on existing consumer behavior and private-public partnership…
• Train and accredit new small private retailers to dispense both OTC and some prescription medicines.
• Support ADDO retailers with a private campaign that also improves health outcomes for patients.
• Provide microfinancing services to retailers to expand ADDO.
• Local government officials monitor outlet practices.
• Medicines are both OTC and prescription medicines (e.g., ACTs). 
…and which may have commercial potential.
• The ADDO model provides value to retailers for which  
a fee could be charged
– Expanded product options
– Training
– Marketing support
– Large market potential
• ADDO addresses a large market
3.5
16.0
19.5
9.6
1.8
7.8
Population per outlet
000’s
Outlets
000’s
Current (est.)
Target
Current gap
• Safe and effective drug retail is a key health challenge.
– Small retail outlets (duka la dawa baridi) are a key source of pharmaceuticals for rural and poor Tanzanians.
– Up to 70 percent of fevers are managed in private sector dispensaries in Tanzania.
– While duka la dawa baridi are only licensed to sell non-prescription medicines, they often sell others too.
	 The Business of Health in Africa  ( 	
Donors, on the other hand, usually rely on the 
private sector to leverage their local expertise and 
exposure to local conditions. Although private 
sector participation in outsourced donor services 
is dominated by NGOs, a number of commercial 
ventures have recently created financially viable 
operations by achieving superior operational effi-
ciency.
Businesses of this nature are typically small, 
within the range of $0.3–$1 million in revenue. 
Several businesses adopting this model have 
been social enterprises, since often the outsourc-
ing fees offered by governments and donors to 
serve the poor or rural sectors are not sufficient to 
cover a fully commercial entity. 
The importance of these models is fundamen-
tal, given that they can relieve the burden on pub-
lic systems, thus freeing additional capacity. Given 
the high levels of operational efficiency they can 
achieve, they often maximize the effectiveness of 
public and donor money. 
 
Figure A4.8 
Source: Country interviews; McKinsey analysis.
Case study, outsourcing for donors: MEDA’s LLIN Voucher Program, Tanzania 
MEDA’s LLIN voucher program provides a private-market mechanism to subsidize the distribution of long-lasting insecticide treated nets. 
This system improves access to LLINs while supporting the development of a private market.
LLIN voucher program flow chart Financially sustainable
• Service charge of ten percent to 
the donors.
• Overcame early manufacturer 
concerns about payment.
• Manages risk of vouchers 
leaking out of system with 
written voucher accounting.
High development impact
• Subsidized access (not free) to 
LLINs supports development of 
private market.
• Creates transparency across the 
system through voucher 
tracking.
• Removes inefficiencies along 
supply chain by eliminating the 
flow of cash across the system.
Growth opportunities
• Expand service to other 
subsidized products, such as 
diagnostics, drugs, etc.
• Introduction of free or near-free 
nets is a risk to potential for 
sustainable private market.
Donors Manufacturing Distributor Retailer
District
medical officer
Primary health clinic
Private sector
 entity Pregnant 
women
Voucher printer
Data
Base
“The voucher
from the clinic
gives me a
discount to buy
a bed net.”
“My sales have
increased a lot due
to vouchers.”
“Pregnant mothers
are protected from
mosquitoes.”
“We see fewer
cases of malaria
due to LLIN use.”
“Our revenues have gone up
and a sustainable private
market is developing.”
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Annex 5:  Examples of Successful Business Models in 
Medical and Nursing Education
As mentioned in Section II, Sub-Saharan Africa has the lowest availability of qualified medi-cal resources in the world (Figure A5.1). 
Personnel numbers are well below WHO stan-
dards126 in 36 out of 45 Sub-Saharan African 
countries, and there is a cumulative shortage of 
about 1.3 million Human Resources for Health 
(HRH), 750,000 of whom are health delivery 
workers (Figure A5.2). This represents about 30 
percent of the global HRH shortage.
Although there are close to one million total 
HRH workers in Sub-Saharan Africa, the number 
in the 36 “shortage” countries is only 590,000; a 
staggering 140 percent increase in HRH in those 
countries is required to provide even the most ba-
sic health services.
Beyond this major issue, there has also been 
little improvement in HRH coverage over the 
last 40 years in the region, whereas other coun-
tries, such as India and Morocco, have seen phy-
sician and nurse densities increase by 200–400 
percent. 
Growth in numbers of physicians across coun-
tries in Sub-Saharan Africa has stagnated and, in 
some countries, even decreased. Across other cad-
res, numbers are growing slowly, but the growth of 
   Figure A5.1
’s
Africa suffers from
24 percent of the global
burden of disease
but has access to only
three percent of health
workers and less than
one percent of the world’s
financial resources.*   
Human resources for health by region
Distribution of health workers by level of health expenditure and burden of disease, 
by WHO region.
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* Even with grants and loans from abroad.
   Note: 36 of the 57 countries with critical shortages of health workers (as defined by WHO) are in Africa.
   Source: World Health Report, 2006; McKinsey analysis.
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HRH is inadequate to keep pace with population 
growth and offset the current shortage.
Figure A5.3 shows a comparison of the HRH 
landscape in Ghana, Senegal, and Kenya. Although 
these countries vary in their systems and degrees 
of success meeting their HRH needs, all of them 
have an HRH shortage and exhibit immediate de-
mand for growth in private medical schools.  
Over the next decade, over 64,000 new physi-
cians will be needed to fulfill growth estimates for 
health services provision. The HRH shortage will 
likely continue unless energy is focused on ad-
dressing the crisis through either private solutions 
or public-private partnerships, since the public 
sector does not appear to have sufficient resources 
to turn the situation around.
The private sector role within this market has 
nevertheless been limited thus far. This is mostly 
due to government regulations, the high capital 
investment costs peculiar to some element of 
medical and nursing education, and, in some cases, 
the inadequate spending power of students. 
Student financing would considerably increase 
the pool of prospective students and could cata-
lyze increased growth of private medical and nurs-
ing education. There is evidence, however, that the 
current medical education capacity is incapable of 
meeting the Sub-Saharan African demand. In 
Ghana, for example, public institutions can only 
absorb about 40 percent of the pool of qualified 
students who apply to nursing programs.
As shown in Figure A5.4, it is estimated that 
private medical and nursing education will repre-
sent about nine percent of the projected cumula-
tive investment opportunity, or about $1.1–$1.9 
billion. 
Given that a considerable number of doctors 
leave Sub-Saharan Africa after completing their 
education, the capacity of educational institutions 
will have to grow considerably in order to produce 
the more than 80,000 new physicians necessary. A 
similar challenge holds true for nursing schools, 
pharmacist training schools, and community health 
worker training facilities. The private sector will 
   Figure A5.2
Medical doctors (MDs), nurses, and midwives by WHO region, 2006
People per 1,000 capita
11.1
7.0
2.9
2.0
1.7
1.3
Sub-Saharan 
Africa
South-East Asia
Eastern 
Mediterranean 
Western Pacific
Americas 
Europe 
SSA HRH per 1,000 capita
0.21
1.07
0.03
0.07
Medical doctors (MD)
Nurses and midwives
Substitute medical doctors
Community health workers
WHO threshold*
2.5
1.28Total (MDs, nurses, midwives)
1.38Total (all delivery)
0.04
0.01
Managers
Clinical researchers
0.01Population health leadership
1.44Total (all)
* Derived from Anand Baernighausen regression that shows 2.5 workers per 1,000 capita needed for at least 80 percent coverage for two 
basic health interventions, i.e., one-year-olds immunized against measles and skilled health personnel present during child birth.
Source: Joint Learning Initiative, WHO; McKinsey analysis. 
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need to enter in order to partially fill the demand 
gap. Medical and nursing education is asset inten-
sive, and therefore most of the investment is for 
large and midsize enterprises, with over half of the 
investments being greater than $3 million.
Successful	Strategies	
Strategies to succeed in this challenging environ-
ment do exist and will represent the basis for com-
petitiveness either on a national or a regional basis:
• Partnerships with foreign institutions. In the 
United States, demand for nurses heavily out-
weighs the supply of registered nurses.127 The 
Nursing Relief for Disadvantaged Areas Act of 
1999 sought to address this issue by introduc-
ing the H-1C visa program, which allows for-
eign nurses to work for three years in the U.S. 
Since the U.S. is motivated to fill this shortage, 
Sub-Saharan African schools could partner 
with U.S. private hospitals or clinics to guaran-
tee a flow of qualified nurses to the U.S.; U.S. 
institutions would partly finance the establish-
ment of facilities in addition to supporting the 
development of the curriculum. Nurses would 
return to home countries after their time spent 
working in the U.S.
• Cross-subsidization from other disciplines. 
Since medical and nursing education typically 
requires a significant capital expenditure, it is 
likely that private schools would need to be op-
erational for a number of years before they 
could become cash positive. Cross-subsidizing 
medical and nursing education programs with-
in a larger context of other disciplines would 
allow businesses to become financially viable 
much sooner. For example, Central University 
in Accra, Ghana, is planning to start a large-
scale school specializing in the education of 
pharmacologists, nurses, and physician’s assis-
tants; however, the school has been in opera-
tion previously for ten years, during which time 
it focused on business and divinity studies.
    Figure A5.3
Medical and nursing education in selected countries
• Private medical schools.
Distance education.•Opportunities
• Nursing schools. • Nursing schools.
Schools for other medical 
professionals, such as lab 
technicians.
•
Industry
structure
• Five-to-six-year medical education for doctors 
offered by two large public universities, 
none private, producing ~450 doctors per 
year (14 physicians per 100,000 people in 
2002—above 1975 levels but same as 1988 
levels).
58 nursing schools in Kenya as of 2004, 
both private and public.
Enrolled nurses represent half of registered 
medical personnel in Kenya.
Shortage of trained professionals in rural 
areas creates need for distance training 
programs.
~Ten percent of Kenyan-born nurses worked 
outside Africa in 2002.
•
•
•
•
• Six-year medical education offered by 
two large public universities.
Public schools only able to absorb 
40 percent of qualified applicants; 
expansion of private education needed 
to train qualified applicants and meet 
country health needs (nine physicians 
per 100,000 people in 2002 is below 
1975 levels).
Ghana currently trains ~1,000 nurses 
per year with need for more.
Health ministry support for more 
medical professionals, especially nurses. 
Public education subsidized so private 
education ($2,500 per annum) costs 
students more to attend. 
20–25 percent of Ghanaian-born 
nurses worked outside Africa in 2002.
•
•
•
•
•
• Significant private commercial 
medical education, particularly of 
nurses: ~60 percent of nurses in 
Senegal are trained in private schools.
High demand for nursing school 
positions in country’s 13 private
nursing schools given limited capacity 
at public schools.
Four-to-eight-year medical 
education programs offered by 
two public universities.
25–30 percent of Senegalese-born 
nurses worked outside Africa in 
2002.
•
•
•
KenyaGhana Senegal
Source: Ministries of Health; National Health Accounts; World Bank background paper No. 75, 2004; Center for Global Development; country interviews;  
McKinsey analysis.
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• Utilization of remote learning technologies. 
One of the key constraints associated with the 
education of medical personnel in rural areas is 
that the scale of the pool of students does not 
financially justify the employment costs of 
qualified professors and trainers. The utiliza-
tion of remote learning technologies would 
make access to education a great deal cheaper 
for both schools and students (who would not 
need to relocate to major urban centers in or-
der to further their educations).
Examples	of	Successful	Business	Models
The investment themes described in Figure A5.5 
are selected examples of business models that ef-
fectively utilize the innovative strategies discussed 
above, achieving financial success, but also having 
an enormous development impact.
The likelihood of an investment’s success will 
significantly depend on the country that it tar-
gets. This will be true both because different 
countries will present different market opportu-
nities (both in terms of expected market growth 
and competitive scenario) and because the in-
vestment climate remains significantly heteroge-
neous across the region.
   Figure A5.4
55%
45%
0%
By individual
project size
>3.00
0.25–3.00
<0.25
Medical and nursing education investment 
opportunities, cumulative 2007–2016
Percent, $ million
20
40
40
By financial
objective
For-profit
Social 
enterprise
NGO/
non-profit
1,100–1,900 1,100–1,900
Source: Ministries of Health; National Health Accounts; country 
interviews; McKinsey analysis.
    Figure A5.5
Development impactExamples
Annual revenues
$ million
Setup cost
$ million
Large multi-discipline 
university
• Expands the overall capacity of the health care 
system and addresses the critical reason for 
resource shortage.
• Hubert Kairuki 
(Tanzania). 
• 1.0–5.0 • 2.0–10.0
Schools for nurses, 
midwives, lab
technicians
• Expands the overall capacity of the 
health care system within a country.
• Institut Santé 
Service (Senegal).
Central University 
college (Ghana).*
•
• 0.3–2.0 • 0.3–2.0
Distance learning
for nurses
• Provides access to education to students in 
rural areas and avoids them the cost of relocation.
Increases the availability of specialized skills in 
rural areas.
•
• African Medical & 
Research Foundation
(AMREF) (Kenya).
• 0.2–0.5 • 0.2–0.5
Promising investment themes for medical and nursing education
* Medical and nursing education program planned to be launched in September 2007.
   Source: Country interviews; McKinsey analysis.
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Large Medical Universities Offering  
Multiple Disciplines
Given that most forms of medical education re-
quire similar types of fixed investments in labora-
tories, medical equipment, and buildings, schools 
that have multi-disciplinary courses can become 
financially sustainable through cross-subsidization. 
By offering multiple disciplines, schools increase 
the overall volume of students and can amortize 
their capital costs over a larger revenue base. 
However, this market is strongly driven by gov-
ernment regulation, which does not allow for the 
private sector to participate in medical education 
in many countries. Changing these regulations—
while maintaining enforcement of strict quality 
standards and implementing a student-loan fi-
nancing system—could prove to be an effective 
catalyst for replicating this model. Countries like 
Ghana, Uganda, and Senegal, which have open 
policies encouraging the participation of the pri-
vate sector in education, are best suited to see the 
growth of such business models. 
Universities of this kind naturally require a large 
minimum size to operate, and are expected to have 
a revenue basis in the range of $1–$5 million.
Large medical universities can have a profound 
development impact. The lack of skilled human re-
sources is one of the biggest barriers to health care 
growth in Sub-Saharan Africa. Any model that ad-
dresses this crisis will increase the accessibility and 
affordability of health care across the region. 
Figure A5.6 shows the key features of this busi-
ness model and the financials for one successful 
large medical university located in Tanzania.
Figure A5.6 
Source: Country interviews; McKinsey analysis.
Case study, large medical and nursing university: Hubert Kairuki, Tanzania 
Herbert Kairuki, non-profit, is a fully accredited private medical university in Dar es Salaam. It offers multiple degrees in courses 
ranging from holistic medicine to graduate degrees towards an MD, and has its own teaching hospital.
• University founded in 1997, full  
accreditation by Ministry of Education  
in 2000.
• Owned by an NGO, Mission Mikocheni 
Health and Education Network.
• Enrollment has grown from 27 in 1999/ 
2000 to 195 in 2006/2007 across all 
programs.
• Diploma and degree qualifications in 
medicine and nursing:
– Undergraduate medicine (MD, five years)
– Master of medicine (M.MED, three years)
– Bachelor of nursing (BScN: three years)
– Diploma in nursing (DipN: two years)
– Short course “holistic medicine”  
(six months)
– Pre-university program (Pre-U: six  
months)
• Seek $1 million to $1.4 million funding  
for new hostels and classrooms to  
accommodate.
• Strong industry demand for medical 
professionals and good national  
reputation.
Characteristics HKU has a strong growth outlook
While the school is not yet independently profitable…
…enrollment at HKU is growing rapidly…
…and the most popular programs are also the most lucrative.
10%
Unmet recurrent costs
(subsidized by hospital profits)
90%Student tuition
23%
8%
1%
45% 10% 17% 5%Enrollment
68% 15% 8%
Share of
tuition revenue
MD BScN WholisticDipN Pre-U
195
171160
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75
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2003 20042002 20052001 2006
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Nursing Schools
Traditional nursing schools are still an attractive 
investment opportunity given the lack of nurses 
across Sub-Saharan Africa and the emergence of 
new operating models. Given the acute shortage 
of nurses in the area, there is a large unmet need 
for new nursing institutions. 
Some nursing schools are reaching out to the 
future potential employers of their students in or-
der to subsidize a portion of tuition in return for 
access to top talent. This cross-subsidization mod-
el helps finance a greater volume of students, 
which, in turn, helps amortize costs over a larger 
revenue base.
Schools of this kind vary widely in size, but 
with typically fall within the range of $0.3–$2 
million.
The training of new nurses in Sub-Saharan 
Africa addresses one the core health care prob-
Moderate (nine percent) dependable 
margins
• Single revenue source are student 
fees: $1.1 million.
• Limited margins (estimated five–ten 
percent) but cash flows are stable and 
growth outlook is good.
Future growth 
prospects
Profitability
Figure A5.7 
Source: Country interviews; McKinsey analysis.
Case study, nursing school: Institut Santé Service, Senegal
Institut Santé Service is a 20-year old private nursing school with three campuses across Senegal. Student demand that far outstrips 
public provision of nursing education gives ISS an opportunity to focusing on nursing and related areas. A focus on nursing leads to 
lower costs than for a school with more diversified programs and supports ISS’s competitive pricing. 
• Business model: 
– 567 students (nurses, midwives,  
technicians, lab technicians, and nurse 
assistants) paying $2,000 a year.
– Three schools: main location in Dakar within 
subsidiaries in Kaolack and Ziguinchor.
– 25 permanent employees (Director,  
Curriculum Director, Finance and Accounting, 
Exams coordinator, five section coordinators, 
15 yearly coordinators).
– Professors are all employed on a short-term 
contract basis.
• Private sector demand is very strong given  
the high number of jobs created in the  
sector yearly and limited public capacity  
(~100 nurses per year).
• 85 percent of graduates work in the public 
sector.
• Private nursing schools appear to be a viable 
business, albeit with limited margins.
Expanded description Key investment considerations
lems and adds greatly to the capacity of the health 
care system as a whole. 
Figure A5.7 details a case study regarding a 
nursing school in Senegal.
Distance Education for Nurses
Most nurses across Sub-Saharan Africa are only 
qualified to the lowest level of accreditation. Fur-
thermore, the exodus of specialized nurses to more 
lucrative markets and the lack of teaching insti-
tutes have created an unmet need for specialized 
nursing staff. Furthermore, infrastructure problems 
and cost of instruction prohibit many nurses from 
undergoing further specialized training.
Given the paucity of specialized nursing schools 
across Sub-Saharan Africa, a hybrid model using 
both classroom and distance learning is becoming 
prevalent. The practical in-clinic element of these 
programs imparts the hands-on parts of the 
Strong market growth outlook  
if ISS can identify acceptable  
source of financing
• Demand for places in Dakar campus 
is twice as large as the school’s 
capacity.
• ISS seeks subsidy to finance 
expansion. However, it is well- 
positioned to negotiate favorable 
loan terms given its demonstrated 
sustainability, stable cash flows, and 
positive growth outlook.
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coursework while distance learning imparts theo-
retical elements. These hybrid models use com-
puters and compact disks to facilitate distance 
learning. Distance education can reduce the over-
all cost of nursing training by eliminating large 
cost elements such as boarding, transportation, 
and lost wages due to student time spent on site 
(rather than at their employer). 
Revenues in this area are typically small, in the 
range of $200,000–$500,000.
Countries like Kenya, Tanzania, and Nigeria, 
which have a higher dispersion of their nursing 
pool, are ideally suited to this model. For example, 
within Kenya and Tanzania, talent is spread across 
six to seven major regions. Furthermore, these re-
gions usually have a commercial hub or major hos-
pital that could afford computers and instruction 
equipment. Conversely, given their relatively con-
centrated talent pools, countries such as Malawi, 
Rwanda, and Uganda would not appear to be re-
ceptive markets for such teaching methods. 
The development impact of infusing the local 
health care market with more specialized skills 
would be enormous. The overall quality of health 
care delivery would improve, as would access to 
health services across the population.
Figure A5.8 details a case study of a distance 
learning course in Kenya.
Figure A5.8 
The AMREF E-Learning model
Source: Country interviews; McKinsey analysis
Case study, distance learning for nurses: (AMREF), Kenya
AMREF, a non-profit, offers computer-based distance education to 4,500 nurses through a network of 127 schools and E-Centers.  
Enrolled students work towards certification as registered nurses using a mix of computer and in-clinic learning.
The Methodology
• E-Center learning:
– 12 months (three per module).
– CD-based where necessary  
and internet-based where 
possible.
– Three face-to-face sessions over the course of each 
module introduce content and test learning.
• Clinic-based practical learning:
– Four 1.5 month attachments = six months.
– Students work in a clinic with a mentor nurse, to 
build practical skills.
Content
• Enrolled students earn National Nursing Council of 
Kenya certification as registered nurses.
• Four modules:
– General nursing
– Reproductive health
– Community health
– Specialized health (e.g., mental illness).
Early success built on strong public-private partnerships
AMREF’s E-Learning has enjoyed early success
• Has grown from four sites and 145 students in late 2005 to 127 
sites in 61 towns and cities across all eight provinces of Kenya and 
enrolled 4,500 (20 percent of Kenya’s 22,000 enrolled nurses) 
students in early 2007.
• Reaches nurses in both urban (30 percent) and rural (70 percent) 
areas.
• Students value the opportunity to study further, build skills, and 
advance their careers.
• An annual operating budget of just $0.5 million for the program.
Early success was built on strong public-private partnerships
• Public partner The Nursing Council of Kenya provides stewardship, 
political will, and certification for the program.
• Private-partner Accenture provides financial support and skills 
transfer to develop and manage the E-curriculum.
• AMREF’s own 50-year experience with health care in the region 
provided the capability and credibility to execute.
• A non-surplus non-profit, AMREF covers the program’s costs 
internally; student tuition (~$2500/nurse) goes 80 percent to 
partner schools and 20 percent to The Nursing Coucil of Kenya.
AMREF is pursuing an ambitious growth imperative
• Target of reaching 22,000 nurses in Kenya within 5 years.
• Other countries have interest in AMREF’s program.
• AMREF may expand to other medical professions.
• The key growth challenges are institutional and financial capacity.
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Annex 6:  Methodology for Market Sizing
The approach taken in this report to projecting investment opportunities in the health care market in Sub-Saharan Africa (summarized 
in Figure A6.1) involved:
• Projecting the growth of the overall health care 
market in Sub-Saharan Africa (exclusive of 
South Africa and exclusive of pharmaceuticals 
and medical products);
• Translating the projected growth into an in-
vestment opportunity in Sub-Saharan Africa 
(exclusive of South Africa and exclusive of 
pharmaceuticals and medical products); and
• Calculating the investment opportunity for 
pharmaceuticals and medical products, inclu-
sive of South Africa, and adding this to the rest 
of the total Sub-Saharan African investment 
opportunities. 
Priate	Health	Care	Market	Projection
A strong linear correlation (R2=0.89) between 
nominal GDP per capita and Total Health Expen-
diture (THE) per capita allows for estimates of 
future THE (Figure A6.2). Reliable estimates of 
    Figure A6.1
Projecting the share
of the private 
sector provision
Translating private
revenue growth into
investment need
Methodology for estimating the investment opportunities generated by increase in private sector health care 
in Sub-Saharan Africa
Description Data Source
• Determine the overall GDP growth 
expected within SSA based on population 
growth and GDP/capita growth estimates.
Determining overall
GDP growth
•
•
GDP/capita growth estimates.
Population growth estimates.
• IFC
• Global Insight
Translating GDP
growth into THE*
• Project THE based on the proportionality 
relationship between THE/capita and 
GDP/capita.
Verify findings with historical growth 
of THE within SSA. 
•
• THE/capita and GDP/capita. 
historical numbers.
THE historical growth in SSA.•
• WHO
• WHO
• Project the share of the private sector 
provision by sub-sector, provider type 
(for-profit vs. NGO), and size of 
investment need.
• Share of private sector
provision. 
Breakdown of private 
sector provision. 
•
• National Health Accounts 
(NHA), household surveys.
In country interviews.•
• Translate the overall revenue growth 
within the private sector provision to 
investment need by utilizing asset 
turnover ratios for each sector.
• Asset turnover ratios.
Asset lifetime.
External investment need.
•
•
• In-country interviews.
IFC investment experience.
In-country interviews/
primary research.
•
•
Process stage
*Total Health Expenditure.
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GDP per capita can be used to project future 
THE per capita based on the correlation below. 
Note that the correlation is extremely strong in 
the lowest range of GDP. For the 45 countries in 
Sub-Saharan Africa (excluding South Africa), 
most of which lie in the lowest segment of the 
curve (R2=0.95) (see Figure A6.3), while world-
wide the correlation is R2=0.89.
As the level of GDP per capita increases with-
in a country, so does the THE per capita. Pro-
jected THE per capita can then be multiplied by 
population estimates to arrive at future expendi-
tures. Based on this model, it is projected that 
THE in Sub-Saharan Africa will grow from $16.7 
billion in 2006 to $35.4 billion in 2016. The pro-
jected THE annual growth rate of 7.1 percent 
combines THE per capita growth (itself deter-
mined by GDP per capita growth) and popula-
tion growth. 
THE growth in the past ten years has been 
fuelled by a significant increase in GDP (about 
six percent nominal growth derived from an av-
erage growth of 2.4 percent in population and a 
3.5 percent increase in nominal GDP per capita, 
most of which has been concentrated in the last 
five years), as well as by an increase in donors’ 
expenditures. 
In making projections for the next ten years, an 
increase in nominal GDP of 7.7 percent linked to 
a GDP per capita growth of 5.7 percent and a 
population growth rate of 1.9 percent has been 
assumed; however, it has been conservatively as-
sumed that the THE growth will be slower than 
the GDP growth due to the fact that a significant 
component of GDP will be associated with natu-
ral resources businesses and, therefore, will not be 
spread uniformly across the population. A conser-
vative view has also been taken on the willingness 
of donors to continue to increase levels of aid at 
the rate that they have over the last decade.
Due to the underlying conditions mentioned in 
Section I, there are differing levels of private sec-
tor participation across Sub-Saharan Africa. As a 
result, estimates of private sector participation 
have taken into account the private sector “friend-
liness” of each country and the different scenarios 
    Figure A6.2
GDP/capita (nominal) vs. THE/capita, worldwide
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Source: WHO; McKinsey analysis.
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for private sector participation that might be ex-
pected within each. Current estimates indicate 
that the private sector comprised approximately 
50 percent of expenditures in 2005.
It is estimated that the private sector will in-
crease its share in the health care market by al-
most ten percent given its accelerated increase in 
share in some of the faster-growing economies in 
the region. However, this growth might not change 
the composition of the private sector itself, and 
the various segments within the private sector 
might not grow at the same rate at which they do 
now (Figure A6.4).
Translation	of	Reenues	into		
Inestment	Opportunities	
After calculating overall private health expendi-
tures, aggregate investment opportunities are de-
termined using asset turnover ratios for different 
components of the health sector. These ratios rep-
    Figure A6.3
GDP/capita (nominal) vs. THE/capita, worldwide
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resent the average required investment to realize 
health revenues or expenditures. For example, for 
inpatient facilities, the average investment cost as 
a percentage of revenues is estimated to be 175 
percent (based on interviews and analysis of case 
studies in developing countries). 
The translation of 2007–2015 revenue to exter-
nal investment opportunities involves two steps:
1. Determining industry-specific asset-to-turnover 
ratios separately for new assets and replacement 
of existing assets; and
2. Determining the percent of investment oppor-
tunity that would come from external sources 
(again, separately for new assets and replace-
ment of existing assets).
Asset-to-turnover ratios are based on the most-
relevant case studies encountered. Investment 
cost-to-revenue ratios are determined using two 
primary drivers: (1) the cost of the asset needed to 
generate the forecast revenue levels; and (2) the 
Source: WHO; McKinsey analysis.
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life of the asset. Figure A6.5 shows the details for 
health services provision.
Based on the investment-cost-to-revenue ratio 
and the projected revenue growth in the market, 
the model determines the need for new capacity 
and the need to refurbish existing capacity. 
New capacity is assumed to require a greater 
share of external financing than the refurbishment 
of existing capacity. The underlying rationale for 
this difference is that enterprises will seek signifi-
cant external funding for growth projects, whereas 
the replacement of existing assets can largely be 
financed through internal operational cash flows.
Based on this approach, it is estimated that 
$9.8–$17.3 billion will be needed to finance the 
needs of the private health sector (excluding phar-
maceuticals and medical products) in the future.
    Figure A6.4
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    Figure A6.5
Assumptions for translating revenues to investments
Average capital
asset need to
generate $1 million
in yearly revenues
($ thousand)
Translating 
revenues to 
annual 
investments
• Collect case studies 
for each type of 
investment by 
sub-sector.
Derive average 
required investment 
to realize a certain 
revenue volume by 
dividing overall 
capital asset need 
by the expected 
lifetime of the 
asset and the 
revenue potential 
of that asset.
•
A
Estimated life
of asset (years)
B
Outpatient Inpatient Drug retail Prevention Other
750 1,750 150 500 250
15 15 5 5 5
Translation of
revenues into
investment
needs
C
• For every dollar of increase in inpatient sales, $1.75 of
assets are needed.
• For every dollar of assets installed, 1/15 needs to be refurbished
or upgraded every year.
Source: Case studies; country interviews; McKinsey analysis.
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Estimate	of	Manufacturing		
Inestment	Opportunities
The future growth of Sub-Saharan Africa generics 
manufacturing, inclusive of South Africa, is pro-
jected from three factors: (1) the same GDP per 
capita/THE per capita relationship as drove the 
growth of the overall health care market; (2) sub-
stitution of generics and lowered use of patented 
products in South Africa; and (3) scenario-based 
projected changes in Sub-Saharan African manu-
facturers’ share of the future generics market. 
Based on this methodology, Sub-Saharan African 
manufacturers’ ex-factory revenues are projected 
to grow from $1.1 billion in 2007 to between 
$1.8 billion and $3.2 billion in 2015. 
A similar methodology was used to project the 
future size of the Sub-Saharan African medical 
supplies manufacturing market. Sub-Saharan Af-
rican medical supplies manufacturers’ revenues 
for 2015 are projected to be between $170 mil-
lion and $270 million.
Translating market growth into investment op-
portunities for both generics manufacturing and 
supplies manufacturing follows a similar method-
ology as the broader health sector. Given the glob-
al flow of pharmaceutical products and medical 
supplies, those opportunities need to be viewed 
through the lens of cost competitiveness. As with 
each analyzed industry, separate ratios and as-
sumptions are used for generics and supplies man-
ufacturing, respectively. 
Projections of 2007–2015 investment oppor-
tunities in South Africa’s life sciences innovation 
sector are based on two factors: (1) a calculation 
of 2007 private sector investment tied to national 
research and development investment as a per-
centage of GDP; and (2) scenario-based projec-
tions of the future percentage of GDP spent on 
research and development (accounting for pro-
jected growth in GDP).
The commercialization of neglected disease 
product development is considered to involve two 
stages: (1) Phase 3 clinical trials; and (2) taking a 
product to market. An annual investment oppor-
tunity combining these two stages is calculated 
and used to estimate the recurrent annual invest-
ment opportunity between 2007 and 2015. 
The resulting estimate of the overall need for 
external capital for the manufacturing and inno-
vation sector as a whole is in the range of $1.6–
$2.6 billion.
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Accreditation: The process by which an organization recognizes a provider, a pro-
gram of study, or an institution as meeting predetermined standards.
ACT: Artemisinin-based Combination Therapy.
Actuarial	(adjective):	Of or pertaining to statistical calculations based on projections 
of utilization and costs for a defined risk that are used to determine insurance rates 
and premiums.
ADDO: Accredited Drug Dispensing Outlets.
Adverse	selection: A problem encountered by health care providers or insurers 
that attract members who are sicker than the general population. Specifically, a ten-
dency for unhealthy people to purchase health insurance and for healthy people to 
forego insurance as an unnecessary expense.
AMREF: African Medical & Research Foundation.
Analgesics:	A group of medications that reduce pain.
Ancillary	services:	Supplemental services, including laboratory, radiology, physical 
therapy, and inhalation therapy that are provided in conjunction with medical or 
hospital care.
API:	Active pharmaceutical ingredients. Active chemicals used in the manufacturing of 
drugs.
ARV: Antiretroviral drug.
Bilateral	aid: Development assistance provided by one party or country directly to 
another.
Biodiversity:	The number and variety of organisms within one region. This includes 
also the variability within and between species and within and between ecosystems.
Bioequivalence:	The scientific basis on which generic and brand-name drugs are 
compared. To be considered bioequivalent, the bioavailability of two products must 
not differ significantly when, in studies, the two products are given at the same dosage 
under similar conditions.
BMGF:	The Bill & Melinda Gates Foundation.
Capitation:	A payment system in which health care providers are paid a fixed 
amount to care for each person over a given period (usually a year). Providers are not 
reimbursed for services that exceed the allotted amount. The rate may be fixed for all 
members or it can be adjusted for the age and gender of the member, based on actu-
arial projections of medical utilization.
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Catastrophic	 health	 insurance:	 Health insurance, which provides protection 
against the high cost of treating severe or lengthy illnesses or disability. Generally such 
policies cover all, or a specified percentage of, medical expenses above an amount that 
is the responsibility of another insurance policy up to a maximum limit of liability.
CEMAC: Communauté Economique et Monétaire de l’Afrique Centrale.
Chronic	care: Long-term care of individuals with long-standing, persistent diseases 
or conditions. This includes care specific to the problem as well as other measures that 
are undertaken to encourage self-care, promote health, and prevent loss of function.
COGS:	Cost of Goods Sold.
COMESA:	Common Market for Eastern and Southern Africa.
Coverage:	In the context of this report, this mainly refers to insurance coverage. The 
guarantee against specific losses provided under the terms of an insurance policy.
CRO:	Contract Research Organization.
DFI:	Development Finance Institution.
DFID:	The Department for International Development (United Kingdom).
Diagnostics: The art or practice of medical diagnosis. Also refers to instruments or 
techniques used in medical diagnosis.
Dissolution	testing:	The process of testing something, such as a pharmaceutical or 
a polymer, to observe its dissolving characteristics—that is, how quickly it dissolves.
EAC:	East African Community.
ECOWAS: Economic Community of West African States.
EMEA:	European Agency for the Evaluation of Medicinal Products.
EPO:	Erythropoietin.
FBO: Faith Based Organization.
FDA: The Food and Drug Administration. An agency within the United States De-
partment of Health and Human Services that administers Federal laws regarding the 
purity of food, the safety and effectiveness of drugs and the safety of cosmetics.
FDI: Foreign Direct Investment.
FIND:	Foundation for Innovative Diagnostics.
Formulation	(drug):	The act of developing or preparing a drug, or the final product 
itself.
GDP:	Gross Domestic Product.
Generic	drug:	A drug which is exactly the same as a brand-name drug; generic drugs 
can only be manufactured and marketed after the brand-name drug’s patent has ex-
pired.
GFATM:	The Global Fund to fight AIDS, Tuberculosis, and Malaria. Also referred to 
as The Global Fund.
GMP:	Good Manufacturing Practice.
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Health	care:	Care, services, and supplies related to the health of an individual. Health 
care includes preventive, diagnostic, therapeutic, rehabilitative, maintenance, or pal-
liative care, and counseling, among other services. Health care also includes the sale 
and dispensing of prescription drugs or devices. 
HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome.
HMO:	Health Maintenance Organization. An organization that arranges for, or con-
tracts with, a variety of health care providers to deliver a range of services to consum-
ers who make up its membership. HMOs employ managed care strategies that em-
phasize prevention, detection and treatment of illness. HMOs often use primary care 
physicians as the coordinator of patient care needs. 
HRH: Human Resources for Health.
Indemnity:	Health insurance benefits provided in the form of cash payments rather 
than services. Insurance program in which covered person is reimbursed for covered 
expenses. An indemnity insurance contract usually defines the maximum amounts 
that will be paid for covered services. 
Informal	health	care	provider:	A subset of private sector providers. Typically in-
cludes traditional health practitioners and unregistered vendors supplying traditional 
and modern drugs outside a registered health facility or pharmacy. 
Inpatient	care:	Care given to a patient who is admitted to a hospital or other med-
ical institution for at least one overnight stay; distinct from care given when visiting 
such institutions as an outpatient.
IP: Intellectual Property.
ISO-Certified:	Certified by the International Organization for Standardization.
ITN:	Insecticide Treated Nets.
IVF:	In-vitro fertilization. A technique in which egg cells are fertilized by sperm out-
side a woman’s womb.
Life	sciences:	A field encompassing biotechnology, pharmaceuticals, diagnostics, de-
vices, human health care and related medical technologies, nutraceuticals and well-
ness. In this report it does not include agricultural biotechnology, and industrial bio-
technology (biomaterials/bioprocesses), which are often included in the definition.
LLIN:	Long-lasting insecticide treated nets.
Malnutrition:	A broad term commonly used as an alternative to undernutrition, but 
technically it also refers to over-nutrition. People are considered malnourished if their 
diets do not provide adequate calories and protein for growth and physical mainte-
nance or if they are unable to fully utilize the food they eat due to illness (undernutri-
tion). People are also considered malnourished if they consume too many calories 
(overnutrition).
MFI:	Microfinance institution. 
MRI:	Magnetic Resonance Imaging. An MRI scanner is an advanced radiological 
device commonly used in the detection of cancer and neurological conditions.
MTN:	Mobile Telephone Networks, South Africa.
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Multilateral	aid:	Aid involving more than two nations or parties, usually in the 
form of donations through a multilateral organization such as the United Nations or 
the World Bank.
Mutuelle:	Community based insurance program, where the entity is owned by pol-
icy owners rather than stockholders.
MVI:	Malaria Vaccine Initiative.
NAFDAC:	National Agency for Food, Drug Administration, and Control (Nigeria). 
NGO:	Nongovernmental Organization.
NHA:	National Health Accounts.
Non-profit:	An organization whose primary objective is to support an issue or mat-
ter of private interest or public concern for non-commercial purposes, without con-
cern for monetary profit. Status of nonprofits does not permit them to be a source of 
income, profit or other financial gain for the entities that establish, control or finance 
them.
NQCL:	National Quality Control Laboratories.
OPEX:	Operating Expenses.
OTC:	Over-the-counter. Refers to health care products available without a prescrip-
tion.
Out-of-pocket	payment:	A fee paid by the consumer of health services directly to 
the provider. 
Outpatient	care:	Treatment or diagnosis provided in hospitals or clinics that does 
not require an overnight stay. A type of ambulatory care. 
Payer:	The public or private organization that is responsible for payment of health 
care expenses. Payers may be insurance companies, government institutions, self- 
insured employers, or individuals.
PDP:	Product development partnership.
PEPFAR:	The United States President’s Emergency Plan for AIDS Relief.
Phase:	Drug development is divided into phases that are determined by the main 
objectives of the drug development process:
• Preclinical: This phase encompasses laboratory or animal studies that show the bio-
logical activity of the compound against the targeted disease; the compound is also 
evaluated for safety and possible formulations. 
• Phase 1: A Phase 1 clinical trial is the first step in testing a new investigational 
medication (or new use of a previously marketed drug) in humans. Phase 1 studies 
are mainly concerned with evaluating a drug’s safety profile, including the safe dos-
age range. 
• Phase 2: Phase 2 clinical trials involve volunteers who have the disease or condi-
tion in question. These trials help physicians and researchers begin to learn more 
about the safety of the new drug treatment and how well the drug treats the tar-
geted disease or condition.
• Phase 3: After a drug has been shown to have positive results in small groups of 
patients, it may be studied in a larger Phase 3 trial to confirm efficacy and to iden-
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tify adverse events that may occur with long-term use. A Phase 3 trial usually 
compares how well the study drug works compared to an inactive placebo and/or 
another approved medication.
• Phase 4: Phase 4 clinical trials are sometimes called “post-marketing” trials because 
these studies begin after the Phase 1-3 study results have been given to the FDA 
for evaluation. 
Premium:	Money paid out in advance for insurance coverage. A monetary amount 
paid to an insurer in exchange for providing coverage under a contract. A periodic 
payment by the insured to the health insurance company or prescription benefit 
manager in exchange for insurance coverage. This amount varies depending on the 
health plan or drug formulary in question.
Preventive	care:	Health care that emphasizes disease prevention, early detection, 
and early treatment, thereby reducing the costs of health care in the long run. Health 
care that seeks to prevent disease or foster early detection of disease and morbidity 
and that focuses on keeping patients well in addition to healing them when they do 
become sick. 
Primary	care:	Basic or general health care provided outside of a hospital environ-
ment, usually by general practitioners.
Private	sector:	For the purposes of this report, the term private sector includes: 
• For-profit organizations;
• Social enterprises – often described elsewhere as not-for-profit organizations;
• Non-profits including nongovernmental organizations (NGOs) and faith-based or-
ganizations; and
• Privately motivated individuals and groups of individuals.
It does not include private practitioners in the informal sector (traditional healers and 
informal drug retailers, for example).
Provider:	This term usually refers to a health care institution (usually a hospital) or 
doctor who “provides” care. A health plan, managed care company, or insurance car-
rier is not a health care provider. Those entities are called payers.
Public	health:	The aspect of medical activity directed towards improving the health 
of the whole community. 
Public	sector: In the context of this report, the delivery of health-related goods and 
services by and for the government, whether national, regional or local/municipal.
Quality:	Quality is, according to the Institute of Medicine (IOM), the degree to 
which health services for individuals and populations increase the likelihood of de-
sired health outcomes and are consistent with current professional knowledge. Qual-
ity can be defined as a measure of the degree to which delivered health services meet 
established professional standards and consume value judgments.
R&D:	Research and Development.
Reinsurance:	The practice by an HMO or insurance company of purchasing insur-
ance from another company in order to protect itself against part or all of the losses 
that may be incurred in the process of honoring the claims of policyholders.
Risk	pooling:	The practice of bringing several risks together for insurance purposes 
in order to balance the consequences of the realization of each individual risk.
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SADC:	Southern Africa Development Community.
Secondary	care:	Services provided by medical specialists in a hospital environment.
SME:	Small and medium-sized enterprises.
Social	Enterprise:	A self-sustaining enterprise with a minimum (i.e., lower than 
commercial) expectation of financial return; the financial management of such an 
enterprise typically entails reinvestment of profits in enterprise activities.
Specialist:	A doctor who specializes in a particular area of medicine (as opposed to 
a physician providing only primary care).
SSA:	Sub-Saharan Africa.
Standards:	According to the Institute of Medicine, standards are authoritative 
statements of: (1) minimum levels of acceptable performance or results; (2) excel-
lent levels of performance or results; or (3) the range of acceptable performance or 
results.
STD:	Sexually Transmitted Disease.
Stent:	A device that is placed in an artery to keep the inner wall of the artery open. 
A small metal coil or mesh tube that is permanently left in the artery.
TB:	Tuberculosis.
THE:	Total Health Expenditure.
UNICEF:	The United Nations Children’s Fund.
USAID:	The United States Agency for International Development.
Utilization:	The use of services and supplies. Utilization is commonly discussed in 
terms of patterns or rates of use of a single service or type of service, such as hospital 
admissions, physician visits, and prescription drugs.
UTM:	Union technique de la mutualité.
VoIP:	Voice over Internet Protocol.
WHO:	The World Health Organization.
WHOPES:	World Health Organization Pesticides Evaluation Scheme.
$: United States dollars.
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Notes
 1. WHO, “Spending on health: A global overview” Fact sheet
 2. WHO, 2006 World Health Report
 3. WHO, 2006 World Health Report
 4. WHO, 2005 World Health Report
 5. WHO, 2006 World Health Report
 6. NHA reports from most recent year available between 1995–2002 for Ethiopia, Kenya, 
Malawi, Namibia, Nigeria, Rwanda, Tanzania, Uganda, Zambia, Zimbabwe; other 
sources for all other countries
 7. The term providers is used broadly throughout this document in reference to any type 
of health care practitioner, facility, or retail outlet
 8. Note: National payment schemes include both state-funded systems and social insur-
ance funds
 9. WHO, 2006 World Health Report
 10. This figure excludes South Africa
 11. World Bank 
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